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Abstract 
 
Biodegradable microneedles (MNs) are currently being developed to painlessly facilitate the 
effective permeation of therapeutic substances across the skin barrier.  As sugar glasses are 
utilised in nature to protect proteins and other delicate structures upon dehydration, such 
materials may be an appropriate substrate for the preparation of biodegradable MNs.  The aim 
of this work was to investigate for the first time the feasibility of preparing biodegradable MNs 
from sugar glasses and to test their potential utility for drug delivery applications.   
 
Solid sugar products were fabricated from 32 different solutions containing a range of 
individual sugars and binary sugar combinations, utilising a low temperature dehydration 
methodology.  Subsequently, a novel vacuum-forming micromoulding methodology was 
developed and optimised to produce sugar glass microneedle (SGMN) arrays from silicon 
master structures.  The sugar materials and MN structures were characterised using a variety 
of microscopic, thermal and x-ray diffraction analyses.  The ability of SGMNs to puncture 
human skin was assessed in an in vitro skin model, whilst SGMN facilitated drug delivery was 
investigated using modified static Franz-type diffusion cells.  A range of model substances 
including methylene blue (MB) dye, ibuprofen sodium (IBU), sulforhodamine B (SRB), FITC-BSA 
and β-galactosidase (β-gal) were incorporated within SGMN arrays.  Furthermore, novel SGMN 
adhesive patches containing SRB within the backing only were fabricated using silicone and 
acrylate adhesives.  Long-term stability of SGMN arrays was assessed under a range of differing 
storage conditions. 
 
Initial characterisation studies suggested that non-crystalline sugar material was formed from 
anhydrous trehalose and sucrose (75:25 %w/w) sugar solutions.  This finding was critical to 
future SGMN fabrication and incorporation of model substances within the material.  Process 
optimisation led to fabrication of SGMNs with strong morphological fidelity to master 
structures, which reliably penetrated human skin to facilitate diffusion of MB dye.  
Furthermore, SGMNs were shown to dissolve rapidly and completely in human skin and deliver 
MB, IBU, SRB and FITC-BSA to the deeper skin layers.  Diffusion study data suggested that 
SGMN arrays incorporating a range of model substances facilitated permeation across skin in a 
bolus delivery manner.  Additionally, it was found that SGMN adhesive patches were able to 
control permeation of SRB, a model hydrophilic compound.  Sugar glasses containing β-gal 
were shown to stabilise enzyme functionality at approximately 40 % of initial activity over a 3 
month period when stored under desiccation.  Elevated humidity and temperature storage 
was detrimental to SGMN morphology, with 10 % relative humidity at 20 °C being optimal for 
MN preservation.   
 
Overall, this study suggests the utility of SGMNs for the stable incorporation and effective 
intra- or trans-dermal delivery of a range of model substances, including hydrophilic and 
macromolecular molecules.  Furthermore, it was shown that a novel SGMN adhesive patch 
may provide the capability to control drug release across skin.  Sugar glasses demonstrated a 
stabilising effect upon a functional protein cargo, although it appeared that storage conditions 
had a strong influence upon physical SGMN stability. 
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1 General introduction 
1.1 Overview 
Drug delivery systems that target specific body sites or provide controlled delivery have long 
been a goal of pharmaceutical scientists (Langer 1998).  Advances in genetic engineering and 
biotechnology have led to the generation of potent, therapeutically-active, large molecular 
weight, hydrophilic molecules; many of which are peptides and proteins (Amsden and Goosen 
1995).  Although oral delivery of these medicaments is desirable, they tend to be extensively 
degraded in the liver and gastrointestinal tract if given via this route.  Hence, there is a need 
for alternative routes of administration and suitable drug delivery systems (Brown et al. 2006).  
This study was motivated by the opportunity to investigate delivery of a range of model 
substances across skin via a novel microneedle patch drug delivery device.      
 
Transdermal drug delivery has emerged as an attractive option to deliver medicaments to the 
body.  Drug release can be easily controlled and systemic delivery via this route bypasses 
hepatic degradation (Langer 1998).  However, as this chapter details, passive transdermal 
delivery is limited by the extraordinary resistance of human skin to the ingress of exogenous 
material.  In an attempt to overcome the skin barrier, various enhancement techniques have 
been proposed, which will be discussed herein.  One transdermal delivery system in particular, 
described as a microneedle device, has been the focus of considerable research activity over 
the past 10 -15 years.  Since the first “microneedle patch”, introduced by Henry et al. (Henry et 
al. 1998), a plethora of microneedle designs and devices have been investigated.  Each of these 
permutations has a number of advantages and limitations which will be explored in this 
chapter.   
 
Amorphous sugars are utilised in nature (Potts 1994) and the pharmaceutical industry (Uritani 
et al. 1995) to help preserve the delicate nature of proteins and other labile biological 
structures during dehydration.  This chapter provides an introduction to molecular glasses and 
their unique properties for macromolecule stabilisation.  Subsequently, it was hypothesised 
that sugar glasses may provide a suitable material for the stable incorporation of a wide 
variety of molecules including peptides and proteins.  A final discussion is provided in this 
chapter to reiterate the key aspects of this work and to rationalise the investigation of sugar 
glasses for biodegradable microneedle fabrication.            
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1.2 Human skin 
1.2.1 Biological function 
The integument of the human body, the skin barrier, is one of the most vital organs in 
determining survival.  Although it appears relatively basic and homogenous, human skin is 
extremely complex and provides many different functions.  The primary role of the skin is a 
physical barrier to protect the delicate internal portion of the body from its surroundings 
(Barry 1983).  This barrier prevents the introduction of foreign substances into the body whilst 
preventing excessive loss of important endogenous materials, such as water (Brown et al. 
2006).  The protective or barrier function protects the body from a diverse range of potentially 
harmful external stimuli including micro-organisms, chemicals, electrical or mechanical shock, 
radiation and heat.  Additionally, the skin serves a mechanical function to contain body fluids 
and therefore it is involved in the regulation of body temperature by controlling water loss 
through sweating.  The skin is also an important site of synthesis and metabolism of 
compounds, such as vitamin D, an important factor in calcium regulation.  Previtamin D3 is 
formed by photosynthesis of a cholesterol precursor in skin in the presence of sunlight 
(MacLaughlin et al. 1982).  Subcutaneous adipose tissue is vital to the protection of internal 
organs from mechanical injury and also serves as an energy store for processes such as heat 
production (Cinti 2005).  Other functions of the skin include sensation of potentially harmful 
external stimuli via skin receptors, including tactile (pressure), pain and heat, and the disposal 
of chemical wastes, such as urea, via glandular secretions (Barry 1983). 
 
1.2.2 Structure and anatomy 
Human skin covers a surface area of approximately 1.8 m2 and constitutes 16 % of body weight 
(Gawkrodger 2008) making it the heaviest single organ of the body.  It combines with the 
mucosal linings of the respiratory, digestive, and urogenital tracts to form a capsule which 
separates the internal body structures from the external environment (Barry 1983).   To 
provide the functions described above, human skin comprises three distinct layers.  The outer 
layer, termed the cellular epidermis, consists of cells which are biochemically active, stratified 
and avascular (Kermici et al. 1977).  Beneath the epidermis lies the dermis, mainly comprised 
of connective tissue, and at the base of the dermis lies the fatty, subcutaneous layer (Barry 
1983), Figure 1.1.   
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Figure 1.1  Diagrammatic cross section of human skin demonstrating layered assembly.   
Adapted from source (Williams 2003). 
 
Each of the layers in Figure 1.1 has a different role to play in skin function and hence the 
structure varies widely throughout the tissue.  In the context of this work, skin is regarded as a 
barrier to cutaneous drug delivery and will be discussed in these terms.  The composite 
structure of the skin permeability barrier is indicated by discrete skin layers; the stratum 
corneum (approximately 10 µm), the viable epidermis (approximately 100 µm), and the 
papillary dermis (approximately 100-200 µm) (Scheuplein and Blank 1971). 
 
1.2.2.1 Epidermis 
The epidermis is defined as a stratified squamous epithelium (Gawkrodger 2008).  It forms a 
multi-layered envelope that varies in thickness, depending upon anatomical location, ranging 
from about 0.8 mm on the palms and the soles down to 0.06 mm on the eyelids.  Cells which 
provide epithelial tissue, keratinocytes, differ from those of all other organs in that as they 
ascend from the proliferative layer of basal cells they change in an ordered fashion from 
metabolically active dividing cells to dense, dead, keratinized protein (Barry 1983).  The 
epidermis is therefore further divided into several layers or strata starting with the basal layer 
or stratum basale just above the dermis proceeding upward through the spinous and the 
granular layers to the top layer, the stratum corneum (SC) (Wickett and Visscher 2006).  These 
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four layers therefore represent the various stages of maturation of keratin by keratinocytes 
(Gawkrodger 2008).  The process can be seen in Figure 1.2.   
 
Figure 1.2  Diagrammatic representation of the epidermis showing discrete layers.   
Adapted from source (Wickett and Visscher 2006). 
 
1.2.2.2 Stratum corneum 
The cells of the SC represent the terminal point in keratinocyte differentiation (Eckert 1989).  
This layer is formed and continuously replenished by the slow upward migration of cells from 
the germinative basal layer of the epidermis to the SC.  This complex process includes gross 
dehydration and polymerisation of the intracellular material, resulting finally in keratin filled, 
biologically inactive, shrunken cells (Scheuplein and Blank 1971).  During the transition 
keratinocytes lose approximately 70 % of dry weight and become flattened.  Hence, the 
terminal corneocyte is a flattened polyhedron  with a hardened and thickened cell envelope 
containing involucrin (Eckert 1989), and cytoplasm replaced by keratin tonofibrils in a matrix 
formed from keratohyalin granules (Gawkrodger 2008).  Corneocytes of the SC are uniquely 
adapted to providing a protective barrier for the human body, before they are eventually 
sloughed from the skin surface (Eckert 1989) during desquamation.   
 
During the transitional process, a change in the physical state of the tissue and a 
commensurate change in its diffusivity occur.  A transformation occurs from an aqueous fluid 
medium, containing approximately 70 % water (Anderson and Cassidy 1973),  characterised 
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approximately by liquid-state diffusion, to a dry semisolid “keratin” membrane which is 
characterised by a much lower fibre-type diffusivity (Scheuplein and Blank 1971).  When dry, 
the SC is a very dense tissue, about 1.5 g  cm-3 (Barry 1983), and provides for the mechanical 
strength of the epidermis through its multicellular anatomy and the overlap of adjacent cells 
(Scheuplein and Blank 1971). 
 
Hence, this extremely thin layer is the ultimate stage in the epidermal differentiation process 
(Naik et al. 2000), forming a laminate of compressed keratin-filled corneocytes (terminally 
differentiated keratinocytes) anchored in a lipophilic matrix (Christophers 1971; Elias 1981; 
Elias 1983).  Consequently, the SC is a heterogeneous membrane consisting of approximately 
20 % lipids, 40 % keratinised protein and 15 – 20 % water (Anderson and Cassidy 1973).  The 
lipids of this extracellular matrix are partly derived from membrane-coating granules 
(Gawkrodger 2008) and are distinctive in many respects (Gray et al. 1982).  Firstly, they 
provide the only continuous phase (and diffusion pathway) from the skin surface to the base of 
the SC.  Their composition (comprising ceramides, free fatty acids and cholesterol) is unique 
among biomembranes and particularly noteworthy is the absence of phospholipids.  However, 
despite a deficit of polar bilayer-forming lipids, the SC lipids exist as multilamellar sheets and 
the predominantly saturated, long-chain hydrocarbon tails facilitate a highly ordered, 
interdigitated configuration.  This arrangement of lipids allows formation of gel-phase 
membrane domains as opposed to the more usual (and more fluid and permeable) liquid 
crystalline membrane systems (Naik et al. 2000).   
 
The SC architecture as a whole has been proposed to play a critical role in the barrier function 
of the epidermis (Potts and Francoeur 1991).  The staggered corneocyte arrangement in a lipid 
continuum (similar to a brick and mortar assembly) (Elias 1981) is suggested to bestow a highly 
tortuous lipoidal diffusion pathway rendering the membrane 1000-times less permeable to 
water relative to most other biomembranes (Potts and Francoeur 1991).  Due to its highly 
specialised structure, the SC is known to exhibit selective permeability and allows only 
relatively lipophilic compounds to diffuse into the lower layers of skin (Brown et al. 2006).   
 
1.2.2.3 Stratum granulosum 
As Figure 1.2 shows, below the SC lies the stratum granulosum.  The cells in this layer contain 
electron-dense keratohyalin granules, to which the stratum granulosum owes its name (Eckert 
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1989).  These granules contain profilaggrin, the high-molecular-mass precursor of the protein 
filaggrin, which is thought to aid in aggregation of keratin filaments (Dale et al. 1985).  Also 
present are the lipid-filled lamellar (membrane coating) granules that eventually fuse with the 
plasma membrane and release their lipid contents into the extracellular space (Elias et al. 
1988).  This layer is often referred to as a “transitional zone” as the stratum granulosum 
defines a region between living cells and dead keratin (Barry 1983).   
 
1.2.2.4 Stratum spinosum 
Immediately above the basal layer is the stratum spinosum.  This layer is named due to the 
spine-like appearance of the cell borders in histological section, which are caused by the 
presence of numerous desmosomes formed between adjacent cells (Obland 1958).  
Desmosomes are intercellular bridges that form through adherence of adjacent cytoplasmic 
extensions known as spines or “prickles.”  These links maintain the integrity of the epidermis 
whilst tissue fluid fills the capillary space between desmosomes to separate neighbouring cells 
and permit nutrients and oxygen to pass outwards (Barry 1983).          
 
1.2.2.5 Stratum basale 
The stem cell population of keratinocytes is found attached to the basal lamina, which 
separates the dermal layer from the epidermis (Eckert 1989).  These undifferentiated cells lack 
the obvious biochemical and morphological markers that are expressed by cells in the upper 
epidermal layers.  Typically stem cells are columnar and replete with keratin filaments around 
the nucleus.  Junctions between adjacent cells, described as desmosomes, and 
hemidesmosomes (junctions between basal cell and basal lamina) (Eckert 1989) can be 
observed.  Mitosis of the basal cells constantly renews the epidermis and this proliferation in 
healthy skin balances the loss of dead horny cells from the skin surface.  The epidermis thus 
remains relatively constant in thickness (Eckert 1989). 
 
Other cell types found within the basal layer include melanocytes, Merkel cells and dendritic 
cells.  Melanocytes are most numerous on the face and other exposed sites and make up 5 -
10 % of the basal cell population.  These cells synthesize melanin and transfer it via dendritic 
processes to neighbouring keratinocytes.  Merkel cells are found infrequently in the basal layer 
and are closely associated with terminal filaments of cutaneous nerves, appearing to have a 
role in sensation (Gawkrodger 2008).  The most important antigen-presenting cell of the 
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epidermis, formed from a dendritic cell lineage, is the Langerhans cell.  These cells are vital to 
the immune function of the skin as they engulf exogenous material, process it into 
immunogenic peptides, and present it to T lymphocytes (Williams and Kupper 1996).  Whilst 
these cells normally reside within the epidermis, upon activation during an inflammatory 
response, they can mobilise and migrate to the lymphatic system of the dermis and travel to 
regional lymph nodes (Kripke et al. 1990) to bring about a systemic immune response.           
 
Below the basal cell layer lies the complex dermo-epidermal junction, which constitutes an 
anatomic functional unit (Briggaman and Wheeler 1975).  The junction spans four 
components: (1) the basal cell plasma membrane with its specialised attachment devices, the 
hemidesmosomes, (2) the lamina lucida, (3) the basal lamina, and (4) the fibrous components 
below the basal lamina, which include anchoring fibrils, dermal microfibril bundles, and 
collagen fibrils.  The “basement membrane” corresponds to the fibrous zone below the basal 
lamina (Barry 1983).   
 
1.2.2.6 Dermis 
The dermis is a tough supportive connective tissue matrix found immediately below and 
intimately connected with the epidermis (Gawkrodger 2008).  It can be divided into two layers, 
the reticular (lower) and the papillary (upper) layer.  The papillary layer is approximately 100-
200 µm in thickness and is attached to the basal lamina (Scheuplein and Blank 1971).  The 
dermis is typically 3-5 mm thick and hence makes up the bulk of the skin (Barry 1983).  It is 
essentially an aqueous medium composed of a matrix of connective tissue woven from fibrous 
proteins (approximate composition, collagen 75 %, elastin 4 % and reticulin 0.4 %) which 
embed in an amorphous ground substance of mucopolysaccharide providing about 20 % of the 
mass (Wilkes et al. 1973).  The ground substance contains a variety of lipid, protein and 
carbohydrate materials, with the most important being the mucopolysaccharides hyaluronic 
acid and dermatan sulphate (chondroitin sulphate B) (Barry 1983).  Collagen and elastin fibres 
found throughout the dermis provide strength and elasticity to the tissue (Gawkrodger 2008).  
The dermal matrix supports blood vessels, nerves and lymphatics and is penetrated by skin 
appendages including sweat glands, apocrine glands and pilosebaceous units (Barry 1983).  
Sweat glands and hair follicles which extend from the dermis have been described as “shunt” 
pathways for transdermal drug delivery.  However, these routes account for less than 0.1 % of 
the total surface area for passive diffusion and hence their contribution to drug delivery is 
negligible (Scheuplein and Blank 1971).  Therefore, the barrier function of human skin is widely 
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thought to be a function of the SC, although it has been found that the aqueous tissues of the 
viable epidermis and dermis provide a residual resistance to drug transport (Potts and Guy 
1992).  
 
1.2.2.7 Hypodermis (subcutis) 
The hypodermis consists of subcutaneous fat that spreads all over the majority of the body as 
a fibro-fatty layer.  The cells manufacture and store lipids in large quantities and bundles of 
collagen fibres weave between the cells to provide flexible linkages between underlying 
structures and superficial skin layers.  The subcutis provides a thermal barrier and a 
mechanical cushion and is a high energy depot (Barry 1983).        
 
1.2.3 Factors governing percutaneous absorption 
There is now a body of evidence which informs passive diffusion of medicaments across 
human skin.  Permeation of small hydrophilic molecules is governed by the rate of partition 
into the lipid lamellae of the SC.  Conversely, small hydrophobic molecules are rate controlled 
by partition from the SC into the aqueous environment of the viable epidermis (Brown and 
Langer 1988).  Additionally, permeation of drugs decreases with increasing molecular size, and 
500 Da is widely considered as the upper limit for passive diffusion (Brown et al. 2006).  
Further, because the SC is composed of metabolically inactive cells, no active transport 
mechanisms exist in this layer and therefore passive diffusion dictates the rate of permeation 
in conventional cutaneous delivery systems (Scheuplein and Blank 1971).  Therefore, as 
equation 1 shows, drug absorption from passive transdermal systems can be described by 
simple diffusion mathematics (Hadgraft and Lane 2006). 
J = KD (capp – crec) 
h    (Equation 1) 
The rate of permeation across SC follows Fick’s first law of diffusion (Flynn et al. 1974) which 
describes steady-state flux per unit area (J) in terms of the partition of the permeant between 
the applied formulation and the skin (K), its diffusion coefficient (D) in the lipid lamellae of 
diffusional path length (h), the applied concentration of the permeant in the vehicle (capp), and 
the concentration of the permeant in the body, or in the case of an in vitro study, receptor 
phase (crec) (Hadgraft and Lane 2006).  The partition coefficient (K) is a measure of the 
willingness of a permeant to leave its vehicle and partition into the SC. 
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Operationally, K is defined as the octanol / water partition coefficent (Koct), or its logarithm, log 
P (Williams 2003).   The greater the log P, the more lipophilic the molecule and the more 
readily it will partition into the SC lipids.  K, D and h can be represented together as the 
permeability coefficient (Kp), as shown in equation 2. 
Kp = P D 
            h    (Equation 2) 
Furthermore, an empirical relationship exists between Kp and molecular weight (MW) and log P 
as shown in equation 3 (Potts and Guy 1992). 
log Kp (cm sec 
-1) = -6.3 + 0.71 · log Koct – 0.0061 · MW  (Equation 3)    
From equation 3 it can be deduced that log Kp decreases with increasing MW, which generally 
correlates with increasing molecular volume (MV).  The relationship between the D and MV is 
exponential (Potts and Guy 1992) and therefore it can be argued that MW decreases Kp by 
decreasing D and hence that permeation of larger molecules is restricted by their larger size.  
 
In most in vitro transdermal diffusion studies, crec is much smaller than capp and equation 1 is 
simplified to equation 4. 
   J = Kp capp    (Equation 4) 
Hence, the maximum flux of a compound is achieved when capp is equal to the solubility limit of 
drug in the applied formulation (Hadgraft and Lane 2006).  Additionally, it has been shown that 
relatively simple processes, such as skin occlusion, lead to elevated hydration of the SC thereby 
facilitating permeation of model compounds including steroids (Wester and Maibach 1983).  A 
similar effect can be achieved by physical disruption of the SC barrier, for example by adhesive 
tape stripping, which has been shown to increase passive transdermal drug delivery 
(Scheuplein 1976).  Therefore, if the barrier properties of the SC are efficiently attenuated 
delivery of a wide range of drug molecules is theoretically feasible.  
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1.3 Cutaneous drug delivery  
1.3.1 Scope of drug delivery approach 
As discussed previously, the delivery of hydrophilic and larger MW molecules across the SC 
barrier is extremely limited.  Consequently, a wide variety of different techniques aimed at 
enhancing the permeation of these substances across skin have been developed.  The advent 
of biotechnology in the latter half of the 20th century has led to the generation of 
therapeutically-active, large MW (>500 Da) polar and hydrophilic molecules.  Most of these 
macromolecules are peptides and proteins, but they also include nucleic acids, vaccines, 
hormones and antibodies (Brown et al. 2006).  This class of materials tends to be extensively 
degraded by enzymes in the liver and gastrointestinal tract if given by oral delivery; hence, 
there is a need for alternative routes of administration and suitable drug delivery systems 
(Brown et al. 2006).  Cutaneous delivery of these drug molecules presents a potentially 
attractive alternative delivery route.   
 
1.3.2 Advantages and limitations of cutaneous delivery 
For the majority of drugs the conventional route of drug delivery is via the oral route.  This 
route of delivery is desirable as a wide range of medicaments can be formulated into tablets 
and capsules, it is convenient, it is easy to use, cost-effective, pain free and requires no 
specialist training to administer (Park et al. 2005).  However, drug administration via the oral 
route can result in variable systemic levels of the active form of the drug, both within and 
among individuals, as a result of the variable absorption or release of drug from the 
formulation, differences in food intake, or initial entry of drug into the portal circulation (Shaw 
et al. 1976).  In addition, degradation and metabolism in gastrointestinal fluids, which have 
extremely low pH (≈2), and hepatic first-pass elimination via enzymatic metabolism and biliary 
excretion (Benet et al. 1996) can limit oral drug delivery.   
 
Orally inactivated molecules and macromolecules, such as proteins, are usually administered 
by hypodermic injection, which avoids the gastrointestinal tract but causes pain, requires 
medical expertise to administer (Davis et al. 2004), and introduces the risk of infection.  Both 
oral and hypodermic routes of delivery also have added limitations as bolus delivery methods, 
where the full dose of drug is introduced into the body at once.  To prevent irritating and 
potentially toxic effects of initial high doses and sub-therapeutic effects as drug concentration 
decays at later times, tablets and injections often need to be administered multiple times per 
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day or, in some cases, prolonged-release formulations can be used (Park et al. 2005).  
Consequently, the potential exists for developing a minimally invasive, self-administered 
delivery system capable of delivering a range of drug molecules, including biologically active 
macromolecules (Sullivan et al. 2008), where oral bioavailability is low.   
 
Transdermal drug delivery offers the potential to address many of the aforementioned issues.  
Transdermal patches can be formulated to provide controlled release of the medicament 
across skin whilst there is an extensive underlying capillary network available for systemic drug 
delivery.  This route of delivery also bypasses the liver and gastrointestinal tract and hence 
does not degrade macromolecules delivered in this manner (Bronaugh and Maibach 1999; 
Prausnitz 2001).  However, delivery across intact skin at therapeutic rates permits transport of 
a very limited number of small, quite lipophilic molecules only and excludes transport of 
biotherapeutics, due to their large size (Sullivan et al. 2008).  Proteins, in particular, being 
hydrophilic macromolecules, do not passively permeate across skin, and hence permeation 
enhancement strategies are needed to enable delivery into and across the barrier (Li et al. 
2008).     
 
The challenge of cutaneous drug delivery therefore is to formulate a device containing a 
hydrophilic or biological therapeutic medicament into a stable, patient acceptable form which 
provides controlled delivery across skin at therapeutically relevant rates.       
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1.4 Traditional and novel cutaneous drug delivery methods 
Transdermal delivery is a term that should be restricted to the situation in which a solute 
diffuses through the skin and into the systemic circulation to exert a therapeutic effect.  In 
contrast, dermal  or topical delivery should only be used to define drug targeting to 
pathological sites within the skin, thereby ensuring minimal systemic absorption (Brown et al. 
2006).  To achieve these goals a number of permeation enhancement techniques have been 
investigated to facilitate skin drug delivery.       
 
1.4.1 Passive methods 
Passive methodologies of cutaneous drug delivery include conventional means of applying 
drugs to skin such as ointments, creams, gels, and “passive” patch technologies.  These dosage 
forms have been developed and/or modified to enhance the driving force of drug diffusion 
(thermodynamic activity) and/or increase the permeability of the skin (Brown et al. 2006).  
Examples are discussed below. 
 
1.4.1.1 Chemical penetration enhancers  
Chemical penetration enhancers (CPEs) may act by one or more of three main mechanisms 
(Barry 1983): 
1. Disruption of the highly ordered structure of SC lipid. 
2. Interaction with intercellular protein. 
3. Improved partitioning of the drug, co-enhancer or solvent into the SC.  
Classes of penetration enhancer include, anionic surfactants, cationic surfactants, zwitterionic 
surfactants, non-ionic surfactants, fatty acids, fatty esters, fatty amines, azone-like compounds 
and sodium salts of fatty acids (Karande et al. 2005).  Each enhancer acts by altering one of the 
three main pathways described.  The key to altering the polar pathway is to cause protein 
conformational change or solvent swelling, whilst the fatty acid enhancers increase the fluidity 
of the lipid protein portion of the SC (Pathan and Setty 2009).  Some enhancers act on both 
polar and non-polar pathways by altering the multilaminate pathway for penetration (Pathan 
and Setty 2009).  Penetration enhancers have demonstrated efficacy in increasing systemic 
drug delivery both in vitro and in vivo, for example, caffeine serum concentration in rats was 
many times greater when Transcutol® and oleic acid were present in the topical formulation 
compared to an aqueous solution alone (Touitou et al. 1994).    
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The major drawback of CPEs is that they can be irritating to skin, and this behaviour is related 
to the ratio of hydrogen bonding to polar interactions.  Hydrogen bonds are of significant 
importance in holding the proteins in their native structures and competitive bonding from 
CPEs can potentially alter the native hydrogen bonding in proteins leading to unfolding.  
Consequently, irritation potential scales directly with hydrogen bonding ability of CPEs 
(Karande et al. 2005).   
 
1.4.1.2 Supersaturated systems 
This technique is an attractive option as it provides the potential for enhanced penetration of 
drug without disturbing the lipids of the SC.  Instead it relies on raising the activity of a 
substance within its formulation beyond that of its solubility limit (Pellett et al. 1997).  For 
example, it has been shown that the flux of piroxicam increases linearly with the degree of 
saturation within a single vehicle (Pellett et al. 1994).  However, due to the nature of these 
systems they are inherently unstable and in many instances the drug tends to crystallise out of 
solution (Pellett et al. 1997).   
      
1.4.1.3 Prodrugs / metabolic approach 
The use of prodrugs to facilitate transdermal drug delivery involves direct covalent bonding of 
a lipophilic moiety to a hydrophilic permeant via conjugation to primary and secondary 
amines, hydroxyls, and other functional groups of the drug to form a prodrug (Bundgaard 
1992).  Numerous examples are now available demonstrating enhanced delivery of hydrophilic 
compounds across skin due to attachment of lipophilic groups.  The lipophilic groups improve 
partitioning of the parent compound into the SC lipids and are then cleaved in vivo by enzymes 
within the epidermis to render the drug free and active (Amsden and Goosen 1995).  Specific 
examples include small molecules, such as 5-fluorouracil (Sasaki et al. 1990), and also certain 
macromolecules, for example thyrotropin-releasing hormone (Møss and Bundgaard 1990), 
where significantly greater permeation of prodrug was observed in comparison to the parent 
molecule alone.  Furthermore, the lipophilic pro-moiety can preserve the functionality of the 
parent compound within the bloodstream prior to the drug reaching its therapeutic site of 
action (Møss and Bundgaard 1990).  Drawbacks to this approach include limitations on 
molecular size, and variable enzymatic cleavage from patient to patient resulting in 
irreproducible bioavailability (Amsden and Goosen 1995).                
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1.4.1.4 Liposomes and other vesicles 
Liposomes are colloidal particles, typically consisting of phospholipids and cholesterol.  
These lipid molecules form concentric bimolecular layers that may entrap and deliver drugs to 
the skin (Barry 2001).  Research efforts into liposomes initially focused on their use as drug 
carriers to target particular organs within biological organisms (Fendler and Romero 1977; 
Weinstein et al. 1979).  Liposomes were subsequently applied to topical drug administration 
(Mezei and Gulasekharam 1980).  Early reports concluded that the liposomal “capsule” was 
able to penetrate and cross biological membranes with some selectivity (Mezei and 
Gulasekharam 1980); however this was later shown not to be the case in intact skin (Schreier 
and Bouwstra 1994; Touitou et al. 1994).  Most reports cite a localising effect whereby the 
vesicles accumulated drugs in the SC or upper skin layers (Mezei and Gulasekharam 1980; 
Touitou et al. 1994).  This effect is not entirely redundant however, as these systems may be 
used to build up a drug reservoir within the skin.  
 
1.4.2 Active methods 
To overcome the extraordinary barrier of the SC, several attempts have been made recently to 
develop novel strategies for delivering drugs across skin (Al-Qallaf and Das 2008).  Passive 
methods of skin delivery have shown a number of limitations and in particular permeation 
enhancement is only demonstrated for solutes with a MW of approximately 500 Da (Bos and 
Meinardi 2000).  This excludes many of the new large MW biopharmaceuticals, including 
peptides and proteins (Brown et al. 2006).  This has led to the development of alternative 
active techniques.  These methods of enhancement involve the use of an external energy 
source to act as a driving force and/or reduce the barrier nature of SC (Brown et al. 2006).   
 
1.4.2.1 Iontophoresis 
Iontophoresis involves the application of a low level electric current either directly to the skin 
or indirectly via the dosage form to enhance permeation of the topically applied therapeutic 
agent (Wang et al. 1993).  A small electrical current (usually <500 microamperes cm−2) is 
utilised to facilitate the transfer of charged drugs across skin.  Charged species are repelled 
into and through the skin as a result of an electrical potential across the membrane; the 
efficiency of this process is dependent on the polarity, valency and ionic mobility of the 
permeant as well as on the composition of the delivery formulation and the current profile.  
Typically, two electrolyte chambers containing electrodes (one of which contains the ionised 
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therapeutic molecule of similar polarity, i.e. cationic drug in anodal chamber) are placed on the 
skin surface and driven by a constant current source.  The magnitude of current determines 
the amount of charge generated in the circuit and, in turn, the number of ions transported 
across the skin.  This method ensures a controlled and efficient form of drug delivery as the 
amount of compound delivered is directly proportional to the quantity of charge passed (Naik 
et al. 2000).  Increase in drug permeation can be attributed to either one or a combination of 
the following mechanisms; electrorepulsion (for charged solutes), electroosmosis (for 
uncharged solutes) and electropertubation (for both charged and uncharged) (Brown et al. 
2006).  Iontophoretic systems have been approved mainly for administering drugs into the 
body for medical purposes and specialised uses such as diagnosis of medical conditions (e.g., 
cystic fibrosis) and glucose monitoring (Brown et al. 2006).  In respect to therapeutic 
macromolecules however, delivery by iontophoresis may be limited to proteins with a 
maximum MW of 10 - 15 kDa (Li et al. 2008).  These devices must also be designed to enhance 
patient compliance by utilising a patient-friendly, portable and efficient iontophoretic system 
(Brown et al. 2006).  Further, potential drawbacks to the technology have been noted.  For 
example, application of clinically acceptable currents, currently set at 0.5 mA cm−2 (Brown et 
al. 2008), have been shown to decrease skin electrical resistance possibly due to cell damage 
which is not fully reversible (Burnette and Ongpipattanakul 1988). 
  
1.4.2.2 Electroporation 
Electroporation involves the application of high voltage pulses to induce skin perturbation 
(Brown et al. 2006). It has been proposed that transient pores are generated during 
electroporation, which may account for the increase in skin permeability (Weaver et al. 1999).  
High voltages, typically greater than 100 volts, and short treatment durations (milliseconds) 
are most frequently employed in this technique.  Other electrical parameters that affect 
delivery include pulse properties such as waveform, rate, and number (Banga et al. 1999).  The 
technology has been used successfully to enhance the skin permeability of molecules with 
differing lipophilicity and size.  Model compounds delivered have ranged from relatively small 
molecules, such as calcein (CAL) (Prausnitz et al. 1993), to macromolecules with a MW up to 
40 kDa (Guy et al. 1987).  Enhanced delivery of naked DNA to the skin has been achieved in 
vivo in a hairless mouse model, with a 100 - fold stimulation of gene expression compared to 
that obtained by intradermal injection (Zhang et al. 2002).  However, in vivo studies have 
demonstrated adverse effects of the technique including erythema and oedema (Prausnitz et 
al. 1993) and stimulation of muscle contraction (Escobar-Chavez et al. 2009) which bring into 
question the long-term utility of the methodology.  
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1.4.2.3 Abrasion 
Abrasion techniques involve the direct removal or disruption of the upper layers of the skin to 
facilitate the permeation of topically applied medicaments.  The delivery potential of skin 
abrasion techniques are not restricted by the physicochemical properties of the drug (Brown 
et al. 2006) as the SC barrier is negated.  Previous work has illustrated that such methods 
enhance and control the delivery of hydrophilic permeants, for example vitamin C (Lee et al. 
2003), vaccines and biopharmaceuticals (Mikszta et al. 2002; Mikszta et al. 2003). 
 
1.4.2.4 Ultrasound 
Ultrasound is defined as any sound having a frequency greater than 16 kHz.  Passage of these 
waves through skin causes compression and expansion of water resulting in pressure 
variations.  Such variations can cause cavitation, fluid flow, mixing (which reduces the 
boundary layer thickness) and temperature elevation (Kost 1993).  For ultrasound drug 
delivery to be successful, the waves must act on the SC to facilitate the permeation of 
macromolecular substances (Amsden and Goosen 1995).  It has been found that a water-
soluble tracer was located within the hydrophilic portion of the lipid lamellae of the SC 
following ultrasound treatment (Bommannan et al. 1992a).  This suggests that the ultrasound 
facilitated pathway for water-soluble drugs is therefore via the extracellular route, although 
delivery via hair follicles and sweat ducts may also be important (Amsden and Goosen 1995).  
Ultrasound has been shown to increase permeation of a range of model medicaments 
including small MW salicylic acid (Bommannan et al. 1992b) and macromolecular insulin 
(Tachibana and Tachibana 1991).  However, again questions have arisen over the safety and 
reversibility of ultrasound delivery as it has been shown that high energy depositions over 
prolonged periods alter epidermal morphology (Bommannan et al. 1992a).  Further, due to the 
nature of the technique, collapse cavitation may occur as the ultrasonic intensity increases 
which can be damaging to cells and vesicles (May and Allen 2002).  Subsequently, this process 
leads to an intensity and exposure time dependent increase in body tissue temperature (Lavon 
and Kost 2004); constituting a further risk factor.                 
 
Numerous other methodologies have been explored to circumvent the human skin barrier.  
These include magnetophoresis (Murthy 1999), needless injection, which involves firing of 
drug particles across skin at supersonic speeds (Longbridge et al. 1998), laser treatment (Lee et 
al. 2003) and radio frequency thermal ablation (Sintov et al. 2003).  Workers have also 
examined combinations of active enhancement methods, for example iontophoresis and 
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microporation (Badkar and Banga 2002), and have shown that these approaches can be much 
more effective than either technique used alone (Brown et al. 2006).  However, it is apparent 
that each of these techniques suffers from limitations and to date there is not one fully 
optimised system for enhancing cutaneous drug delivery.       
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1.5 Microfabricated microneedles 
1.5.1 Definition 
The concept of a microneedle (MN) array was first proposed by Gerstel and Place in the 1970s 
(Gerstel and Place 1976).  Microneedles are perceived as a novel, hybrid cutaneous delivery 
approach aimed at achieving the delivery efficacy of hypodermic injections and the safety and 
patient compliance of the transdermal patch (Sullivan et al. 2008).  Microneedles have 
significant advantages over other enhancement strategies as they form microconduits, or 
channels, across the SC, see Figure 1.3.  Furthermore, they do not rely on application of a 
sophisticated external energy source or chemical manipulation to disrupt the skin barrier.   
 
Figure 1.3  Schematic view of human skin and microneedle array.   
Adapted from source (Lv et al. 2006).  
    
The sharp tips and short length of MNs reduce the probability of encountering a nerve, and 
hence they provide a minimally invasive means to transport molecules with various physical 
and chemical properties into the intradermal layer of skin (Wu et al. 2008).  Theoretically, 
delivering drug just under the SC causes no pain since the nerve endings appear deeper within 
the skin, Figure 1.3.  Furthermore, it is very effective for drug delivery as the presence of a 
large number of capillaries within the dermal layer helps efficient absorption of drugs into the 
vascular system (Lv et al. 2006).   
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1.5.2 Microneedle permutations 
1.5.2.1 Solid microneedles 
Leveraging techniques from the microelectronics industry, early MN arrays were typically 
fabricated from silicon (Henry et al. 1998; Ji et al. 2006; McAllister et al. 2003; Moon and Lee 
2005; Wilke et al. 2005; Wu et al. 2008) and metal (Gill and Prausnitz 2007; Li et al. 2010; 
Martanto et al. 2004).  Solid MNs have been shown to increase skin permeability by orders of 
magnitude for a diverse range of compounds.  One of the earliest reports of enhanced 
transdermal drug permeation following MN treatment was by Henry et al.  In this study 20 x 20 
conical silicon MN arrays, containing MNs with a length of 150 µm, were inserted into human 
epidermal membrane in vitro for 10 secs or 1 h.  Microneedle application was shown to 
increase permeability of a model permeant, CAL, by four orders of magnitude compared to 
untreated membrane.  Furthermore, it was found that enhanced permeability occurred 
rapidly, within 1 h, and was maintained for up to a period of 5 h (Henry et al. 1998).  Additional 
studies conducted utilising the same silicon MN arrays were conducted by McAllister et al.  In 
an analogous set up, permeation of model medicaments across human epidermal membrane 
were investigated.  In these studies silicon MNs were inserted and maintained in situ.  This was 
shown to increase permeability to a wide range of molecules including CAL, insulin and Texas-
red labelled bovine serum albumin (BSA) by orders of magnitude.  In addition, it was found 
that MN insertion and removal increased permeation by a further order of magnitude for all 
compounds and facilitated delivery of nanoparticles with a diameter of up to 50 nm (McAllister 
et al. 2003).  Additionally, frustum tipped pyramidal silicon MNs with a length of 280 µm have 
been shown to facilitate diffusion of nanoparticles with a diameter of up to 150 µm across 
human epidermal membrane (Coulman et al. 2009).    
 
Furthermore, in vivo studies have shown transdermal delivery of insulin to diabetic rats using 2 
dimensional, tapered stainless steel MNs measuring 1000 µm.  Due to the length of these 
needles, and application utilising a pneumatic insertion device, they penetrated deep into the 
dermal layer (Martanto et al. 2004).  Once inserted, a glass chamber was fixed in place around 
the MN array and a commercially available solution of human insulin was placed into the 
chamber.  Following defined time periods, MN arrays were removed from the skin and the 
insulin solution remained in contact with the skin for 4 h (Martanto et al. 2004).  In a manner 
analogous to subcutaneous injection, MN insertion for 10 mins facilitated decreases in blood 
glucose levels up to 80 % over 8 h, with no apparent lag time, following cutaneous insulin 
application (Martanto et al. 2004).  Additionally, it was found that a single, short MN 
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application (10 secs) produced the greatest decrease in blood glucose (Martanto et al. 2004).  
Other groups have investigated stainless steel MNs for cutaneous macromolecule delivery.  For 
example, Lin et al. utilised MNs measuring 430 µm for the delivery of oligodeoxynucleotide 
(ODN) from an aqueous gel formulation (Lin et al. 2001).  Pre-treatment of hairless guinea-pigs 
with MNs, or application of integrated MN patches, with and without iontophoretic 
enhancement, permitted delivery of ODN over a 24 h period at therapeutically relevant rates 
(Lin et al. 2001).  Ding et al. investigated transcutaneous immunisation by application of 
diphtheria toxin and influenza subunit vaccines to the shaved abdomens of mice following MN 
application (Ding et al. 2009).  An initial prime dose was applied followed by two booster doses 
and blood samples were taken at each time point.  Antibodies generated to diphtheria toxin 
were shown to increase significantly following solid MN facilitated vaccine delivery (Ding et al. 
2009).  However, all these studies involved application of MN devices and the drug formulation 
in a multi-step process.  In a clinical setting, this may lead to complication for the end-user and 
result in variations in the dose administered.   
 
1.5.2.2 Coated microneedles 
An approach to achieve more integrated delivery of medicaments via solid MN structures is to 
coat the drug formulation onto the surface of needles (Cormier et al. 2004; Han et al. 2009; 
Kim et al. 2011; Matriano et al. 2002; Widera et al. 2006; Zhu et al. 2009).  This technique has 
been widely investigated for intradermal vaccination purposes, targeting immunocompetent 
cells within skin, such as Langerhans cells.  For example, Matriano et al. found that 330 µm 
long titanium MNs dry-film coated with ovalbumin (OVA) produced immune responses up to 
50 times greater than those observed following the same subcutaneous or intramuscular (IM) 
dose in a hairless guinea-pig model (Matriano et al. 2002).  In another approach, Yan Jin et al. 
fabricated biocompatible polycarbonate MN structures with a length of 500 µm onto which 
they smeared a solution of OVA in PBS.  These devices were applied to the shaven back areas 
of mice in a series of 3 injections and serum levels were found to be similar to conventional 
needle delivery following the third injection (Yan Jin et al. 2009).  More recently, Kim et al. 
found that inactivated influenza virus solution dip-coated onto solid metal MNs and air-dried 
elicited large immunogenic responses in mice (Kim et al. 2011).  Optimisation of the coating 
formulation for influenza virus was achieved using trehalose as an excipient.  Subsequently, 
the virus was shown to retain reasonable activity over a period of 1 month when dried onto 
MNs and retained the ability to elicit significant antibody titres in vivo (Kim et al. 2011).  
Coated MNs prepared in this manner have been shown to protect animals from subsequent 
lethal viral challenge (Kim et al. 2011; Zhu et al. 2009).  Additionally, coatings have been shown 
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to dissolve within minutes in situ (Zhu et al. 2009) to rapidly deliver drug into the skin.   The 
success of these devices has culminated in a Phase 2 clinical trial of a titanium MN patch 
coated with human parathyroid hormone analogue, teriparatide (TPTD), fabricated by Zosano 
Pharma for the treatment of osteoporosis in postmenopausal women (Cosman et al. 2010).  
Injectable TPTD is currently licensed for treatment of osteoporosis in the US, but its clinical 
efficacy is limited by practical factors (Fraenkel et al. 2006) such as poor adherence to daily 
subcutaneous injection (Cosman et al. 2010).  The patch in this study consisted of 1300 MNs 
with an average length of 190 µm coated with TPTD on their tips and an adhesive backing 
(Cosman et al. 2010).  165 postmenopausal women were enrolled and it was found that the 
MN patch significantly increased lumbar spine bone mineral density (BMD) at 6 months 
compared to placebo.  In addition, it was shown that the patch provided a significantly greater 
total hip BMD compared to both placebo and subcutaneous TPTD injection (Cosman et al. 
2010).  The only negative aspect of this study was the lack of blinding of participants using 
subcutaneous injection treatment (Cosman et al. 2010).                    
 
1.5.2.3 Hollow microneedles 
Hollow MNs fabricated from silicon (Stoeber and Liepmann 2000), glass (Martanto et al. 2006; 
McAllister et al. 2003; Wang et al. 2006) and metal (Davis et al. 2005) have allowed 
microinjection into skin through needle apertures.  Silicon MNs with a channel diameter of 
40 µm and a length of 200 µm have demonstrated fluid transport in vitro into chicken thigh 
(Stoeber and Liepmann 2000).  Furthermore, microinjection experiments were performed in 
diabetic, hairless rats whereby insulin solution was delivered by a single hollow glass MN to 
the dorsal skin.  In this study, MNs were applied to anaesthetised animals and penetrated to a 
depth of 500 – 800 µm using a circular drilling motion.  Up to 32 µL of drug solution was then 
injected into the skin under a pressure of 10 or 14 psi for 30 mins (McAllister et al. 2003).  
Decreases in blood glucose levels up to 70 % over a 5 h period suggested the efficacy of 
microinjection (McAllister et al. 2003).  Similar in vivo microinjection studies were performed 
utilising the same diabetic animal model and tapered, hollow nickel MN arrays (4 x 4 pattern) 
measuring 500 µm in length, with a bore of 75 µm (Davis et al. 2005).  This study showed a 
47 % reduction in blood glucose level over a 4 h delivery period which remained relatively 
stable for up to 4 h post-delivery (Davis et al. 2005).  More recently, Van Damme et al. 
conducted a clinical trial in 180 healthy volunteers utilising 450 µm long silicon MNs to 
investigate intradermal (ID) influenza vaccination (Van Damme et al. 2009).  This study found 
that there was no significant difference in geometric mean titre, a measure of humoral 
immune response to vaccine, between the full dose given intramuscularly compared to either 
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20 or 40 % of the dose given via ID MN injection (Van Damme et al. 2009).  Due to the nature 
of the ID injection process, local reactions at the injection site, such as swelling, were 
significantly greater than those in the IM injection group.  However, in both treatment groups 
these reactions were mild and generally transient (Van Damme et al. 2009).  Although “prick-
pain” was significantly lower in the MN treated groups, it was found that “administration-pain” 
was greater following MN injection.  Importantly it was found that the overall mean injection 
pain did not vary significantly between treatment groups (Van Damme et al. 2009).  Hence, this 
study suggested the utility and dose sparing capacity of vaccines administered intradermally 
via MN injection.            
 
1.5.2.4 Biodegradable microneedles 
Biodegradable MNs have emerged as an attractive alternative to solid MN arrays.  The term 
biodegradable has been used by convention to distinguish these MNs from the solid MN 
permutations discussed previously.  However, in the context of this work biodegradability is 
defined in terms of the ability of the MN material to dissolve or degrade in an aqueous, 
biological medium.  These MNs offer advantage over those made from other materials as they 
can be produced from biodegradable, biocompatible materials and because they can be 
formed by mould based fabrication methods that lend themselves to inexpensive and robust 
mass production (Park et al. 2005).  Furthermore, these MN devices provide the potential for 
incorporation of medicament within the matrix of the array, enabling increased drug loading 
and the opportunity for controlled release.  Due to the degradable nature of these devices, a 
further advantage is that no sharp MN residues are left following application (Sullivan et al. 
2010).  This property provides potential safety benefits over solid MNs and hypodermic 
needles, which may be re-used following administration, and therefore generate biohazardous 
waste.       
 
Initial studies involving biodegradable MNs were similar to those utilising solid MN arrays.  For 
example, Park et al. investigated the permeation of CAL or fluorescein-conjugated BSA in 
aqueous solution across human epidermal membrane in vitro.  Membranes were placed onto a 
tissue support and treated with solid bevelled-tip polyglycolic acid (PGA) MNs, measuring 
600 µm, prior to loading into Franz diffusion cells (Park et al. 2005).  In these studies it was 
found that PGA MNs, containing 20 or 100 needles, increased the permeation of both model 
compounds by a minimum of 2 orders of magnitude over 1 h (Park et al. 2005).  It was 
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perceived that solid MNs fabricated from a biodegradable material would provide a safer 
alternative to silicon or metal MNs if they were to break off and remain in situ.   
 
More recently, a similar approach has been utilised to assess the ability of 500 µm long 
maltose MNs to facilitate the delivery of a nicardipine hydrochloride (NH) across hairless rat 
skin.  Studies were conducted both in vitro, using full thickness rat skin, and in vivo whereby 
skin was pre-treated with maltose MN arrays, containing 27 needles.  Microneedle arrays were 
inserted and left in situ prior to application of a NH solution containing ethanol.  It was 
determined that the MNs would dissolve rapidly upon puncture of the SC, due to the high 
water content of the underlying epidermal tissue (Kolli and Banga 2008).  These MNs were 
shown to significantly increase transepidermal water loss (TEWL) following insertion and 
removal, analogous to hypodermic needle insertion (Kolli and Banga 2008).  Furthermore, a 
significant increase in NH flux in vitro and area under the curve in vivo was noted following 
maltose MN pre-treatment of skin (Kolli and Banga 2008).  In a subsequent study maltose MNs 
were shown to insert into rat skin in vitro and dissolve immediately.  It was found that the 
microchannels remained open for 24 h when covered with a drug solution however (Li et al. 
2009).  Microneedles measuring 500 µm were shown to significantly enhance the permeation 
of large molecular weight antibody, human immunoglobulin G, from aqueous solution by 
orders of magnitude (Li et al. 2009).  It was also observed that MNs with a length of 200 µm 
did not facilitate delivery to such an extent as 500 µm long needles, possibly due to ineffective 
skin penetration (Li et al. 2009).       
 
One of the first reports of model drug incorporation within the structure of a biodegradable 
MN device was by Miyano et al. whereby small molecules ascorbate-2-glucoside (ASG), sodium 
salicylate (SS) and CAL were mixed into the molten maltose candy prior to MN fabrication 
(Miyano et al. 2005).  Maltose MNs containing 5 %w/w ASG, measuring 500 µm in length, 
demonstrated sufficient structural rigidity to penetrate human skin in vivo and were left in situ 
to deliver drug to the deeper skin layers.  This process was not associated with any significant 
dermatological problems (Miyano et al. 2005).  More recently, Lee et al. fabricated maltose 
MNs containing ASG and niacinamide at concentrations of 1 % and 1.5 %w/w respectively.  In 
this method an elevated temperature was again required to dissolve the powders.  However, it 
was shown that the stability of both drugs was unaffected by the fabrication process and for 
up to 2 months storage (Lee et al. 2011b).  These MNs were robust enough to insert into 
guinea-pig skin in vivo to bring about a localised therapeutic effect (Lee et al. 2011b).  In a 
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separate study, Donnelly et al. added 5-aminolevulinic acid (5-ALA) and BSA powder to molten 
galactose before micromoulding (Donnelly et al. 2009a).  Here it was found that substantial 
losses of both 5-ALA and BSA occurred during the fabrication process.  This was attributed to a 
combination of chemical reaction with the disaccharide (Donnelly et al. 2009a) and direct 
degradation due to elevated processing temperatures (Ito et al. 2007).  Similar observations 
were made by Park et al. following fabrication of synthetic polymer MNs encapsulating CAL or 
BSA.  This process involved either direct encapsulation of drug within the polymer MNs, or 
prior encapsulation within carboxymethylcellulose (CMC) or poly-L-lactide for controlled 
release applications (Park et al. 2006).  The polymer MNs were fabricated from synthetic poly-
lactide-co-glycolide (PLGA), a polymer with a melting point of 135 ºC, and it was found that the 
duration of elevated temperature required to form these MNs caused a time-dependent 
denaturation of BSA protein (Park et al. 2006).   
 
An alternative methodology was proposed by Ito et al. whereby a hand drawing process was 
utilised to fabricate self-dissolving MNs from various dense glue solutions of chondroitin 
sulphate, dextrin and albumin containing erythropoietin hormone (EPO).  These MNs were 
dried under desiccation at low temperature and hence EPO, a biomolecule with a MW of 
34 kDa, was successfully incorporated and delivered in vivo (Ito et al. 2006).  The same workers 
later prepared 500 µm long conical MNs from dense drug glues containing insulin (Ito et al. 
2010), ascorbic acid (Ito Y. et al. 2010b) and EPO (Ito Y. et al. 2010a) by condensing solutions 
under vacuum pressure (Ito et al. 2010; Ito Y. et al. 2010b) or a nitrogen gas  stream (Ito Y. et 
al. 2010a) and dispensing the formulations into micromoulds.  These MNs were dried under 
the pressure of a steel plate without elevated temperature.  Furthermore, MNs containing 
recombinant human growth hormone (rhGH) or desmopressin (DDAVP) were fabricated from 
drug glues in a similar manner (Fukushima et al. 2011).  It was shown that all MNs in these 
investigations successfully penetrated in vivo rat skin to deliver incorporated medicaments to 
bring about a biological effect.  In a similar study, solid state biodegradable microstructures 
(SSBMS) measuring 200 µm were fabricated containing up to 10 %w/w FITC-BSA (66 kDa) and 
recombinant protective antigen (rPA; 83 kDa).  Solid state biodegradable microstructures were 
fabricated from a carbohydrate and polyvinyl alcohol (PVA) solution prepared by pressure 
micromoulding and drying at 32 ºC (Wendorf et al. 2011).  These SSBMS dissolved within 
minutes to successfully deliver FITC-BSA to human skin in vitro and elicited significantly 
enhanced immune responses to rPA compared to control following application to rats in vivo 
(Wendorf et al. 2011).   
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Further biodegradable MNs were fabricated from viscous hydrogel formulations of natural 
polymeric materials CMC, amylopectin and BSA.  Model drugs incorporated were 
sulforhodamine B (SRB), BSA and lysozyme added at various final weight concentrations up to 
30 %w/w (Lee et al. 2008).  This study showed that functional macromolecule, lysozyme, 
retained 96 % activity within MN structures following 2 months storage at room temperature 
(Lee et al. 2008).  Although these MNs appeared to demonstrate good stabilisation of 
incorporated protein, it is known that lysozyme is unusually stable (Prestrelski et al. 1993), and 
hence these findings may not be extrapolated to other macromolecular systems.  In another 
approach, 600 µm long CMC MNs were fabricated containing 5 %w/w rhGH utilising a relatively 
low-temperature centrifugation casting methodology (Lee et al. 2011a).  Incorporated 
hormone was stabilised by the addition of trehalose to the formulation and was shown to elicit 
a biological effect both in vitro and in vivo when administered to cell culture and hairless rat 
models respectively (Lee et al. 2011a).  In vivo, rhGH pharmacokinetics were shown to be 
similar to conventional subcutaneous injection and MN application was found to be well 
tolerated causing only slight, transient erythema (Lee et al. 2011a).  
                 
In an attempt to incorporate drug substances within rapidly dissolving biodegradable polymer 
MNs, polyvinylpyrrolidone (PVP) was utilised as a matrix substance.  Microneedles containing 
sulforhodamine, fluorescently labelled BSA and β-galactosidase (β-gal) were fabricated by a 
vacuum moulding and in situ photo-polymerization methodology (Sullivan et al. 2008).  These 
750 µm long MNs demonstrated effective delivery of BSA and functional β-gal to full thickness 
pig skin in vitro and were shown to preserve nearly 100 % β-gal activity following incorporation 
within PVP MN structures (Sullivan et al. 2008).  Furthermore, PVP MNs incorporating 
lyophilised inactivated influenza virus vaccine were shown to generate robust antibody and 
cellular immune responses in mice providing complete protection against subsequent lethal 
challenge.  Polyvinylpyrrolidone MN vaccination resulted in more efficient lung virus clearance 
and enhanced cellular recall responses compared to IM injection following viral challenge 
(Sullivan et al. 2010).  It was also found that cellular immune responses were superior 
following PVP MN vaccination compared to coated metal MN delivery (Sullivan et al. 2010).  
Additionally, the MNs were shown to almost completely dissolve within 5 mins in ex vivo pig 
skin and by 15 mins in vivo in mice (Sullivan et al. 2010).  Alternatively, Chu et al. investigated 
MN structures fabricated from blends of PVA and PVP containing SRB incorporated within the 
needles either in a gradient fashion or as a homogeneous mix throughout the matrix (Chu et al. 
2010).  Localisation of SRB within the needle tips facilitated approximately 80 % drug delivery 
within 10 mins in excised porcine skin, compared to 20 % with no localisation of drug (Chu et 
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al. 2010).  Alternatively, MNs were fabricated from Gantrez™AN-139 mucoadhesive copolymer 
containing 1 %w/w theophylline.  Drug-free MNs measuring 600 µm were shown to insert into 
human skin in vivo to a depth of approximately 460 µm (Donnelly et al. 2011).  Loading above 
1 %w/w had a highly plasticising effect on the polymer, making it unsuitable for MN fabrication 
(Donnelly et al. 2011).  These MNs were shown to deliver 83 % of incorporated drug cargo 
across neonatal porcine skin in vitro (Donnelly et al. 2011).  Further conical shape 600 µm long 
MNs were created from poly (methylvinylether maleic anhydride) containing insulin loaded at 
two different concentrations.  Loading of MNs at both concentrations did not adversely affect 
MN morphology or robustness and only slight losses of insulin were incurred during fabrication 
(Migalska et al. 2011).  In vitro analysis of insulin diffusion across dermatomed neonatal 
porcine skin demonstrated that only 40 – 55 % of the drug contained within the needles 
permeated the skin (Migalska et al. 2011), accounting for approximately 1 % of total drug 
loading.  However, the effectiveness of the MNs to deliver insulin in vivo in diabetic rats was 
confirmed by a dose-dependent decrease, up to 74 %, in blood glucose level (Migalska et al. 
2011). 
Chapter 1 
27 
A range of exemplar biodegradable MN structures are shown in Figure 1.4.  
(A) (B) (C)  
(D) (E) (F)  
(G)  (H)  
(I) (J) (K) 
Figure 1.4  Biodegradable microneedle permutations.   
(A) 600 µm bevelled-tip PGA MNs, (B) 1500 µm tapered-cone PGA MNs (Park et al. 2005), (C) 600 µm 
bevel-tip and (D) 750 µm tapered-cone PLGA MNs containing calcein in their tips (Park et al. 2006), (E) 
500 µm tetrahedron shaped maltose MNs next to a 26 G hypodermic needle (Kolli and Banga 2008), (F) 
500 µm pyramidal maltose MNs (Li et al. 2009), (G) 1200 µm tapered conical maltose MNs encapsulating 
sulforhodamine B (Lee et al. 2011b), (H) 270 µm pyramidal galactose MNs (Donnelly et al. 2009a), (I) 
600 µm pyramidal carboxymethylcellulose MNs (Lee et al. 2008), (J) 750 µm conical polyvinyl 
pyrrolidone MNs encapsulating sulforhodamine (Sullivan et al. 2008) and (K) 500 µm conical 
chrondroitin sulfate MNs partially loaded with Evans blue dye and insulin (Ito et al. 2010).  (Bar = 100 
µm).   
 
To date there have been many different approaches to MN fabrication and cutaneous drug 
delivery.  Currently, there does not appear to be one fully optimised system however, which 
will be discussed in the next section.                
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1.5.3 Advantages and limitations of microneedle technology       
The innovation of MN facilitated drug delivery offers the potential to overcome many of the 
issues surrounding the complex cutaneous delivery of therapeutic proteins and other 
hydrophilic molecules.  Microneedle devices have been fabricated from a variety of materials 
and have demonstrated the ability to facilitate enhanced delivery of a diverse range of 
different compounds across skin.  Furthermore, dose sparing biological responses have been 
noted for specific medicaments, for example intradermal vaccine delivery (Van Damme et al. 
2009).  Notably, there are now many reports of stable molecule and biomolecule incorporation 
within biodegradable MN structures which have been fabricated from a wide range of both 
natural and synthetic materials.  It is perceived that this MN design in particular offers a 
number of additional advantages.  Firstly, they tend to be formed by mould based fabrication 
methods which facilitate a low unit cost.  As a corollary, biocompatible materials can be 
utilised which are degraded safely within the body.  These materials also permit drug loading 
within the device matrix, potentially facilitating increased loading and stabilisation of labile 
medicaments.  In addition, this approach lends itself to providing controlled drug release 
through variations in material composition and drug encapsulation prior to incorporation 
within the MN structure (Park et al. 2006).  Furthermore, dissolving MNs offer an attractive 
method of delivery as they can be designed to degrade in situ and therefore do not leave 
behind sharp or hazardous waste structures.  This reduces the potential for subsequent needle 
re-use or needle-stick injuries from contaminated needles to occur (Haq et al. 2009).       
 
From a clinical, patient focused perspective, it has been shown that MNs circumvent many of 
the issues surrounding hypodermic needle delivery of medicines (Bal et al. 2008; Haq et al. 
2009).  Although effective, drug delivery via hypodermic needles has a number of potential 
drawbacks such as causing pain and apprehension for the patient (Kleinknecht 1994; Öst 1992) 
and the requirement of medically trained personnel to deliver the dose (Davis et al. 2004).  In 
addition, it has been shown that hypodermic needle puncture of model membranes in vitro 
results in significantly greater microbial penetration compared to MN penetration (Donnelly et 
al. 2009b).  Furthermore, MN insertion in vivo in humans appears to be generally well 
tolerated without causing any significant adverse effects (Van Damme et al. 2009).  Hence, it is 
envisaged that ultimately patients will be able to safely use MN devices in their own homes 
and will not have to rely on visits to hospital and GP surgeries for injections.   
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There are however a number of potential issues over the use of MN devices.  Early solid MN 
fabrication methods were often time consuming and expensive due to reliance on multi-step, 
cleanroom-intensive processes (Park et al. 2005) using complex dry and wet etch technologies.  
Also, if silicon or metal needles were to break off in skin, this could result in possible 
complications (Kolli and Banga 2008).  Furthermore, solid MN devices have relied upon multi-
step application processes where the drug formulation and MN device are applied separately.  
This process is undesirable as it makes drug delivery more complex and provides a greater 
chance for dosing errors to occur.  Coated MNs offer the advantage of application of both the 
dosage formulation and the MN device in the same process.  However, due to the relatively 
small surface area of MN arrays, total drug loading is limited to doses in the microgram range 
(Zhu et al. 2009) that tend to be delivered in one bolus dose.  Furthermore, there is the 
potential for a huge loss of coated material upon MN insertion (Cormier et al. 2004; Yan Jin et 
al. 2009), resulting in wastage of drug formulation.  To overcome these issues, biodegradable 
MNs have been fabricated as a safer alternative to solid MNs.  However, the methodologies 
utilised for creating these devices have often involved melting of materials at high 
temperature to micromould structures (Miyano et al. 2005; Park et al. 2005).  This has made 
incorporation of labile biological molecules within MN structures unfavourable in some 
instances (Donnelly et al. 2009a; Park et al. 2006).  From a practical perspective, it will also be 
critical to evaluate microchannel duration in skin tissue in vivo to determine channel closure 
kinetics and hence stability of dose delivery.  Reports generally suggest that channels close 
within 24 h following MN puncture (Fukushima et al. 2011; Haq et al. 2009) although it has 
been shown that channels will close more rapidly, unless occlusion or some other technique is 
employed to prolong channel opening (Banks et al. 2011; Kalluri and Banga 2011).  This is a 
particularly pertinent issue for controlled release from dissolving MN devices aimed at 
providing prolonged drug release.     
 
The focus of this project is to investigate the fabrication of biodegradable MN structures at low 
processing temperature for stable molecule incorporation.  Sugars have been investigated by a 
number of researchers and present a potentially attractive material for biodegradable MN 
manufacture.  Sugar glasses are characterised as an amorphous form of the material and are 
extensively utilised in nature to protect delicate biological structures (Potts 1994) during 
periods of water stress.  Sugar glasses can be formed via a number of different methodologies, 
including techniques involving low temperature processes.  Therefore these materials were 
selected as an attractive substrate for biodegradable MN fabrication.    
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1.6 Molecular glasses 
1.6.1 Definition 
The term glass is usually taken to encompass, “a wide range of inorganic substances which 
differ widely in chemical composition and physical properties, but which possess the essential 
characteristic of having been cooled from a state of fusion to become a solid without 
crystallisation.  Glass at room temperature can be regarded as a liquid, which is of such a high 
viscosity that it behaves as a rigid elastic solid” (Franks 2003).  It has been proposed however 
that this definition is too restrictive, and other authors have provided much broader 
definitions.  A more encompassing interpretation of a glass is an amorphous solid in which the 
molecules form a “non-periodic and non-symmetric network.”  Theoretically, the molecular 
mobility within these glassy state systems is many orders of magnitude lower than in liquid 
systems (Elliott 1990).  Glasses are formed by rubber to glass transitions that can be generated 
by any cooling or drying processes applied to many amorphous compounds (van den Berg et 
al. 1995).  The glass transition in amorphous systems is a temperature-, time- (or frequency), 
and composition-dependent, material-specific change in physical state, from a "glassy" 
mechanical solid to a "rubbery" viscous fluid.  In terms of thermodynamics, the glass transition 
is operationally defined as a second order transition (Slade and Levine 1988).   
 
In the past, the study of glasses has almost entirely been dominated by materials scientists.  
Hence, the considerable progress in development of novel materials has generally been 
confined to glasses based on metals, silicates, oxides, ceramics and polymers.  The realisation 
that amorphous solids in general, and glasses in particular, also play an interesting and 
important role in technologies not necessarily related to materials science came relatively late 
(Franks 2003).  However, it was quickly realised that glass formation had wide and varying 
applications, particularly in the biological and pharmaceutical sciences.  This is particularly true 
in the study of freeze-drying formulation, and subsequent product storage, where it is now 
well known that amorphous sugars can stabilise biological molecules such as proteins (Schebor 
et al. 1997; Uritani et al. 1995), liposomes and lipoplexes (Crowe et al. 1985; Hincha et al. 
2002), and even viruses (Bieganski et al. 1998; Levy and Fieldsteel 1982).  Figure 1.5 shows the 
structure of a sucrose glass formed by freeze-drying.  
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Figure 1.5  Scanning electron micrograph of a freeze concentrated aqueous sucrose solution after the 
sublimation of ice during freeze-drying.   
The cavities denote spaces previously occupied by ice crystals.  The filaments represent the glassy 
sucrose containing dissolved residual water (Franks 2003). 
 
1.6.2 Natural role of sugar glasses and the glass transition temperature 
Glass forming sugars have great significance in nature as they are used to protect biological 
tissues in the dehydrated state (Potts 1994).  It has generally been accepted that cells 
containing sugar usually form a glassy state of sugars under extreme conditions (Seo et al. 
2006).  Carbohydrates play an important role in the stabilisation of biological components 
under water stress, which can be produced by either freezing or drying samples.  Proteins and 
tissues mainly become damaged under such conditions due to the generation of large salt 
concentration gradients (Grigera and Bolzicco 2008).  Although it is not known precisely how 
this method of protection is afforded by carbohydrates, it has been reported that the glass 
transition temperature (Tg) of sugars and sugar-containing materials may be linked to their cell 
protection abilities (Buitink et al. 2000). 
     
It was discovered that carbohydrate glass plays a central role in anhydrobiosis many decades 
ago (Carpenter et al. 1987a).  Anhydrobiosis is defined as the capability of an organism to 
survive essentially complete dehydration, commonly when over 99 % of its body water is 
removed, which results in dry but viable tissues containing as little as 0.1 % water.  The dry 
organism may remain in this unique living state for decades, or perhaps even centuries under 
favourable conditions.  When water becomes available once more, the organism rapidly swells 
and resumes active life (Crowe et al. 1992).  It has been suggested that the ability of 
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anhydrobiotic organisms and plants to survive extreme dehydration is largely due to their 
ability to synthesize high concentrations of disaccharides.  These sugars, for example sucrose 
or trehalose, serve to protect sensitive biological structures, for example, proteins, 
membranes, or even whole cells in vitro (Guo et al. 2000; Leslie et al. 1995) via a synergistic 
mechanism involving direct interactions with biomolecules and glass formation (Buitink and 
Leprince 2004; Crowe et al. 1998).  Intrinsic characteristics of a hydrophilic glass that are 
important to protein stabilisation appear to include its amorphous nature and retarded 
dynamics of the protein, relative to physiological conditions, within the matrix (Cicerone and 
Soles 2004).  The amorphous sugar appears to replace water molecules which surround the 
protein in the physiological state.  Subsequently, this process seems to cause stabilisation of 
the native structure of the protein in the dehydrated state (Allison et al. 1999).  It has been 
found that intimate contact is necessary for effective hydrogen bonding to occur, and this is 
only made possible by the amorphous nature of the glass (Cicerone and Soles 2004).   It seems 
likely that spatial constraints imposed by the crystalline phase do not allow this, as evidenced 
by the observation that proteins are not stabilised in the crystalline phase of an otherwise 
effective preservant (Izutsu et al. 1994). 
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1.6.3 Material properties of vitrified glasses 
Glasses formed by the rapid cooling of a melt are thermodynamically unstable systems in a 
higher energy state relative to both the crystalline state and the meta-stable supercooled 
liquid state, (Zhou et al. 2007).  This is represented diagrammatically in Figure 1.6.   
   
Figure 1.6  Phase diagram of an amorphous phase showing glass annealed at Ta for duration t.   
Tm and Tg are the melting and glass transition temperatures, respectively.  Sc and Hc are configurational 
entropy and enthalpy, respectively.  ΔH is the enthalpy lost during annealing and the dotted line 
represents the meta-stable supercooled liquid state.  Adapted from source (Zhou et al. 2007). 
 
The meta-stable nature of amorphous solids means that they often exhibit decreased physical 
and chemical stability (Aso et al. 2001; Pikal et al. 1978) due to their higher free energy, 
enthalpy and entropy (Zhou et al. 2007) in comparison to the crystalline state.  In general 
molecular mobility has been discussed as a critical factor for dictating physical stability of 
amorphous substances (Hancock et al. 1995), but it is not the sole predictor (Zhou et al. 2007).  
Therefore, it is still relatively difficult to predict the stability of amorphous dosage forms 
compared to solutions (Zhou et al. 2007).  In many pharmaceutical systems a correlation has 
been demonstrated between molecular mobility and chemical stability (Shamblin et al. 2006), 
protein aggregation (Yoshioka et al. 2003) and crystallisation (Bhugra et al. 2006) in the 
amorphous state; although not all systems exhibit similar behaviour (Luthra et al. 2008).  Zhou 
et al. developed this further and stipulated that molecular mobility and also configurational 
entropy are important in determining the crystallisation tendency in the rubbery state (Zhou et 
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al. 2007).  Therefore, at temperatures above Tg, it has been postulated that crystallisation 
would be governed by (1) the configurational entropy, because this is a measure of the 
probability of molecules being in the appropriate conformation, and (2) mobility, because this 
is related to the number of collisions per unit time (Zhou et al. 2007).  Water can also affect 
the chemical stability of solid protein formulations, and it does this in at least three ways: (1) 
as a solvent, (2) as a reactant in a reaction such as hydrolysis, and/or (3) as a plasticising agent.  
Water acts as a plasticiser of amorphous solids inducing a physical transition from a brittle, 
dynamically constrained glassy state to a more mobile, rubbery state with decreased viscosity 
(Hageman 1992) and lowers Tg (Nowakowski and Hartel 2002; Roos and Karel 1991b).         
 
The stabilising effect of amorphous sugar glass has been explained by the formation of a sugar 
matrix which acts as a physical barrier between particles (particle isolation) (Allison et al. 2000) 
and strongly reduces diffusion and molecular mobility (vitrification) (Leopold et al. 1994).  Both 
the physical barrier and the lack of mobility provided by the glassy matrix, prevent aggregation 
and degradation of the dried material.  Under dry conditions, the glass is maintained as long as 
the temperature is kept below the characteristic Tg of the stabilising sugar used (de Jonge et 
al. 2007).  Vitrification at Tg effectively locks the liquid structure into an amorphous solid 
matrix due to the densification process which occurs during cooling or drying.  The rate of 
densification is related to the structural relaxation time of the material (Noel et al. 2005).  
When glass is stored below Tg, a non-equilibrium state exists, and this, coupled with mobility 
over a longer time scale, leads to the so-called “physical aging” phenomena.  Physical aging, or 
annealing, refers to structural relaxation of the non-equilibrium glass toward the meta-stable 
equilibrium or supercooled liquid state, that is the ideal glass, Figure 1.6 (Zhou et al. 2007).  
Physical aging relates also to a change in material properties including compliance, stiffness 
and brittleness (Struik 1978) which slowly evolve with time due to the densification process 
(Noel et al. 2005).  Above the Tg, the glass moves toward the rubber state, which has a higher 
degree of mobility (de Jonge et al. 2007), and hence proteins and other biological molecules 
begin to lose preservation of their native state within the glass.   If annealed properly, as the 
excess enthalpy and entropy of the non-equilibrium glass decrease, the molecular mobility 
within the glass should also decrease.  The rate and extent of this decrease may be important 
to chemical and physical stability within the glass (Zhou et al. 2007). 
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In nature the disaccharide trehalose is widely utilised in anhydrobiotic organisms and is 
generally thought of as having the best biopreservative abilities in vitro (Curtis et al. 2006).  
Trehalose, (α-D-glucopyranosyl-α-D-glucopyranoside) is shown in Figure 1.7. 
 
Figure 1.7  Molecular structure of trehalose.   
Trehalose is a non-reducing sugar as the two glucose subunits are joined through their anomeric 
centres.  Adapted from source (www.sigmaaldrich.com, accessed 03/10/2011).  
 
Trehalose is a non-reducing disaccharide whose glassy amorphous state can easily be 
produced by the rapid quench of its liquid phase and also by rapid dehydration of its dihydrate 
form (T2H2O) (Willart et al. 2001).  It has been suggested that unique preservative properties of 
amorphous trehalose include those that invoke either the inclusion (Belton and Gil 1994) or 
exclusion (Carpenter and Crowe 1989) of water from the surface of proteins, direct interaction 
of trehalose by adhering to the protein (Cordone et al. 1999), and intrinsic viscosity effects of 
the glass alone (Sampedro and Uribe 2004).  The uniquely high Tg of trehalose (Green and 
Angell 1989) has been ascribed to the latter mechanism of protection and therefore it is 
claimed to be responsible for the preservation of functional proteins in the glassy state (Curtis 
et al. 2006).  The inherently slow relaxation dynamics of the polyhydroxyl glass is expected to 
retard motions and reactions, both intrinsic and extrinsic to the protein that lead to degraded 
protein function (Cicerone and Soles 2004).   
 
Sucrose is a further glass forming disaccharide that is found widely in nature to protect 
biological entities.  For example, seeds commonly contain a large amount of sucrose, together 
with a high proportion of oligo- and poly-saccharides, a combination that has been found to 
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elevate the Tg and maintain seed viability for long-term storage (Koster and Leopold 1988).  
This property of sucrose has been realised for some time, and the disaccharide has been 
utilised more extensively in the pharmaceutical industry than trehalose, despite the Tg of 
trehalose being over 40 °C higher than that of sucrose (Green and Angell 1989).  The structure 
of sucrose (β-D-fructofuranosyl-α-D-glucopyranoside) is similar to trehalose, as shown in 
Figure 1.8.  Sucrose is a non-reducing sugar and consists of a molecule of glucose linked to a 
molecule of fructose.    
 
Figure 1.8  Molecular structure of sucrose.   
Adapted from source (www.sigmaaldrich.com, accessed 03/10/2011).  
 
The benefits of one of these excipients over the other appear to be equivocal, dependent upon 
the system under investigation.  For example, sucrose has been found to be more effective in 
preserving the native structure of lysozyme during lyophilisation (Allison et al. 1999) and 
freeze-dried monoclonal antibody stored at 5 °C (Duddu and DalMonte 1997), when compared 
to trehalose.  In addition, it has been demonstrated that carbohydrate glasses formed from 
combinations of sugars can effectively inhibit crystallisation of the material (Roos and Karel 
1991a).        
 
Subsequently, a strong focus of this work was to explore the material properties of both of 
these disaccharides and to determine their suitability for forming sugar glass microneedles 
(SGMNs).  It is envisaged that SGMN arrays containing an incorporated drug cargo may 
facilitate effective transdermal drug delivery. 
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1.7 Thesis aim and objectives 
Due to the unstable and delicate nature of biotechnology derived pharmaceuticals, such as 
proteins, peptides and nucleic acids, they present significant challenges for stable production 
and effective and reliable delivery (Brown et al. 2006).  These medicaments have typically been 
administered via hypodermic needle directly into the systemic circulation.  Although an 
effective means of delivery, this route presents a number of issues and is often not a preferred 
method of drug administration by patients (Öst 1992).  Due to their small size MNs offer the 
potential to alleviate the pain and blood vessel trauma associated with hypodermic needle 
insertion (Haq et al. 2009) and may address some of the current limitations and inadequacies 
in the delivery of many of the newer biologically active therapeutics on the market.   
 
To date, MNs have been formed from a variety of materials and a number of different 
permutations have been investigated for transdermal drug delivery applications.  To address 
limitations of early solid devices, MNs formed from biodegradable materials, whereby drug 
can be incorporated within the MN matrix, have emerged as an attractive alternative.  The aim 
of this approach is to stably incorporate medicaments within MN structures using materials 
and processes that do not adversely affect the drug cargo. 
 
Sugar glasses are amorphous forms of sugars which have been utilised widely in the 
pharmaceutical industry as excipients to aid in preservation of delicate macromolecules during 
preparation and storage (Schebor et al. 1997).  Furthermore, there are now many reports of 
biodegradable MN fabrication utilising carbohydrate substrates (Lee et al. 2008; Miyano et al. 
2005).  Therefore, it was hypothesised that sugar glass material presented an attractive 
substrate for biodegradable MN fabrication and incorporation of model therapeutic molecules 
for transdermal drug delivery.     
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1.7.1 Aim 
The aim of this thesis was to fabricate and characterise sugar glass material utilising low 
temperature processing and to investigate the feasibility of micromoulding biodegradable 
sugar glass microneedle devices.  The capability of these devices to incorporate a range of 
model substances, including macromolecules, and to deliver them across human skin in vitro 
was a key focus. 
 
1.7.2 Objectives 
1. Develop a low processing temperature methodology to form amorphous sugar glass 
materials. 
2. Characterise sugar glass materials using a range of different techniques, including thermal 
and x-ray analyses, to determine material properties. 
3. Quantitatively assess the stability of model macromolecule contained within sugar glass 
material. 
4. Investigate and optimise fabrication of biodegradable SGMN structures from sugar glasses 
utilising a micromoulding methodology. 
5. Investigate the capacity to incorporate a range of model substances with differing 
physicochemical properties within SGMNs. 
6. Qualitatively and quantitatively assess the ability of SGMNs to penetrate human skin 
barrier to deliver incorporated substances. 
7. Assess long-term stability of sugar glasses under different conditions to investigate 
optimal storage conditions for SGMNs. 
8. Quantitative assessment of in vitro drug delivery potential of SGMN arrays containing a 
small molecule across heat separated epidermal membrane. 
9. Quantitative assessment of in vitro drug delivery potential of SGMN arrays containing 
larger molecular weight moieties across heat separated epidermal membrane. 
10. Investigate in vitro drug delivery potential of integrated SGMN array transdermal patches 
containing model drug substance across heat separated epidermal membrane. 
11. Assess dissolution of SGMN arrays in situ in full thickness human skin in vitro. 
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2 Characterisation of sugar glasses 
2.1 Introduction 
In the past, a number of different methods have been investigated to form amorphous sugar 
glass (SG) materials.  Classically, glasses are prepared by the rapid cooling of a melt, which 
bypasses crystallisation (Willart and Descamps 2008).  Below the melting temperature (Tm) the 
liquid becomes metastable and the chance of forming a glass strongly depends upon the 
persistence of the metastable liquid during the quenching process (El Adib et al. 1989).  This is 
shown schematically in Figure 2.1 where the time taken for a given amount of crystalline phase 
to evolve is plotted as a function of temperature for a typical undercooled melt system (Willart 
and Descamps 2008).     
 
Figure 2.1  Schematic time-temperature transformation diagram for crystallisation during 
conventional vitrification.   
(Tg = glass transition temperature, Tm = melting temperature).  Adapted from source (Willart and 
Descamps 2008).   
 
At the glass transition temperature (Tg) the liquid falls out of equilibrium, which is denoted 
during differential scanning calorimetry as a fall in heat capacity during the scan (Willart and 
Descamps 2008).  The random disordered state of the liquid phase is frozen within the glassy 
matrix, at least to a great extent, and the atoms within the glass vibrate about these new 
frozen points.  Hence, a characteristic of glassy phases is an absence of any identifiable 
structural pattern detectable by X-ray scattering (Willart and Descamps 2008).  This 
conventional route to glass formation is demonstrated by pathway (1) in Figure 2.2.  During 
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formation, the glass is trapped within a local minimum of the potential energy landscape 
distribution whose arrangement subsequently dictates the structure of the amorphous phase.  
Therefore, the physical state of the glass may vary with the history of the sample, such as 
preparation process and subsequent aging.  For example, annealing a glass below its Tg or 
modifying the cooling rate will affect the relaxation times within the system and have a strong 
impact on stabilisation capabilities (Willart and Descamps 2008). 
 
As stated, a glass can be regarded as a liquid which is of such a high viscosity that it has the 
properties of a rigid elastic solid material (Franks 2003).  The viscosity of such liquids in their 
glassy state is usually determined as 1013 poises (Kauzmann 1948).  Importantly in the context 
of this work, it has been shown that this state may be achieved via a number of alternative 
techniques to the quench of the melt method.  Other methods include spray-drying, 
lyophilisation and direct milling of solid crystal, as shown in Figure 2.2 pathway (2) (Willart and 
Descamps 2008).  However, regardless of formation technique, as the Gibbs energy diagram in 
Figure 2.2 shows, glassy systems tend to have greater free energy in relation to crystal and 
liquid (stable and undercooled) states, and hence demonstrate reduced physical stability 
(Willart and Descamps 2008). 
 
Figure 2.2  Gibbs free enthalpy curve for crystal, liquid and glass.   
Paths (1) and (2) correspond to conventional and solid state vitrification pathways respectively.  
Adapted from source (Willart and Descamps 2008).   
As Figure 2.2 shows, the amorphous product is in a higher energy state relative to the 
metastable supercooled liquid state.  Therefore, under usual conditions, the glassy form of a 
material is more soluble than any crystalline form of the same compound at a given 
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temperature.  Hence, solid compounds may either be crystalline or glassy with each state 
possessing differing consequential properties (Shamblin et al. 2000), such as reactivity (Liu et 
al. 2002), solubility, hygroscopicity, and mechanical properties (Noel et al. 2005).     
 
As stated previously, glasses can be formed by rubber to glass transitions generated by any 
cooling or drying processes applied to many amorphous compounds (van den Berg et al. 1995).  
Polyhydroxyl compounds, such as sugars, generally fulfil the requirements of very slow 
crystallisation combined with a specific rheology and chemistry.  As water is removed from a 
dilute solution of the sugar, the viscosity of the resulting supersaturated residue increases 
towards the critical 1012 - 1014 Pa·s required for vitrification.  However, the vitrified solid may 
still contain up to 50 %w/w water in this state and this depends upon the dehydration method 
and chemical properties of the solute under investigation (Franks 1997).  Figure 2.3 
demonstrates a variety of different methods for the preparation of amorphous pharmaceutical 
systems (Surana et al. 2004).     
 
Figure 2.3  Some common methods of inducing amorphous character in pharmaceutical systems.   
Adapted from source (Surana et al. 2004).  
  
As Figure 2.3 shows, there are many different routes to the formation of an amorphous solid.  
The common feature of all these routes is that they form a disordered solid state (Surana et al. 
2004).  However, it has frequently been reported that there is a local or short-range order 
within the material, despite the absence of long-range crystalline order (Shalaev and Zografi 
2002).  It has been proposed that the method of production of the amorphous material is one 
of the most important determinants of the order within the structure (Surana et al. 2004) and 
hence the tendency for nucleation and crystal growth (Shalaev and Zografi 2002).         
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An aim of this current work was to form amorphous sugar materials without using excessive 
temperature or mechanical force.  This dictated that a mild processing methodology should be 
used to form a glassy sugar system.  Therefore, the most attractive route to the production of 
an amorphous sugar was via dehydration of a sugar solution.  However, in amorphous systems 
both the surrounding temperature and the substance determine the rate of spontaneous 
crystallisation.  Crystallisation is governed by two independent steps: firstly nuclei must form 
and then these nuclei must grow to form crystals (Kauzmann 1948).  It has been shown that 
slow dehydration of pure sugar solutions at low or ambient temperatures often promotes 
nucleation and crystallisation (Wright et al. 2002).  To circumvent this problem, workers have 
reported that slow evaporation of 1/1 mixtures of trehalose and sucrose sugar solutions at low 
or ambient temperatures appear to result in the formation of a sugar glass (Wright et al. 2002; 
Wright et al. 2003).  This approach was an appealing way to attempt production of solid sugar 
glasses for micromoulding into the geometry of a biodegradable microneedle array.            
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2.2 Chapter objectives 
1. Explore and optimise formation of amorphous sugar glasses via a low temperature 
dehydration technique. 
2. Screen dehydration properties of a number of individual sugar and binary sugar 
combination solutions for reliable sugar glass formation. 
3. Explore the residual water content of sugar glasses formed. 
4. Characterise dehydrated sugar products using a number of different techniques 
including visual, microscopic, thermal and X-ray based analyses.  
5. Determine optimal sugar glass forming material for biodegradable microneedle 
fabrication. 
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2.3 Materials and methods  
2.3.1 Materials 
All reagents were obtained from Fisher Scientific Ltd. (Loughborough, UK) and were of 
analytical grade unless stated otherwise. 
 
2.3.2 Methods 
2.3.2.1 Preparation of sugar glasses 
Dehydrated sugar formulations were prepared using trehalose anhydrous (TRA) (30987-0250, 
99 %, varied batches), trehalose dihydrate (TRD) (18255-0250, 99 % min., A0251934), sucrose 
(SUC) (17714-0010, 99.7 %, A0240570), maltose monohydrate (MAL) (M/1450/48, >90 %, 
0600669), mannitol (MAN) (M/2405/53, 99+ %, A0242017) and xylitol (XYL) (22598-0250, 
99+ %, A0264195).  Briefly, 400 mg of sugar (either individual sugars or binary mixtures of 25, 
50 and 75 %w/w) was dissolved in 2 mL of deionised water yielding a 16.7 %
w/v solution.  Each 
solution was introduced into a 100 mL beaker and allowed to dehydrate in a fume cupboard, 
flow rate 0.53 m/s, at room temperature for 24 h followed by 24 h at 50 °C (Fraenkel et al. 
2006).  Sugar glasses were examined visually and photographed using a digital camera, (Nikon, 
Coolpix 5600, Japan), to confirm whether a uniform glass had been created.   
 
2.3.2.2 Determination of residual water content of sugar glasses 
Three sugar solutions, (TRA/SUC 75:25 %w/w, TRD/SUC 75:25 %
w/w, MAL/TRA 75:25 %
w/w) were 
formed as in section 2.3.2.1 and dehydrated for 24 h in a fume cupboard at room temperature 
followed by 24 h at either 50 or 60 °C.  Changes in sample weight were recorded to determine 
water loss during dehydration.  Following the initial 48 h of drying, samples were maintained 
at 50 or 60 °C until no further weight change was recorded.  Once dehydrated to dry weight, 
samples were placed under ambient conditions and stored up to 360 h (Fraenkel et al. 2006).  
 
2.3.2.3 Preparation and scanning electron microscopy of sugar glass films 
Polydimethylsiloxane (PDMS) pre-polymer, in the form of Sylgard® 184 silicone encapsulant (R 
W Greeff, Glasgow, UK), and curing agent were combined in a 10:1 ratio, mixed and degassed 
for 30 mins under 900 mBar vacuum at room temperature (RT).  A PDMS mould of a glass slide 
was prepared by covering the slide with PDMS solution, degassing under vacuum (RT 30 mins 
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900 mBar), and curing at 100 °C for 1 h.  This formed a PDMS well of approximately 1 x 25 x 
75 mm into which sugar solutions were pipetted and dehydrated for 48 h to form sheets of 
sugar glass.  Samples were stored under vacuum in a desiccation chamber before analysis.  The 
samples were manually sectioned transversely and sputter coated with gold prior to 
visualisation using scanning electron microscopy (SEM; Philips XL-20, Philips, Eindhoven, The 
Netherlands) (Fraenkel et al. 2006).  
 
2.3.2.4 Thermal characterisation of sugars 
Unprocessed sugars and solid sugar films of 100 % TRA, 100 % SUC and TRA/SUC 75:25 %w/w 
(prepared as described in section 2.3.2.3) were analysed by differential scanning calorimetry 
(DSC; Perkin-Elmer Series 7).  Samples (approximately 10 mg) in crimped aluminium pans were 
heated between 20 and 220 °C at a rate of 10 °C min-1.  Samples of 5 mg were further analysed 
by thermogravimetric analysis (TGA; Perkin-Elmer Series 7) in a platinum pan between 20 and 
220 °C at a heating rate of 10 °C min-1 (Fraenkel et al. 2006).  The content of water within each 
sample was inferred by measuring the percentage weight loss of the sample at the end of the 
heating sequence.     
 
2.3.2.5 Powdered X-ray diffraction analysis of sugars 
Sugar films were prepared, as described in section 2.3.2.3 and stored in sealed centrifuge 
tubes under desiccation until analysis.  Samples were ground using a pestle and mortar to 
produce a powder and mounted into a sample cell.  The sample cell was placed inside the 
vacuum chamber of a Nanostar™ (Bruker AXS, Germany) and an X-ray beam was produced by 
a Kristalloflex 760 X-ray generator (Bruker AXS, Germany).  The beam was focussed using two 
cross-coupled Göbel mirrors and then reduced in size via a series of three pinholes to produce 
an X-ray beam of 0.4 x 0.8 mm, with a wavelength of 0.154 nm.  Each sample was analysed at 
two different sample to detector path lengths, 4 and 22 cm, and the main X-ray beam was 
passed through each sample cell for 6 h.  The X-ray scatter pattern from the sample was 
collected using a HiStar gas filled detector and an air background image was also collected. 
 
2.3.2.6 Single crystal X-ray diffraction analysis of sugars 
Unprocessed sugars and solid sugar films of 100 % TRA, 100 % SUC and TRA/SUC 75:25 %w/w 
(prepared as described in section 2.3.2.3) and then filtered through a 0.2 μm filter, were 
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analysed by single crystal X-ray diffraction.  Unprocessed sugars were mounted onto wire 
loops and placed onto metal stubs for analysis.  Sections of sugar film were mounted directly 
onto the metal stubs using molten wax.  Data from the samples were measured on a Rigaku R-
Axis IV image plate mounted on a Rigaku Ru300 rotating anode generator (wide-focus, 50 kV, 
100 mA) using graphite-monochromated CuKα radiation (1.54 angstrom wavelength) with 
Osmic mirrors.  
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2.4 Results and discussion 
2.4.1 Sugar glass fabrication 
The formation of sugar glasses has been well described and there are a variety of methods for 
producing these materials.   A number of different methodologies were considered for 
amorphous sugar glass production, and various different methods were explored.  In the 
chosen method, a simple low temperature dehydration technique was utilised to form solid 
sugar glasses.  The rationale behind using this methodology, described in section 2.3.2.1, was 
that the amorphous material would be required to fill an inverse micromould.  Therefore, an 
amorphous sugar produced by an energetic process, for example crystalline melting or ball 
milling, would not be suitable for filling such a mould.  Creating a sugar solution and 
dehydrating it to create an amorphous glass, as described by Wright et al. (Wright et al. 2002), 
was seen as an attractive option for filling these moulds. 
 
Solutions of individual sugars and sugar alcohols, and binary combinations of these, were 
dehydrated to determine those that formed solid sugar glasses and those that crystallised, as 
shown in Figure 2.4. 
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(A)  (B)  (C) 
(D)  (E)  (F) 
(G)  (H)  (I) 
(J)  (K)  (L) 
(M)  (N)  (O) 
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(P)  (Q)  (R) 
(S) 
Figure 2.4  Images of dehydrated solid sugar products.   
Macro photographic images of sugars following dehydration.  (A) D - trehalose anhydrous (TRA), (B) D 
(+) - trehalose dihydrate (TRD),  (C) D - mannitol (MAN), (D) D (+) - sucrose (SUC), (E) TRA/MAN 25:75 
%
w
/w, (F) TRA/MAN 50:50 %
w
/w, (G) TRA/MAN 75:25 %
w
/w, (H) TRD/MAN 25:75 %
w
/w, (I) TRD/MAN 50:50 
%w/w, (J) TRD/MAN 75:25 %
w/w, (K) TRA/SUC 25:75 %
w/w, (L) TRA/SUC 50:50 %
w/w, (M) TRA/SUC 75:25 
%w/w, (N) TRD/SUC 25:75 %
w/w, (O) TRD/SUC 50:50 %
w/w, (P) TRD/SUC 75:25 %
w/w, (Q) SUC/MAN 25:75 
%w/w, (R) SUC/MAN 50:50 %
w/w, (S) SUC/MAN 75:25 %
w/w. 
 
Each of the solutions containing single sugars crystallised upon dehydration, as shown in 
Figures 2.4 (A) – (D).  This was unsurprising given that crystallisation occurs when sugar 
solutions of pure sugars are evaporated slowly at low or ambient temperatures (Wright et al. 
2002).  Where a sugar combination consisted of two sugar molecules of approximately the 
same molecular weight however, for example two disaccharides, a stable solid sugar glass 
could be formed (Fraenkel et al. 2006) (see Appendix 2); TRA/SUC 75:25 %w/w, Figure 2.4 (M), 
TRD/SUC 75:25 %w/w, Figure 2.4 (P), and TRA/SUC 50:50 %
w/w, Figure 2.4 (L).  Similar 
observations have been noted by Wright et al. who reported that using a mixture of 
disaccharides circumvented crystallisation of sugar solutions during evaporation (Wright et al. 
2002; Wright et al. 2003).  It was speculated that sugar combinations containing molecules of 
different relative molecular size, for example a disaccharide and a hexose, such as TRA/MAN 
50:50 %w/w, Figure 2.4 (F), did not interact during dehydration and therefore co-crystallised 
(Fraenkel et al. 2006).  For example, mixtures containing disaccharides and sugar alcohols 
failed to form sugar glasses under the same processing conditions.  It was speculated that the 
low Tg of MAN and XYL, 303 and 247 K respectively, hindered the formation of a solid glass 
under these conditions (Fraenkel et al. 2006).  The Tg of these two sugar alcohols is close to 
ambient temperature and therefore sugar combinations containing these sugars will have 
lower Tgs (Willart et al. 2006) and hence are less likely to form a stable amorphous state under 
ambient conditions.    Further, sugar combinations containing xylitol, a pentose, did not form a 
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stable solid product by the end of the dehydration period.  This behaviour was attributed to 
the hygroscopic nature and extremely low Tg of xylitol making the glass unstable at room 
temperature and humidity (Fraenkel et al. 2006). 
 
As disaccharides appeared to be good candidates for amorphous glass formation, another 
disaccharide, maltose, was investigated.  Solutions of maltose, and combinations with other 
sugars, were dehydrated to observe the glass forming propensity of this sugar. 
 
(A)  (B) (C) (D) 
(E)  (F)  (G)  
(H)  (I)  (J)   
(K)  (L)  (M) 
Figure 2.5  Images of dehydrated solid sugar products.   
Macro photographic images of sugars following dehydration.  (A) D (+)- maltose (MAL), (B) MAL/TRD 
75:25 %w/w, (C) MAL/TRD 50:50 %
w/w, (D) MAL/TRD 25:75 %
w/w, (E) MAL/TRA 75:25 %
w/w, (F) MAL/TRA 
50:50 %w/w, (G) MAL/TRA 25:75 %
w/w, (H) MAL/SUC 75:25 %
w/w, (I) MAL/SUC 50:50 %
w/w, (J) MAL/SUC 
25:75 %w/w, (K) MAL/MAN 75:25 %
w/w, (L) MAL/MAN 50:50 %
w/w, (M) MAL/MAN 25:75 %
w/w.   
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As shown in Figure 2.5 (B) – (I), the majority of sugar combinations containing MAL, and even 
pure MAL, Figure 2.5 (A), appeared to form a solid amorphous product following dehydration.  
Once more, sugar combinations containing MAL and a sugar alcohol did not form a glassy 
product, Figure 2.5 (K) – (M).  This supported the data shown in Figure 2.4, and further 
suggested that only certain combinations of disaccharides would form amorphous phases 
following this method of sugar glass formation.   
 
2.4.2 Determination of residual water content of sugar glasses 
To maintain optimal functionality of macromolecular cargo contained within the matrix of a 
SG, processing temperatures should be kept low.  Prior to the formation of a vitrified glass, 
heat labile medicaments will not be adequately protected, which is particularly critical for 
many proteins whose functionality is dependent upon the working temperature that they are 
exposed to.  For example, enzymes will, at certain processing temperatures, denature and lose 
their three dimensional conformation and hence their functionality.  For example, β-
galactosidase has been shown to be stable up to 55 °C (Yoshioka et al. 2003) whilst it 
denatures at temperatures over 70 °C (Ladero et al. 2006; Yoshioka et al. 2003).  Therefore, it 
was hypothesised that such an enzyme would be more stable in a sugar glass formed at 50 °C 
rather than at 60 °C.   
 
As the water content of sugar glasses is a key parameter governing the structure and stability 
of the material, this study compared the residual quantity of water remaining within sugar 
glasses created at both 50 and 60 °C.   
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(A) 
(B) 
Figure 2.6  Analysis of water content in sugar solutions.   
Sugar solutions were dehydrated at ambient temperature for 24 h then at, (A) 60 °C until 144 h or (B) 50 
°C until 192 h.  After 144 or 192 h, solid sugar glasses were maintained under ambient conditions until 
288 or 356 h respectively.  Changes in sample weight upon dehydration and storage were used to 
determine water content.  Data presented as mean ± standard deviation (S.D.) (n=3). 
 
Figure 2.6 shows the change in water content of three different sugar solutions with 
dehydration time, at both 50 and 60 °C.  For all sugar solutions the majority of water loss 
occurred during the first 24 h.  A further 24 h of dehydration at elevated temperature removed 
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the remaining water to leave a solid glass.  This was the case for sugar solutions dehydrated at 
both 60 °C, Figure 2.6 (A), and 50 °C, Figure 2.6 (B).  However, the weight of all the sugar 
glasses decreased slightly between 48 and 192 h whilst maintained at 50 °C, Figure 2.6 (B). This 
was not observed to such an extent in the sugar glass solutions treated at 60 °C, where the 
minimum water content was achieved by 24 h in the heated oven, Figure 2.6 (A).  Following re-
introduction into ambient conditions, the weight of each of the sugar glasses increased 
marginally, returning to the levels observed at 48 h (Fraenkel et al. 2006). This was expected as 
sugar glasses have a hygroscopic nature (Dittmar 1935).      
 
It was deduced that any residual water remaining within the glass at this point must be 
intrinsically associated with the material and therefore not able to be removed.  Under both 
conditions explored, it was apparent that the TRA/SUC 75:25 %w/w sugar glass retained 
approximately 9 %w/w water in its structure at 48 h.   In comparison, the TRD/SUC 75:25 %
w/w 
and MAL/TRA 75:25 %w/w glasses both contained negligible quantities of water in the solid 
glass state.  It was speculated that the additional water retained in the TRA/SUC 75:25 %w/w 
sugar glass was due to the association of 2 moles of water to each TRA molecule to form the 
dihydrate sugar.  This weight increase was not observed in the TRD/SUC 75:25 %w/w glass as 
the trehalose molecule was fully hydrated before dissolution (Fraenkel et al. 2006). 
 
It was not obvious why the sugar solutions would behave differently during storage following 
production at either 50 or 60 °C.  One possible explanation could have been that the residual 
water content of the sugar glasses formed at 50 °C was marginally greater than the residual 
water content of the sugar glasses formed at 60 °C.  It is known that water can affect the 
stability of amorphous materials, for example, it has been shown to have a plasticising effect 
on glasses, (Lai et al. 1999).  Therefore, the increased quantity of water within each of the 
glasses formed at 50 °C could have increased the propensity of the glass to adsorb water 
following removal from the oven and subsequent storage under ambient conditions.  
Importantly, however, even though the water content was seen to increase in these glasses, 
the macroscopic structure of the glasses remained the same.  There was no obvious 
crystallisation of the sugars, or a change towards the rubbery state of the material, and so it 
was concluded that the two different production temperatures did not have a significant effect 
on the overall properties of the glasses formed.                  
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2.4.3 Scanning electron microscopy of sugar glass films 
To support the data obtained in Figures 2.4 and 2.5 the solid sugar products were further 
examined under SEM, Figure 2.7.   
(A)  (B) 
(C)        (D) 
(E)                  (F) 
Figure 2.7  Scanning electron micrographs of transverse sections of dehydrated sugar films.  
(A) 100 % TRA, (B) 100 % SUC, (C) 100 % TRD, (D) 100 % MAL, (E) TRA/SUC 75:25 %w/w, (F) TRD/SUC 
75:25 %w/w (Bar = 500 µm) (n = 1).   
 
The solid mass formed from dehydrated single sugars TRA, SUC and TRD suggested an ordered 
structure of crystalline nature when transversely sectioned, Figures 2.7 (A) – (C) (Fraenkel et al. 
2006).  In contrast, SEM images of solid sugar transverse sections formed from pure MAL and 
combination sugars TRA/SUC 75:25 %w/w and TRD/SUC 75:25 %
w/w, Figures 2.7 (D), (E) and (F) 
respectively, were shown to form a non-crystalline mass providing no evidence of order.  It 
was interesting to note that pure MAL, Figure 2.7 (D), appeared to have a structure more 
closely related to that of the combination sugars, Figure 2.7 (E) and (F), than the other single 
sugar samples.  This data supported earlier visual studies where pure MAL solution appeared 
to form an amorphous sugar glass following dehydration, Figure 2.5 (A), following dehydration.  
It was not obvious why pure MAL should behave in this way, but this data began to suggest a 
correlation between the visual appearance of a sugar product following dehydration, and its 
physical properties.  If a sugar product appeared to be glassy and transparent following 
dehydration, then under SEM the product looked distinctly different to a solid crystalline mass 
and hence this suggested an amorphous nature of the material.  However, what was not clear 
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was whether the materials formed by the sugar combinations and MAL were less ordered 
through their amorphous structure or were more prone to melting under the electron beam.  
Nevertheless, these data support the utility of this simple dehydration methodology to form 
sugar glasses from selected sugar solutions (Fraenkel et al. 2006). 
 
2.4.4 Thermal characterisation of sugars 
To probe the nature of pure sugar and promising sugar glass forming combinations, the 
materials were further analysed by differential scanning calorimetry (DSC) and 
thermogravimetric analysis (TGA).  The DSC scan of a pure TRA dehydrated film is 
characterised by two sharp endotherms with peaks at 101 and 214 °C with a third more poorly 
defined endothermic region between 130 and 150 °C, Figure 2.8 (A).  The weight loss profile 
with temperature (TGA) for the same material is superimposed in Figure 2.8 (A) and shows a 
total weight loss of approximately 10 %w/w over the heating range.  It was observed that the 
water loss was greatest over the temperature range 90 – 140 °C and hence the endothermic 
peaks observed over this range correspond to dehydration of the dihydrate crystal.  Once 
water was removed from the sample this left the anhydrous sugar which melted at 
approximately 214 °C, correlating with literature values for the melting point of the anhydrous 
trehalose crystal at 210.5 °C (Higashiyama 2002).   This suggested that the hydrated form of 
the sugar was formed during the process and that residual water remained within the glass 
following dehydration (Fraenkel et al. 2006).  We speculate that this residual water was bound 
to the trehalose molecule within the amorphous structure and hence would not be available 
for reaction.  This concept is supported by the work of Surana et al. where they suggest that 
amorphous trehalose prepared by dehydration may possess residual structural history of the 
hydrate from which it was formed (Surana et al. 2004).  
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 (A)   
(B) 
 (C)    (D) 
 (E)  (F) 
(G) 
Figure 2.8  Thermal characterisation of solid sugar films.   
DSC (solid line) and TGA (dashed line) profiles of unprocessed and dehydrated sugars. (A) 100 % TRA 
dehydrated sugar film, (B) 100 % SUC dehydrated sugar film, (C) unprocessed TRD, (D) unprocessed TRA, 
(E) TRA/SUC 75:25 % w/w, (F) TRD/SUC 75:25 % 
w/w, (G) TRA/SUC 75:25 % 
w/w (following 1 month 
desiccated storage) dehydrated sugar films. 
 
The profiles shown in Figure 2.8 (C) and (D) show the DSC and TGA scans of unprocessed TRD 
and TRA powder respectively.  Unprocessed TRA, Figure 2.8 (D), showed a distinctly different 
thermal profile to the dehydrated TRA film, Figure 2.8 (A), which showed only a single melting 
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endotherm at approximately 200 °C, corresponding to melting of the trehalose crystal.  As a 
corollary, no weight loss was observed through the temperature range, indicating that no 
water was present in the sample.  Unprocessed TRD, Figure 2.8 (C), however, displayed 
endothermic peaks and respective weight losses at approximately the same temperatures as 
the dehydrated TRA film, further indicating that TRD was formed following dehydration of 
aqueous TRA solution (Fraenkel et al. 2006; Surana et al. 2004).  The thermal profile of pure 
SUC dehydrated film, Figure 2.8 (B) suggested that no residual water content was contained 
within the structure.  This was demonstrated by the single endothermic peak observed at 
191 °C, attributed to melting of pure SUC crystal, and no evidence of weight loss by TGA 
(Fraenkel et al. 2006).  Figure 2.8 (E) shows DSC and TGA scans of TRA/SUC 75:25 %w/w 
dehydrated film.  This film appeared to have a more complex nature than the individual sugar 
films.  A sharp endothermic peak was observed at 97 °C, corresponding with the loss of water 
from the sample, but no other discrete thermal events were observed.  A poorly defined 
endothermic region was shown between 130 and 170 °C and a gradual weight loss of the 
sample was observed from approximately 80 to 220 °C.  The thermal behaviour of the 
TRD/SUC 75:25 %w/w dehydrated film, Figure 2.8 (F) was shown to be very similar to the 
TRA/SUC 75:25 %w/w dehydrated film, Figure 2.8 (E) (Fraenkel et al. 2006), supporting the 
similar apparent nature of the dehydrated products (see Appendix 2).  Although there was no 
evidence of a distinct endothermic step in the heat flow, indicative of a glass transition (Franks 
2003), as there were no obvious endothermic peaks at elevated temperatures, it was deduced 
that these samples were likely to be non-crystalline in nature.  In replicate samples, the 
endothermic peak at 97 °C was not always observed, Figure 2.8 (G), correlating with the 
duration of storage under desiccation following formation of the glass.  However, the key 
feature in all replicate samples was the absence of endothermic peaks at elevated 
temperature (Fraenkel et al. 2006). 
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2.4.5 Powdered X-ray diffraction analysis 
To explore the nature of dehydrated sugar glass films further, samples were analysed by 
powdered X-ray diffraction analysis, Figure 2.9.  In this analysis, samples that demonstrated 
areas of crystallinity showed distinct dark spots within the diffraction pattern, for example, 
Figure 2.9 (B).  As a camera length of 22 cm was used this method detected the presence of 
longer range order within the material, from 0.22 to 300 nm.       
(A) (B) (C)  
(D)    (E)     (F)   
Figure 2.9  Powdered X-ray diffraction analysis of dehydrated sugar films using a 22 cm camera.   
(A) 100 % TRA, (B) 100 % SUC, (C) 100 % TRD, (D) 100 % MAL, (E) TRA/SUC 75:25 % w/w, (F) TRD/SUC 
75:25 % w/w (n = 1).   
 
As shown in Figure 2.9 the pure sugar dehydrated films TRA and SUC appeared to show distinct 
areas of crystallinity in their structure, Figures 2.9 (A) and (B) respectively.  This supported 
previous findings suggesting that individual sugars formed solid crystalline masses following 
dehydration, Figures 2.4, 2.7 and 2.8.  However, in this study pure TRD dehydrated film, Figure 
2.9 (C), did not appear to demonstrate a crystalline nature.  This was in contrast to previous 
findings, Figures 2.4 (B) and 2.7 (C), which appeared to show that the TRD film had a crystal 
structure.   
 
In support of previous studies, the pure MAL dehydrated film, Figure 2.9 (D), appeared to have 
a non-crystalline nature, denoted by the absence of dark spots in the diffraction pattern.  This 
behaviour was partly observed within the TRA/SUC 75:25 %w/w and TRD/SUC 75:25 %
w/w 
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dehydrated films, Figures 2.9 (E) and (F) respectively, where a blank diffraction pattern was 
generally observed.  However, in both Figures 2.9 (E) and (F) there was evidence of some small 
dark spots within each diffraction pattern.  This suggested that these combination sugar films 
had some evidence of crystallinity within their structure.  In a similar manner to the pure TRD 
film, this result was in contrast to prior studies, Figures 2.4, 2.7 and 2.8.  Where dehydrated 
films formed from sugar combination solutions appeared to form an amorphous solid with no 
evidence of crystallinity. 
 
To investigate the short range order, up to 0.22 nm, within these materials they were viewed 
at a sample to camera length of 4 cm, Figure 2.10.  From these scatter patterns it appeared 
that over shorter ranges of measurement pure TRA, TRD and TRA/SUC 75:25 % w/w dehydrated 
films were X-ray amorphous, Figures 2.10 (A), (C) and (E) respectively.  In this analysis, it 
appeared once more that pure TRD film, Figure 2.10 (C), and in this case only pure TRA 
dehydrated film, Figure 2.10 (A), demonstrated an absence of crystallinity which was in 
contrast to previous findings.  Interestingly, the diffraction patterns of pure MAL and TRD/SUC 
75:25 %w/w dehydrated films suggested order within the material over a shorter range.  Once 
again this behaviour had not been indicated by previous studies conducted on these materials.              
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(A)  (B)  (C) 
(D)  (E)  (F)   
Figure 2.10  Powdered X-ray diffraction analysis of dehydrated sugar films using a 4 cm camera.   
(A) 100 % TRA, (B) 100 % SUC, (C) 100 % TRD, (D) 100 % MAL, (E) TRA/SUC 75:25 % w/w, (F) TRD/SUC 
75:25 % w/w (n = 1).   
 
As discovered during thermal analysis studies, it appeared that the nature of these dehydrated 
sugar materials was not straightforward.  As stated in section 2.1, both the formation 
methodology and subsequent storage conditions can affect the nature of amorphous materials 
(Willart and Descamps 2008).  Therefore, the contrasting data obtained in this study could be 
explained by a number of factors including the duration between sugar film formation and 
preparation of the sample for analysis.  Samples were sent away for analysis and storage 
instructions were given.  However, the exact conditions and duration of storage of these 
samples prior to analysis were unknown; hence this may have had an effect on the results 
obtained.  For example, if samples had been exposed to humid or elevated temperature 
storage conditions prior to analysis, this may have induced crystallinity within samples.  
Conversely, it is known that powdering or milling a sample can induce amorphous behaviour 
(Nagahama and Suga 2002) within a sample due to the shear forces involved.  This may have 
been a factor within the pure TRD sample, for example, where the sample appeared to be 
amorphous in these X-ray studies.       
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2.4.6 Single crystal X-ray diffraction analysis 
To develop and explore the powder X-ray diffraction analysis in section 2.4.5, samples were 
analysed by single crystal X-ray diffraction analysis.  In this methodology no powdering of the 
sample was required before analysis.  The diffraction patterns of various different sugars are 
shown in Figure 2.11.    
(A)     (B)   (C) 
(D)  (E) 
Figure 2.11  Single crystal X-ray diffraction analysis of sugar samples.   
(A) 100 % SUC dehydrated film, (B) 100 % SUC solution, (C) 100 % SUC powder, (D) TRA/SUC 75:25 % w/w 
dehydrated film (glass like part), (E) TRA/SUC 75:25 % w/w film (crystal part), (n = 1).  
  
As an altered method was used in this experiment, specifically the filtering of sugar solutions 
via a 0.2 µm filter before dehydration, it appeared that an amorphous pure sucrose material 
was produced, Figure 2.11 (A).  It was speculated that the filtering process removed any 
particulates that may have acted as nucleation agents for crystallisation.  This was confirmed 
by the control solution of pure SUC solution, Figure 2.11 (B), which showed a similar 
“amorphous” structure to the SUC dehydrated film.  In contrast, pure SUC powder, Figure 
2.11 (C), demonstrated a purely crystalline scattering pattern.  However, the diffraction 
pattern obtained from the TRA/SUC 75:25 %w/w sugar film showed two distinctly different 
profiles in this experiment.  From visual observations, it was noted that within this sugar film 
there were two distinct areas within the sample.  The majority of the sample was optically 
transparent and appeared to be amorphous however there was one area where discrete 
crystals were observed.  By orientating the sample within the X-ray beam it was possible to 
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analyse both areas of the material.  As Figure 2.11 (D) shows, where the transparent part of 
the material was analysed, the structure of the material appeared to be amorphous.  However, 
when the crystalline portion was analysed, Figure 2.11 (E), the scattering pattern confirmed 
that this section of the material contained order within its structure.  
 
These observations were encouraging as they confirmed that previous conclusions drawn from 
early visual data obtained in Figures 2.4 and 2.5 were likely to be correct.  If a sugar 
combination appeared to be glassy and transparent, then it was likely to be amorphous, 
whereas if crystals were observed in the dehydrated product then it was likely to be 
crystalline.   
 
2.5  Conclusion 
The aim of this first chapter of work was to produce amorphous sugar glass materials via a low-
temperature fabrication technique.  Hence, certain routes to amorphisation were not 
applicable, for example, quenching of the crystalline melt.  The rationale for this was twofold.  
Firstly, it was speculated that a low temperature methodology would produce sugar glasses 
that would be capable of incorporating heat labile medicaments and delicate macromolecules 
within their structure.  Secondly, it was necessary for the amorphous material to conform into 
the geometry of a microneedle array.  Therefore, the dehydration of a solution method to 
achieve amorphisation was appealing as it provided the possibility to address both these 
issues.   
It appeared from early studies that a combination of two disaccharides in solution would be 
optimal to produce an amorphous material via this slow dehydration method.  However, it 
appeared that particulate matter in solution could still act as a nucleation agent and cause 
regions of crystallisation during dehydration.  Amorphous sugar glasses formed by this 
technique were shown to have a complex nature and they did not appear to demonstrate all 
the classical features of a glassy system.  However, it was found that where a particular 
dehydrated sugar product appeared to be transparent and amorphous the system displayed 
an absence of crystal melting or X-ray scattering behaviour; both characteristics of an 
amorphous phase.  This suggested that such systems may be suitable for future incorporation 
of unstable compounds and fabrication of biodegradable microneedle structures.     
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3 Optimisation of micromoulding technique for biodegradable sugar 
glass microneedle array fabrication 
3.1 Introduction 
3.1.1 Development of micromould fabrication approaches  
Arrays of solid MNs have demonstrated effectiveness at enhancing delivery of model 
compounds across the skin barrier.  However, their usage poses a number of potential 
problems.  Silicon is not an FDA-approved biomaterial and therefore may cause regulatory and 
safety concerns.  Furthermore, broken silicon or metal MNs could cause skin problems if left in 
situ in the body.  Solid non-coated MNs also require a two-step application process whereby 
MNs are applied in a separate process to the dosage form, which is undesirable.  Finally, 
accurate coating of MNs is not straightforward and these devices only deliver a very small 
amount of drug as a bolus dose (Prausnitz 2004).  Therefore, micromoulding has become a 
commonplace methodology to prepare biodegradable MN structures with three dimensional 
structures.  Some of the earliest reports of micromoulding processes by McAllister et al. 
include those utilising silicon, metal and polymer micromoulds.  Briefly, silicon moulds were 
made by direct etching of silicon wafers to produce cylindrical holes within the wafer.  Metal 
micromoulds were prepared by electroplating onto solid silicon MN master structures before 
removal of the master by reactive ion etching (McAllister et al. 2003).  Polymer moulds were 
produced by coating a layer of PDMS over silicon or polymer master structures and curing.  
This later technique is a low-cost, repeatable methodology which is now widely used by many 
workers (Gittard et al. 2009; McAllister et al. 2003; Park et al. 2005, 2006; Sullivan et al. 2008; 
Xueqiu et al. 2010).  A similar approach has been adopted subsequently where a female 
master micromould is etched from SU-8 epoxy photoresist by UV exposure before a male MN 
master is fabricated from PDMS.  The male master structure is then sputter coated with a thin 
layer of gold before a second layer of PDMS is coated onto the surface to form an inverse 
mould (Chu et al. 2010; Lee et al. 2008; Park et al. 2007).  Alternatively, other groups have 
fabricated metal micromoulds by etching the inverse shape of an array of MNs into a solid 
metal casting mould (Kolli and Banga 2008; Miyano et al. 2005).  More recently, a silicone 
micromould has been reported whereby micromould templates were prepared on the surface 
of silicone sheets using a galvanometer-based laser-machine tool.  Computer-aided design files 
were employed to control the laser milling process and therefore invaginations with varying 
base diameter, height and interspacing could be produced (Donnelly et al. 2011).  This 
sophisticated process allows much greater control over the geometry of the resulting MN 
structures produced.  However, the most straightforward and commonly utilised methodology 
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for creating inverse micromoulds for biodegradable MN manufacture remains the formation of 
a PDMS micromould from a solid master structure.  In this context, it was determined that 
generation of PDMS against silicon MN master structures would be employed to fabricate 
SGMN arrays.   
 
3.1.2 Micromoulding of microstructures 
Once a micromould has been formed it is filled with the desired material to form replicate MN 
structures.  Various groups have explored different techniques to prepare and fill such moulds.  
Metal MNs formed by McAllister et al. were prepared by an electrodeposition methodology 
whereby a nickel layer was deposited onto polymer or silicon micromoulds (McAllister et al. 
2003).  Synthetic slow-degrading polymer MNs have been prepared by melting polyglycolic 
acid (PGA), polylactic acid (PLA) or poly-lactide-co-glycolide (PLGA) and using vacuum to draw 
the melt into the mould (Chu et al. 2010; McAllister et al. 2003; Park et al. 2005, 2006) whilst 
Takano et al. fabricated polyethylene glycol (PEG) MNs by melting powdered PEG into a 
micromachined die (Takano et al. 2009).  A similar methodology has been utilised to form 
natural silk fibroin MNs.  Here a heat pre-treated fibroin solution was poured into the PDMS 
micromould, degassed under vacuum, and fan-dried for 24 h at room temperature to form 
solid MNs (Xueqiu et al. 2010).  Alternatively, Park et al. utilised synthetic polymer 
microparticles, with and without drug encapsulated, to fill micromoulds.  The microparticles 
were packed into the mould and either heated or ultrasonically welded to fuse the particles 
into MN geometries (Park et al. 2007).  This technique permitted greater control over MN 
design, and allowed fabrication of structures with a complex geometry created from multiple 
materials using milder processing conditions (Park et al. 2007).      
 
Another approach to forming polymeric MNs is to use centrifugal force to aid filling of the 
inverse micromould with a viscous material (Donnelly et al. 2011; Donnelly et al. 2009a; Lee et 
al. 2008).  For example, Lee et al. utilised concentrated hydrogels of ultra-low viscosity 
carboxymethylcellulose (CMC), amylopectin and bovine serum albumin (BSA) deposited onto 
female micromoulds and placed into a 45 ° angled rotor at an elevated temperature.  This 
process formed the hydrogel mixture into the mould, whilst removing residual solvent from 
the formulation, to form a solid MN array containing conical or pyramidal MN arrays (Lee et al. 
2008).  Chu et al. used a combination of vacuum at room temperature followed by 
centrifugation to prepare MNs formed from 30, 40 and 50 %w/w blends of polyvinyl alcohol 
(PVA) and polyvinylpyrrolidone (PVP) (Chu et al. 2010).   
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A number of workers have fabricated natural polymer MNs by creating dense “glue” solutions.  
These solutions contain a drug, including both small and large molecular weight moieties, and 
a polymer, such as chondroitin sulphate or dextran, which is compressed and dried into a 
micromould under the pressure of a steel plate (Fukushima et al. 2011; Ito Y. et al. 2010a; Ito 
Y. et al. 2010b).  In a similar manner, solid state biodegradable microstructures have been 
formed by mixing drug powders into polymer / excipient solutions containing PVA, trehalose, 
maltitol and hydroxypropyl-β-cyclodextrin in PBS.  These solutions were spread over the 
surface of a silicone female micromould and briefly pressurised before drying at slightly 
elevated temperature for 1 h.  A backing layer consisting of Eudragit® E PO solution in alcohol 
was pipetted on top of the dried drug formulations before final pressurising and drying at 
elevated temperature (Wendorf et al. 2011).   
 
Alternative approaches include polymerisation of polymers within the micromould itself.  For 
example, Sullivan et al. used a liquid monomer of vinyl pyrrolidone and the free-radical 
initiator azobisisobutyronitrile applied to the mould surface.  Vacuum pressure was used to 
draw the solution into the mould before UV light was employed to photo-polymerise the 
polymer in situ (Sullivan et al. 2008).  A similar methodology was utilised by Gittard et al. 
where a monomer of eShell 200 polymer was used as the starting material (Gittard et al. 
2009).  Solid maltose MNs have been fabricated by forming a maltose candy and casting the 
material into metal micromoulds at elevated temperature (Kolli and Banga 2008; Miyano et al. 
2005).  Finally, Lee et al. recently proposed a sophisticated methodology of forming solid 
maltose MNs whereby a stepwise controlled drawing lithography of a viscous solution of 
melted maltose monohydrate yielded tapered conical shape MNs with varying lengths (Lee et 
al. 2011b).      
 
As stated, there are now a number of different approaches to forming biodegradable MN 
structures using a variety of methodologies.  Accordingly, the main focus of this chapter of 
work was to investigate and optimise a robust micromoulding technique to reliably fabricate 
SGMN arrays using the low temperature method developed in Chapter 2.   
 
3.1.3 Advantages and disadvantages of biodegradable microneedle fabrication techniques 
As discussed above, there are now many different approaches to forming replicate MN devices 
from master structures.  Each approach has its own benefits and drawbacks and therefore 
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different micromoulding techniques are used for different applications.  For example, earlier 
methodologies employing high temperature melting of synthetic polymers (Park et al. 2005) 
and powdered maltose (Miyano et al. 2005) into a micromould were found to produce robust 
MN structures.  However, neither group attempted incorporation of labile medicaments within 
the matrices of the arrays.  More recently, workers found that incorporation of both small 
molecular weight drug and macromolecular protein during melt processing of galactose 
powder to form MNs involved substantial drug losses due to temperature elevation (Donnelly 
et al. 2009a).   
 
Therefore, many attempts have been made to form biodegradable MN structures using 
methodologies involving lower processing temperatures.  An increasingly popular technique is 
the use of centrifugation to fill micromoulds with a viscous polymeric material (Chu et al. 2010; 
Donnelly et al. 2011; Donnelly et al. 2009a; Lee et al. 2008).  This methodology provides the 
potential for drug incorporation within different portions of the MN array, to facilitate bolus or 
sustained release.  However, elevated temperatures are often still required for the initial 
formation of viscous solutions and removal of residual solvent which may potentially damage 
incorporated drug cargo.   It has also been found that polymeric CMC MNs having the same 
dimensions as master silicon or metal MNs do not possess sufficient mechanical properties for 
skin insertion and therefore require a reduction in needle aspect ratio (Lee et al. 2008).  A 
critical objective of this chapter was to investigate the skin insertion capabilities of SGMNs 
with the same geometry as the silicon MN master structures.   
 
To try and address these fabrication issues, novel approaches have included the 
photopolymerisation of liquid monomers in situ within the micromould itself (Gittard et al. 
2009; Sullivan et al. 2008).  These systems easily lend themselves to segregation of the base 
and MNs for drug incorporation within different portions of the array.  This approach allows 
flexibility over drug loading and therefore facilitates bolus and / or controlled release 
depending upon the appropriate indication.  As these MNs are formed from synthetic 
materials, copolymers can be utilised which confer other advantageous properties, for 
example an increase in mechanical strength (Sullivan et al. 2008).  It has also been shown that 
biological activity of incorporated macromolecules is maintained within these systems (Sullivan 
et al. 2008).  However, there are safety concerns over some larger molecular weight synthetic 
polymers, such as polyvinyl pyrrolidone, relating to clearance and kidney damage.  It has also 
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been shown that not all the small scale features within MN arrays, such as MN tips, form 
perfectly (Gittard et al. 2009).   
 
Other workers have investigated single MNs, of millimetre dimensions, formed from thread-
forming polymers produced from viscous solutions at ambient temperature (Ito et al. 2006).  
These MN devices have shown effective delivery of large molecular weight hormone in vivo, 
however they are formed by hand which is a poorly controlled and non-manufacturable 
process (Sullivan et al. 2008).  More recent methodologies utilising a steel plate to dry polymer 
solutions into micromoulds have permitted the stable incorporation and delivery of 
macromolecular medicaments in vivo (Ito et al. 2010; Ito Y. et al. 2010a).  One of the latest 
references to biodegradable MN fabrication is the formation of PLGA MNs incorporating drug 
loaded hydrogel particles.  When left in situ in skin, hydration of the hydrogel particles cause 
disruption of the MN matrix and controlled release of drug (Kim et al. 2012).  This is an 
attractive approach, but one which still requires further optimisation to eliminate issues of 
hydrogel toxicity and elevated processing temperatures.  As described, each biodegradable 
MN fabrication technique has its own merits and some methodologies now look very 
promising, however to date there is not one fully optimised system.  Consequently, a novel 
vacuum-forming methodology will be explored in this chapter to attempt reliable SGMN 
fabrication. 
Chapter 3 
68 
3.2 Chapter objectives 
1. Develop a reliable methodology for forming micromoulds against silicon MN master 
structures for SGMN fabrication. 
2. Investigation of MN fabrication from alternative substrates and potential for generation 
of micromoulds against these MNs. 
3. Investigation of different techniques including vacuum-formation, centrifugation, 
ultrasonication and compression to micromould biodegradable SGMN arrays. 
4. Optimisation of a micromoulding technique for reliable SGMN array fabrication. 
5. Qualitative and quantitative assessment and visualisation of the capacity of SGMN 
arrays generated to penetrate human skin barrier.  
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3.3 Materials and methods 
3.3.1 Materials 
All reagents were obtained from Fisher Scientific Ltd. (Loughborough, UK) and were of 
analytical grade unless stated otherwise. 
The silicon MN arrays used in this study were supplied by Tyndall National Institute, Cork, 
Ireland.  Pyramidal MNs were fabricated using wet-etching in potassium hydroxide and 
subsequent coating with a 0.3 μm layer of platinum (Wilke et al. 2005). 
Human breast skin was obtained from the Aneurin Bevan Health Board Royal Gwent Hospital 
(Newport, Wales, UK) following mastectomy or breast reduction surgery with full ethical 
committee approval and informed patient consent.  
 
3.3.2 Methods 
3.3.2.1 Characterisation of silicon microneedle master arrays 
The master MN structures utilised in this study were octagonal pyramid in morphology being 
approximately 250 µm in length and 200 µm at base width.  Arrays were cross illuminated and 
viewed under light microscope (Olympus BX50, Japan) to confirm uniformity and integrity of 
the needles.  When required, arrays were mounted onto aluminium stubs using adhesive 
carbon discs and imaged under SEM as described in section 2.3.2.3. 
     
3.3.2.2 Polydimethylsiloxane micromoulding   
Polydimethylsiloxane micromoulds were created from master silicon MNs.  Silicon arrays were 
cleaned by ultrasonication in methanol for 10 mins followed by rinsing in fresh methanol and 
air drying for 10 mins.  Pre-mixed, degassed PDMS was added to a well containing the master 
array, prior to degassing for 30 mins and curing, as described in section 2.3.2.3, to form the 
mould.  The master array was subsequently removed to yield the MN mould.  To visualise 
channels within the micromould, the mould was sectioned transversely and cross illuminated 
for viewing under light microscope (Olympus BX50, Japan). 
 
3.3.2.3 Initial fabrication of sugar glass microneedle arrays 
A 16.7 %w/v solution of TRA/SUC 75:25 %
w/w was prepared as described in section 2.3.2.1 and 
150 µL was pipetted onto the surface of a PDMS micromould.  The mould was dehydrated in a 
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fume cupboard for 24 h at ambient temperature followed by 24 h at 60 °C.  The mould was 
cooled to room temperature and the MN array was removed by hand.  The array was viewed 
under light microscopy (Olympus BH-2, Japan) and then mounted onto an aluminium stub, 
sputter coated with gold and imaged under SEM as described in section 2.3.2.3. 
 
3.3.2.4 Investigation of standard deposition fabrication methodology 
A 16.7 %w/v solution of TRA/SUC 75:25 %
w/w was prepared as described in section 2.3.2.1.  
Methylene blue (MB) powder was incorporated at 5 %w/w of final sugar glass weight.  200 µL of 
a sugar solution containing 5 %w/w MB was pipetted onto the surface of a micromould and 
viewed by digital camera, (Nikon, Coolpix 5600, Japan), and light microscope (Olympus BH-2, 
Japan).  The micromould was then placed into a vacuum oven at 300 mBar for 60 mins to form 
MNs.  The solution was dehydrated, as described in section 2.3.2.1, and the mould was viewed 
with time to investigate MN formation. Once formed, sugar glass arrays were removed by 
hand and stored in a vacuum desiccator at room temperature (Fraenkel et al. 2006). 
 
3.3.2.5 Optimisation of novel vacuum deposition methodology  
Sugar glass MN arrays were fabricated using an improved vacuum-loading methodology.  A 
micromould was placed into a 100 mL conical vacuum flask.  The flask was sealed and held 
under a vacuum of approximately 100 mBar for various time periods.  200 µL of a 20 %w/v 
solution of TRA/SUC 75:25 %w/w was injected onto the mould surface and the vacuum was 
then released immediately.  The micromould was removed from the vacuum chamber and 
dehydrated as described in section 2.3.2.1.  Once formed, SGMN arrays were removed by hand 
and stored in a vacuum desiccator at room temperature.  When required, arrays were 
mounted onto aluminium stubs, sputter coated with gold and imaged under SEM as described 
in section 2.3.2.3. 
 
3.3.2.6 Fabrication of sugar microneedle arrays 
Sugar MNs were fabricated from 200 µL aliquots of 20 %w/v solutions of pure TRA and SUC 
sugars utilising the vacuum deposition methodology described in section 3.3.2.5.    
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3.3.2.7 Investigation and comparison of novel sugar glass microneedle array fabrication 
techniques  
A 20 %w/v solution of TRA and SUC 75:25 %
w/w was prepared and MB powder was incorporated 
at 2 %w/w of final sugar glass weight.  The solution was filled into PDMS micromoulds using one 
of three methodologies:- 
A) Vacuum deposition method (section 3.3.2.5).  The vacuum was held for 10 mins prior to 
sugar solution injection onto mould, as shown in Figure 3.1. 
 
Figure 3.1  Schematic of vacuum deposition methodology.   
Reproduced from source (Fraenkel et al. 2006). 
B) Buchner funnel vacuum-forming method.  A PDMS micromould was placed into the base 
of a narrow neck Buchner funnel attached to a vacuum pump.  100 µL of sugar solution 
was pipetted onto the surface of the micromould and a vacuum was drawn through the 
funnel for 10 mins.  Following this period, the vacuum was released and a further 100 µL 
sugar solution was pipetted onto the mould surface, as shown in Figure 3.2. 
 
Figure 3.2  Schematic of Buchner funnel deposition methodology. 
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C) 100 µL of sugar solution was pipetted onto the micromould surface and the mould was 
placed into a petri dish within an ultrasonication bath for 10 mins.  Following this period, a 
further 100 µL sugar solution was pipetted onto the mould surface.    
Following formation, all micromoulds were dehydrated as described in section 2.3.2.1 before 
removal of SGMN arrays by hand. 
 
3.3.2.8 Fabrication of alternative master microneedle arrays  
A variety of potential MN substrates were analysed by light microscope (Olympus BX50, Japan) 
to investigate the suitability of each for the fabrication of master MN structures.  The following 
substrates were considered:- 
A) BD Microfine™ needles (21, 23 and 25 G) 
B) Dermaroller™ needles (length 500 µm) 
C) generic sewing needles 
D) Monoject™ lancets (Sherwood Medical) 
Microneedles of various geometries and length (500 - 1000 µm) were created by inserting a 
line of five individual needles through a base plate material.  Base materials included flat PDMS 
sheets, Araldite® fixative and various plastic sheets.  MN length was controlled by inserting the 
tip of each substrate into various layers of folded Parafilm®.  Once inserted, MNs were secured 
in place using Araldite® fixative and cured for 12 hours.  Following formation, PDMS was 
prepared and formed over the MN arrays to form inverse micromoulds as described in section 
2.3.2.3.  SGMNs containing 1 %w/w MB powder were created against the master MN arrays 
using the ultrasonication methodology described in section 3.3.2.7 (C).        
 
3.3.2.9 Sugar glass microneedle penetration of human skin  
A previously frozen full-thickness skin sample was defrosted for 60 mins.  Subcutaneous fat 
was removed by blunt dissection and the sample was pinned onto a semi-circular cork board.  
The skin surface was patted dry with tissue paper.  Sugar glass and silicon MN arrays were 
mounted onto flattened 2.0 mL syringe plungers using double-sided adhesive tape.  Plungers 
were applied to the skin in a rolling fashion with downward pressure being applied for 10 secs 
and the array being rolled off in the same direction as the application.  Following application, 
the MNs were viewed under light microscopy (Zeiss Stemi 2000-C, Hertfordshire, UK) to 
observe structural integrity.  10 µL of a 2 %w/v MB staining solution was pipetted onto the 
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treated skin area and left to air dry for 10 mins.  Excess dye was removed with tissue paper 
soaked in ethanol prior to viewing under light microscopy (Fraenkel et al. 2006). 
 
3.3.2.10 Measurement of transepidermal water loss   
Transepidermal water loss (TEWL) readings were taken immediately prior to and following MN 
array application to skin using a Dermalab® open chamber TEWL apparatus (Cortex 
Technology, Hadsund, DK).  A one-way ANOVA with Dunnett’s multiple comparison post hoc 
test was performed on the experimental data using the GraphPad Prism 5 software package.  
In all cases, statistical significance was determined by a value of P < 0.05 (Fraenkel et al. 2006).  
 
3.3.2.11 Human skin sectioning and staining  
Samples of MN treated skin were mounted transversely onto cork sections and covered with 
OCT embedding media (RA Lamb, Thermo Fisher Scientific, UK) before snap freezing in hexane 
and storage at -80 °C.  Skin samples were removed from the freezer and maintained on dry ice 
before cryosectioning (Leica CM3050s, Wolf Laboratories Limited, York, UK).  Sections (10 µm) 
were mounted onto glass slides, rinsed in phosphate buffered saline and fixed in acetone.  
Slides were stained with eosin and counterstained with hematoxylin prior to rapid dehydration 
in an ethanol gradient and then xylene before permanent mounting in Histomount™ (National 
Diagnostics, Atlanta, GA, USA) (Fraenkel et al. 2006). 
 
3.3.2.12 Dissolution of sugar glass microneedles in situ 
Ex vivo human skin was defrosted and prepared as described in section 3.3.2.9.  SGMN arrays 
containing 2 %w/w MB powder were mounted onto syringe plungers and rolled onto the skin.  
The plunger was pressed down for 10 secs before being secured in place with Fastaid adhesive 
plaster (Robinson Healthcare, Nottinghamshire, UK).  The arrays were left in situ, under 
ambient conditions, for time periods up to 5 h before removal.  Arrays were viewed before and 
after application under light microscopy (Olympus BH-2, Japan).  Residual MB was removed 
(section 3.3.2.9) prior to visualisation of the skin under light microscopy (Fraenkel et al. 2006).   
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3.4 Results and discussion 
3.4.1 Characterisation of silicon microneedle master arrays and polydimethylsiloxane 
micromoulds 
To determine the precise geometry of silicon MN master structures, they were visualised 
under light and scanning electron microscopy, Figure 3.3. 
(A)  (B)  
(C)  (D) 
Figure 3.3  Characterisation of silicon MN array master structure.   
(A) Macro image of array compared to a 26 G hypodermic needle and (B) scanning electron micrograph 
of (A) (Bar = 1000 µm).  (C) and (D) light photomicrographs of master array from (B) showing (C) 
transverse angle and (D) en face view (Bar = 100 µm).   
 
The images in Figure 3.3 (A) and (B) show a silicon master array prepared at Tyndall National 
Institute by wet-etch fabrication.  Silicon MNs are shown in Figure 3.3 (C) and (D) displaying 
the octagonal pyramidal geometry of the master structure with base width of approximately 
200 µm and needle length of approximately 250 µm (Fraenkel et al. 2006) providing an aspect 
ratio of 1.25.       
 
To form a micromould, pre-polymerised PDMS was poured over the surface of the MN array.  
Due to the low surface tension of the polymer (Roe 1968) it easily conformed to the low aspect 
ratio structure of the master arrays producing inverse micromoulds of the master array that 
had a strong correlation to the geometry of the master array, Figure 3.4 (A); an example of a 
single channel created within the PDMS micromould is shown in Figure 3.4 (B)(Fraenkel et al. 
2006). 
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 (A)   (B) 
Figure 3.4  Characterisation of PDMS micromould.   
(A) macro image of cross-illuminated micromould and (B) light photomicrograph of transverse section 
through the micromould showing an individual mould channel (Bar = 100 µm).   
 
The data shown in Figure 3.4 confirmed the utility of the PDMS micromoulding methodology 
to fabricate precise moulds of master MN structures for future replication studies. 
 
3.4.2 Initial fabrication of sugar glass microneedle arrays 
A number of different methodologies were attempted to investigate production of SGMN 
arrays.  These included methods based upon vacuum formation, compression and 
centrifugation of sugar material into micromoulds (data not shown).  Ultimately, it appeared 
that a relatively simple methodology could be utilised to attempt SGMN array formation.  
Sugar solution was pipetted onto the micromould surface and dehydrated for 48 h, as 
described previously for sugar glass formation.  The aim of this experiment was to observe 
whether the sugar solution would naturally flow into the invaginations of the mould.    
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 (A)     (B)   
     (C)   
Figure 3.5  Characterisation of initial SGMN arrays.   
(A) light photomicrograph of individual cross-illuminated SGMN (Bar = 100 µm) and (B) and (C) scanning 
electron micrographs of array (arrows indicate incompletely formed SGMNs). 
 
As Figure 3.5 (A) and (B) show, the SGMNs that did form during this experiment generally 
formed very well and had strong morphological fidelity to silicon MN master structures, Figure 
3.3 (C).  This was encouraging as it suggested the utility of PDMS micromoulds to form SGMN 
structures via a simple dehydration procedure.  However, certain areas of the MN array did 
not form well, correlating with where air bubbles remained entrapped within the micromould.  
Therefore, solution was unable to enter those portions of the mould.  It was noted that 100 µL 
of sugar solution was sufficient to produce an array of MNs, but it was speculated that the 
moulds could be loaded with an increased volume of sugar solution in future to reliably ensure 
complete filling of the micromould.  Importantly, it was also noted that a number of MNs 
within the array did not form completely, as shown in Figure 3.5 (C).  It was reasoned that poor 
MN formation could have been due to small air bubbles remaining entrapped within the PDMS 
micromould invaginations, for example the top right-hand MN, Figure 3.5 (C).  Alternatively, 
poor MN formation could have been due to damage upon removal from the array; this 
appeared likely with the top left-hand needle in Figure 3.5 (C).   
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3.4.3 Investigation of standard deposition fabrication methodology 
To attempt improvement and reproducibility of the SGMN fabrication technique discussed in 
section 3.4.2, a number of iterations of the micromoulding methodology were investigated.  
Initially, this was based on the work of Park et al. where a vacuum pressure of 300 mBar was 
applied for 10-20 mins to form PLGA MNs into a PDMS micromould (Park et al. 2005).  
Following a number of small optimisation studies (data not shown) a similar methodology to 
Park et al. was utilised, section 3.3.2.4, and the SGMN array shown in Figure 3.6 was produced.         
(A)        (B)   
Figure 3.6  SGMN array fabricated by the standard vacuum forming methodology.   
(A) PDMS micromould containing array (arrow indicates residual air bubbles remaining within array 
base) and (B) SGMN array (Bar = 1000 µm).  
 
As Figure 3.6 (B) suggests, generally when SGMNs formed utilising this vacuum methodology 
they formed well.  However, residual air bubbles (black arrow) remained within the base of the 
array, Figure 3.6 (A).  To explore reasons for this further, the initial stages involved in SGMN 
manufacture were studied using MNs incorporating MB dye.  When the sugar solution was 
placed onto the mould it initially remained on the mould surface forming a large droplet with a 
high contact angle, Figure 3.7 (A).  It appeared that none of the micromould invaginations 
contained any solution at this stage.  This was expected as PDMS is a hydrophobic material and 
because the sugar solution had a high surface tension.  After the moulds had been placed 
under vacuum for 1 h the sugar solution was observed to have begun filling the micromould 
invaginations, Figure 3.7 (B).  The height and contact angle of the solution droplet had also 
decreased following vacuum exposure.  However, it is apparent from Figure 3.7 (B) that not all 
of the invaginations were filled with sugar solution (black arrow) at this stage.  Following 48 h 
dehydration however the sugar glass material appeared to have filled the micromould more 
completely as confirmed by light microscopy, Figure 3.7 (C)(Fraenkel et al. 2006). 
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 (A)  
 (B) 
 (C)   
 (D)   (E) 
Figure 3.7  Investigation of standard deposition process of SGMN fabrication.   
Macro images of a PDMS micromould showing (A) sugar solution containing 5 %w/w MB powder on 
mould surface (prior to vacuum), (B) mould following processing under 300 mBar vacuum for 60 mins 
(arrow indicates empty mould invaginations), (C)  light photomicrograph of a SGMN array within the 
micromould following 48 h dehydration. (D) and (E) representative light photomicrographs of two ‘MNs’ 
formed by this process (Bar = 100 µm). 
 
To confirm successful formation of SGMNs, newly formed MN arrays were removed from the 
PDMS moulds and individual MNs were viewed by light microscopy.  Figure 3.7 (D) shows that 
SGMNs that were fully formed had strong morphological fidelity to the master structure, 
shown in Figure 3.3 (C).  However, it was noted that only 22 SGMNs were exact replicas of the 
36 silicon MN master needles with the remainder being incompletely formed, Figure 3.7 (E).  
This result appeared to be reproducible in subsequent studies and SGMN arrays formed by this 
methodology never formed full arrays of 36 needles.  It was speculated that the vacuum 
applied to the micromould in this method was insufficient to release all of the air trapped 
beneath the sugar solution, or that the duration of vacuum applied was insufficient to remove 
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all the air from within the indentations.  This process represented the completion of a number 
of studies aimed at optimising this vacuum-forming technique and hence it was determined 
that this methodology could be improved no further (Fraenkel et al. 2006).    
 
3.4.4 Optimisation of novel vacuum deposition methodology  
To improve filling of the micromould and to overcome the deficiencies in formation of a 
complete biodegradable SGMN array a novel vacuum-forming methodology was developed, 
Figure 3.1.  In the original vacuum oven method (section 3.3.2.4) vacuum pressure was applied 
after the sugar solution was placed onto the mould surface.  Consequently when the sugar 
solution was applied, it appeared that air bubbles remained entrapped within the micromould 
invaginations.  Following a number of small methodological optimisation studies (data not 
shown), a fabrication method (section 3.3.2.5) was developed whereby a vacuum was 
produced within an enclosed chamber before sugar solution was applied to the mould surface, 
Figure 3.1 (Fraenkel et al. 2006). 
 
To explore an optimal SGMN array fabrication technique utilising this methodology a number 
of different conditions were investigated.  In the first instance, a vacuum was drawn within the 
flask and the sugar solution was injected onto the mould surface immediately.  The vacuum 
was released immediately, and following dehydration this method produced SGMN arrays as 
shown in Figure 3.8 (A).  In another technique, the same processes were applied again, except 
that the micromoulds were placed into an ultrasonication bath for 10 mins following vacuum 
deposition, producing SGMNs as shown in Figure 3.8 (B).  In the final method, a vacuum was 
drawn within the flask for 10 mins prior to injection of solution onto the mould.  The vacuum 
was released immediately and following dehydration the SGMN array in Figure 3.8 (C) was 
produced.        
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 (A)   (B)  
 (C) 
Figure 3.8  Macro images of SGMN arrays formed by novel vacuum deposition techniques.   
The following methodologies were utilised, (A) immediate injection, (B) immediate injection plus 
ultrasonication and (C) 10 min chamber evacuation before injection (Bar = 1000 µm).       
 
As Figure 3.8 shows, all of the SGMN arrays produced utilising the novel vacuum deposition 
methodology had strong morphological fidelity to the silicon MN master array, Figure 3.3 (A).  
These results demonstrated the utility of the new miniature vacuum chamber to form SGMN 
arrays.  As a corollary it appeared that no air was entrapped within the micromould during 
application of the sugar solution (Fraenkel et al. 2006). Again, the individual SGMNs formed 
using this improved methodology, Figure 3.9, had identical morphological fidelity to the 
master structure, Figure 3.3 (C).   
(A)   (B)   (C) 
Figure 3.9  Representative light photomicrographs of individual SGMNs formed by novel vacuum 
deposition techniques.   
The following methodologies were utilised, (A) immediate injection, (B) immediate injection plus 
ultrasonication and (C) 10 min chamber evacuation before injection (Bar = 100µm).     
  
The data presented in Figures 3.8 and 3.9 appeared to show little difference between the 
SGMN arrays produced by each of the methodologies investigated.  It appeared that 
ultrasonication did not improve MN array formation significantly, Figure 3.8 (B), but it was 
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noted that the MNs formed following a prolonged period of vacuum chamber evacuation, 
Figure 3.9 (C), did appear to have a closer morphological fidelity to master silicon MNs.  Most 
importantly however, this process development enabled the precise fabrication of entire 
SGMN arrays, i.e. 36 out of 36 replicate structures, Figure 3.10.  The novel methodology of 
chamber evacuation and vacuum maintenance during loading of sugar solution onto the 
mould reliably formed complete SGMN arrays of 36 needles that did not contain any 
entrapped air, as observed in initial studies.  Therefore, this method was chosen as the process 
to take forward for all future studies (Fraenkel et al. 2006).  
 
Figure 3.10  Scanning electron micrograph of SGMN array formed by the novel vacuum deposition 
method.   
(Bar = 1000 µm).  
 
3.4.5 Fabrication of sugar microneedle arrays 
As a control, MN arrays were formed from solutions of the individual sugars SUC and TRA using 
the optimised vacuum methodology described in section 3.4.4.  The aim of this study was to 
compare the SGMN arrays formed in section 3.4.4 with MN arrays formed from the 
component sugars, Figure 3.11.       
 (A)   (B)   
Figure 3.11  Representative macro en face images of sugar MN arrays within micromoulds.   
Arrays were formed from (A) 100 % SUC and (B) 100 % TRA (representative of n=3). 
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As Figure 3.11 shows, all the arrays formed from both individual sugar solutions appeared to 
crystallise upon dehydration (n=3).  This behaviour correlated with previous data regarding 
dehydration of sugar solutions, section 2.4.1.  However, even though the sugar solutions were 
shown to crystallise, it appeared that some MN structures did form within the PDMS 
micromoulds, Figure 3.12.  
 (A)   (B) 
 (C)   (D) 
Figure 3.12  Representative light photomicrographs of sugar MNs formed.   
Arrays were formed from (A) and (B) 100 % SUC and (C) and (D) 100 % TRA (Bar = 100 µm) 
(representative of n=3).      
    
As shown, 36 “micro-structures” were formed on the arrays fabricated from each of the 
individual sugar solutions.  These structures appeared to have some morphological similarity 
to the silicon master MNs, Figure 3.3 (C).  However, it was apparent that none of the MNs 
formed from 100 % SUC or TRA formed with the same morphological fidelity as the SGMNs 
formed in section 3.4.4.  It was speculated that this result was due to crystallisation of the 
sugar solutions within the PDMS micromould and therefore incomplete filling of the 
invaginations within the mould during dehydration.  This study further supported the use of a 
TRA/SUC 75:25 %w/w sugar solution to enable fabrication of sugar MNs with precise replication 
of silicon master structures.          
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3.4.6 Investigation and comparison of novel sugar glass microneedle array fabrication 
techniques  
To explore and validate the optimised novel vacuum deposition methodology described in 
section 3.4.4 the technique was compared to two other novel micromoulding methods, as 
described in section 3.3.2.7.  Ultrasonication processing had shown potential for SGMN 
manufacture, section 3.4.4, and it was speculated that the use of a Buchner funnel may 
provide a more simplistic method for vacuum-forming SGMNs.  Micromoulding involving the 
Buchner funnel was attempted to evaluate whether vacuum force could be utilised to produce 
SGMN arrays without a vacuum chamber.  This method relied heavily on the assumption that 
the PDMS polymer had some porosity and hence that a vacuum could be drawn through the 
micromould.  Examples of MN arrays formed by each of the techniques are shown in Figure 
3.13.  
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(A) (B) (C) (D) 
(E) (F) (G) (H) 
(I) (J) (K) (L) 
Figure 3.13  Representative light photomicrographs of SGMN arrays formed by novel fabrication 
techniques.   
Arrays were formed by (A – B) Buchner funnel, (E – F) ultrasonication and (I - J) vacuum deposition 
methodologies (Bar = 1000 µm) (representative of n=3).  Representative light photomicrographs of 
individual SGMNs formed by (C – D) Buchner funnel, (G – H) ultrasonication bath and (K - L) vacuum 
deposition methodologies (Bar = 100 µm).  Arrows indicate residual air bubbles remaining within SGMN 
arrays.  
 
As Figure 3.13 shows, generally all of the individual MNs formed by each of the methodologies 
had strong morphological fidelity to the silicon master structure, Figure 3.3 (C).  However, a 
number of MNs were found to be incompletely formed on each of the arrays.  
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The data in Figure 3.14 show the number of whole MN structures produced using each of the 
methodologies.  
 
Figure 3.14  Comparison of SGMN fabrication techniques and MN formation.   
Bars demonstrate the number of MN structures formed using ultrasonication (black), Buchner funnel 
(white) and vacuum deposition (grey) methodologies.  Data presented as mean ± standard deviation 
(S.D.) (n=3). 
 
In combination, the data presented in Figure 3.13 and 3.14, suggested that the vacuum 
chamber forming methodology produced the most reproducible SGMN arrays.  As shown in 
Figure 3.13 (A) and (E), SGMN arrays fabricated using the Buchner funnel and ultrasonication 
methodologies did not always produce complete MN arrays.  Air bubbles were observed within 
the structures of some arrays produced using both these techniques.  This meant that the 
number of individual MNs formed using each method was consistently lower in comparison 
with the vacuum-forming methodology, Figure 3.14.  Although not all of the MNs formed 
perfectly using the vacuum-forming methodology, for example Figure 3.13 (L), the MN arrays 
produced by this technique were the most reproducible.  This study further suggested the 
utility of the novel vacuum methodology described in section 3.3.2.7 for robust SGMN array 
fabrication.  
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3.4.7 Fabrication of alternative master microneedle arrays 
In an attempt to achieve greater flexibility over the morphology and dimensions of SGMNs, 
attempts were made to produce MN arrays from alternative substrates.  Workers have 
previously utilised commercially available hypodermal needles (Verbaan et al. 2008; Verbaan 
et al. 2007) and sharpened stainless steel wire (Verbaan et al. 2008) to fabricate MN arrays.  
Therefore, a range of potential MN master substrates were investigated in this study, as shown 
in Figure 3.15. 
 (A)  (B)   (C)   (D) 
Figure 3.15  Representative light photomicrographs of potential MN substrates.   
Materials examined included (A) 25 G BD Microfine™ needle, (B) sewing needle, (C) Dermaroller™ 
needle and (D) Monoject™ lancet needle (Bar = 100 µm).   
 
Three different gauges of BD Microfine™ needle were investigated and it was observed that 
they all had exactly the same tip dimension, Figure 3.15 (A).  The only variation between each 
needle was the bore size of the needle shaft.  However, this substrate was discounted as 
although the needle tips were precisely machined, a needle that had a bore in the centre 
would be no use for PDMS micromoulding.  Commercial sewing needles, Figure 3.15 (B), were 
found to be poorly machined, and the needle tip geometry was found to vary widely from 
needle to needle, Figure 3.16 (A) and (C).  Hence, these needles were discarded from further 
analysis.  The Dermaroller™ and Monoject™ lancet needles showed more potential for MN 
production however.  Both types of needle were observed to be manufactured to a much 
higher level of uniformity and precision with very fine tip diameters, as shown in Figure 3.15 
(C) and (D) respectively. 
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To form MN arrays, a range of base plate materials were explored, including flat PDMS sheets, 
Araldite® fixative and various plastics, to observe which was the most effective for the creation 
of arrays.  Examples of MNs formed from these substrates are shown in Figure 3.16. 
 (A)   (B)   (C)   (D) 
Figure 3.16  Representative light photomicrographs of alternative geometry MNs and SGMNs formed 
by ultrasonication.   
Images depict (A) sewing needle inserted through PDMS base, (B) SGMN replica of (A), and (C) sewing 
needle with Araldite® base, (D) SGMN replica of (C) (representative of n=5).   
 
As shown in Figure 3.16 (B) and (D), it was possible to form replica SGMN structures, 
containing 1 %w/w MB, of the “microneedles” fabricated in this study.  Following this initial 
optimisation process, it was concluded that neither PDMS nor Araldite® was an optimal base 
material.  It was speculated that a solid plastic base material may be a better substrate for MN 
production as it would be more straightforward to machine and provide easier control of MN 
length.   
 
Combining the preliminary findings of this section, an array of 5 in plane MNs was fabricated 
from Monoject™ lancet needles using a rigid plastic base material.  Female PDMS micromoulds 
were formed against the MN master structures and used to fabricate replica SGMN structures.  
Examples of SGMNs formed by this process are shown in Figure 3.17.     
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 (A)   (B)   (C) 
Figure 3.17  Representative light photomicrographs of SGMNs formed from Monoject™ lancet 
needles.   
Images depict (A) and (B) en face view of SGMNs containing 1 %w/w MB and (C) 90 ° angle view of SGMN 
(representative of n=5).   
 
As the images in Figure 3.17 demonstrate it was possible to produce SGMNs with alternative 
dimensions to the MNs produced utilising silicon MN master structures.  As shown, these 
SGMNs had a very different geometry and aspect ratio to the pyramidal based SGMNs 
produced previously.  Although these structures had a rigid glassy structure, it was often 
observed that the MNs appeared to “bend over” at the tip, Figure 3.17 (B) and (C).  The reason 
for this observation was not clear, but it was speculated that due to the increased depth of the 
micromould the SG material may not have fully dehydrated at the needle tips by 48 h.  
Therefore, upon removal from the mould, the tips may not have had the structural rigidity to 
maintain their lancet shape and hence collapsed.   
 
In summary, it appeared that it would be possible to form biodegradable SGMNs with different 
geometries to the master silicon MNs.  However, production of these arrays, and inverse 
PDMS micromoulds, were not trivial and it was concluded that silicon MN shaped SGMNs 
would be utilised for all future studies.          
 
3.4.8 Sugar glass microneedle penetration of human skin 
To investigate the structural rigidity and skin puncture performance of SGMNs of these 
dimensions the arrays were inserted into excised human skin.  It has been stated that an 
inappropriate pitch, or spacing, between individual MNs with three-dimensional geometries 
will prohibit skin penetration.  For example, if the pitch is too short neighbouring needles will 
hinder each other from insertion (Miyano et al. 2005).  It has also been found that MNs formed 
from CMC and amylopectin having the same dimensions as master silicon MNs do not possess 
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sufficient structural rigidity to penetrate human skin (Lee et al. 2008).  Other workers have 
stated that MNs with a length shorter than 300 µm are ineffective as shorter needles do not 
pierce the skin (Bal et al. 2008).  Therefore, it was an important aim of this work to ascertain 
the skin penetration capabilities of pyramidal SGMNs.   
 
Methylene blue post-staining of the microchannels generated in skin following MN array 
application for 10 seconds showed that SGMNs, Figure 3.18 (B), appeared to penetrate human 
skin with the same efficacy as silicon MNs, Figure 3.18 (A).  This demonstrated that SGMNs of 
these dimensions possess suitable structural rigidity and sharpness to effectively puncture the 
SC of human skin (Fraenkel et al. 2006).  Transverse skin sections further confirmed that 
SGMNs efficiently circumvented the SC to facilitate diffusion of MB dye, applied post-
application, into the epidermal layer, Figure 3.18 (D), in a manner analogous to silicon MNs, 
Figure 3.18 (C). Whilst master silicon MNs were largely unaffected by the skin application 
process, Figure 3.18 (E), Figure 3.18 (F) shows that SGMNs were physically altered following 10 
secs insertion into human skin (Fraenkel et al. 2006).  It was not obvious from this study 
whether SGMNs were damaged due to the relatively brittle nature of the material, or partially 
dissolved during the application process, but it rendered their re-use for skin puncturing 
purposes unlikely (Fraenkel et al. 2006).   
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(A)  (B)  (C)  
(D)  (E)  (F) 
Figure 3.18  Human skin penetration capability of SGMNs.   
MNs were inserted into excised human skin and removed prior to staining with 2 %w/v MB dye. En face 
images of microchannels following insertion of (A) silicon and (B) SGMN arrays (Bar = 1 mm). Light 
photomicrographs of transverse skin sections taken from skin shown in (A) (silicon MNs, panel C) and (B) 
(SGMNs, panel D) respectively (Bar = 100 µm). Light photomicrographs of representative silicon (E) and 
sugar glass (F) MNs following rapid (10 seconds) skin insertion (Bar = 100 µm).   
 
 
Figure 3.19  Transepidermal water loss measurement across human skin following MN treatment. 
Both sugar glass (n=3) and silicon MN treatments (n=4) were shown to significantly increase TEWL 
versus intact skin (n=3). Data presented as mean ± standard error of mean (S.E.). * denotes statistical 
significance at p<0.05. 
 
Skin puncture performance of MN devices was further assessed by measurement of TEWL 
from skin following application.  TEWL data confirmed that human skin insertion of both silicon 
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and sugar glass MNs significantly (p < 0.05) increased water loss over that of intact non-treated 
skin, Figure 3.19 (Fraenkel et al. 2006).   
 
This data demonstrated that pyramidal SGMN with a length of 250 µm and an inter-needle 
spacing of 1 mm were capable of successfully inserting into full thickness human skin.  This 
indicated that MNs formed from sugar glass material were of a sufficient structural rigidity to 
penetrate the SC barrier to a similar extent as master silicon MNs.  This finding is in contrast to 
work carried out by others utilising dissolvable carbohydrate materials for MN manufacture 
(Lee et al. 2008).  Following skin insertion however, it was apparent that silicon and sugar glass 
MNs behaved quite differently.  Sugar glass MNs were shown to degrade rapidly and it was 
speculated that this may be due to the hygroscopic and / or brittle nature of the material.  
Rapid dissolution of natural biodegradable MNs in vitro, on the timescale of seconds, have 
been noted by other workers (Lee et al. 2008; Xueqiu et al. 2010) and therefore it appears that 
sugar glass MNs have similar degradation kinetics.              
 
3.4.9 Dissolution of sugar glass microneedles in situ 
Due to the material properties of sugar glass, it was hypothesised that SGMNs would dissolve 
rapidly and completely within skin to deposit incorporated model drug cargo.  To test this, 
SGMN arrays incorporating 2 %w/w MB powder were inserted into ex vivo human skin and left 
in situ for various time periods.  Figure 3.20 shows the dissolution status of the MNs, with 
complete dissolution being evident between 10 mins, Figure 3.20 (B), and 20 mins, Figure 3.20 
(C), following skin insertion (Fraenkel et al. 2006).  This data correlates closely with reports 
from other workers where biodegradable MNs fabricated from natural substances have been 
shown to dissolve over similar time scales both in vivo (Fukushima et al. 2011; Lee et al. 2011b; 
Miyano et al. 2005) and in vitro (Lee et al. 2008; Xueqiu et al. 2010).   
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(A)  
(B)  
(C) 
(D) (E) (F) 
Figure 3.20  In situ dissolution of SGMNs incorporating 2 %
w
/w methylene blue.   
Representative light photomicrographs of SGMNs: (A) after formation, (B) following 10 mins insertion 
into ex vivo human skin and (C) following 20 mins insertion into ex vivo human skin (representative of 
n = 4) (Bar = 1 mm).  (D) 10 µm hematoxylin and eosin stained transverse tissue section of skin showing 
a single MN puncture site following 20 mins insertion (Bar = 100 µm).  En face images of skin after 
removal of SGMNs incorporating dye at 10 mins (E) and 20 mins (F) insertion time (Bar = 1 mm).   
 
The SGMNs fabricated in this study were shown to penetrate the SC of human skin, Figure 3.20 
(D) and to dissolve in situ.  Figures 3.20 (E) and (F) show the degree of skin staining arising from 
dissolution of MNs containing MB within the needle structure at 10 and 20 mins respectively.  
These images generally support the SGMN array dissolution kinetics detailed in Figure 3.20 (A) 
– (C) and further confirm the utility of these MNs for creating microchannels within skin and 
releasing material incorporated within the matrix of the array leaving behind no hazardous 
waste (Fraenkel et al. 2006).     
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3.5 Conclusion 
The focus of this chapter was to establish a robust micromoulding methodology to fabricate 
biodegradable SGMN arrays.  It was demonstrated that PDMS micromoulds generated against 
silicon MN master structures had strong morphological fidelity to the master structures.  This 
suggested the utility of the moulds for creating replicate MN structures.  Various different 
techniques have been reported for filling micromoulds to form biodegradable MN structures.  
Here it was shown that modifications to the classical vacuum oven based micromoulding 
methodology utilised by other workers facilitated the reliable fabrication of SGMN arrays 
against silicon MN masters at a low temperature.  A number of different master MN 
permutations were fabricated in this chapter and inverse micromoulds were successfully 
produced against them.  Although these MNs and moulds allowed greater flexibility over MN 
length and geometry, it was found that micromoulds produced from silicon MN masters 
permitted fabrication of the most reliable SGMN structures.  It was demonstrated that these 
MN structures had sufficient strength and tip sharpness to effectively puncture human SC 
barrier creating microchannels into the deeper skin layers.  The SGMNs were shown to dissolve 
rapidly in situ to facilitate delivery of an incorporated dye into the epidermis.  However, as 
these studies were investigated in vitro, it may be that the actual degradation of SGMNs in vivo 
is considerably faster.  This study suggests the utility of SGMN arrays for the transdermal 
delivery of potent therapeutics, potentially including hydrophilic macromolecules.    
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4 Stability and incorporation of model substances within sugar glass 
microneedles 
4.1 Introduction 
4.1.1 Incorporation of model substances within biodegradable microneedles 
A wide variety of biodegradable MN permutations have been reported to investigate the 
cutaneous delivery of a range of model substances.  Studies have explored both local and 
systemic delivery of compounds and medicaments via biodegradable MNs utilising both in 
vitro and in vivo models.  In Chapter 3 it was shown that SGMN arrays could penetrate human 
skin to facilitate permeation of dye into deeper skin layers.  One of the potential benefits of 
biodegradable MNs is that drug can be incorporated within the device thereby facilitating 
increased drug loading.  Accordingly, it was important to establish the characteristics and 
limitations of loading within SGMN arrays.   
 
As mentioned previously, other workers have investigated incorporation of model compounds 
within the structure of biodegradable MN devices.  Miyano et al. incorporated the small 
molecules ascorbate-2-glucoside (ASG), sodium salicylate (SS) and calcein (CAL) within molten 
maltose candy at concentrations of 5, 10 and 10 %w/w, respectively.  This was found to be the 
upper limit of concentration attainable, as exceeding this quantity decreased the mechanical 
strength of the MNs so that they would no longer insert into skin (Miyano et al. 2005).  More 
recently, Lee et al. fabricated maltose MNs containing the small molecules ASG and 
niacinamide at concentrations of 1 % and 1.5 %w/w respectively.  In a similar manner to that 
reported by Miyano et al., this process utilised elevated temperature to dissolve the powders; 
although it was found that the stability of these compounds was unaffected by the fabrication 
process and for up to 2 months when stored at ambient temperature and relative humidity 
(Lee et al. 2011b).   
 
Utilising a fabrication methodology analogous to Miyano et al., Donnelly et al. added 5-
aminolevulinic acid (5-ALA) and BSA powder to molten galactose before micromoulding 
(Donnelly et al. 2009a).  In this study it was found that substantial losses of both 5-ALA and 
BSA, approximately 30 and 100 % respectively, occurred during the fabrication process.  
Similar observations were made by Park et al. following fabrication of synthetic polymer MNs 
encapsulating CAL or BSA.  Drug was either directly encapsulated within poly-lactide-co-
Chapter 4 
95 
glycolide (PLGA) MNs, or first encapsulated within CMC or poly-L-lactide for controlled release 
applications (Park et al. 2006).  Due to the high melting point of PLGA, and the duration of 
elevated temperature required to form these MNs, a time-dependent denaturation of BSA 
protein was observed (Park et al. 2006).  Mechanics of MN insertion were assessed and it was 
found that MNs containing 2 %w/w CAL remained strong enough to insert into skin, whereas 
those containing 10 %w/w decreased below the failure force required for skin penetration (Park 
et al. 2006).  As reliable skin penetration is essential to the utility of MN devices, this was an 
important finding and suggested that there may be limitations to drug loading within 
biodegradable MNs.              
 
Accordingly, it was envisaged that the low temperature SGMN fabrication process developed 
in Chapter 3 may facilitate the stable incorporation of a wide range of model substances.  In 
support of this concept, there have been a growing number of reports of low temperature 
micromoulding methodologies for biodegradable MNs.  Ito et al. proposed a process to 
fabricate self-dissolving MNs from various dense glue solutions of chondroitin sulphate, 
dextrin and albumin containing erythropoietin hormone (EPO).  These MNs were dried under 
desiccating conditions at low temperature and hence the biomolecule EPO was successfully 
incorporated and retained its structure when delivered in vivo (Ito et al. 2006).  The same 
workers later prepared MNs from dense drug glues containing insulin (Ito et al. 2010), ascorbic 
acid (Ito Y. et al. 2010b) and EPO (Ito Y. et al. 2010a) by condensing solutions and 
micromoulding utilising low temperature processes.  All these MNs delivered functional drug 
substances capable of producing biological effects in vivo.  Furthermore, MNs containing 12 or 
22 % recombinant human growth hormone (rhGH) or 4 % desmopressin (DDAVP) were 
fabricated from drug glues in a similar manner (Fukushima et al. 2011).  These model 
substances were shown to be almost completely stable within MN structures for 1 month 
when stored at either -80 or 4 °C (Fukushima et al. 2011).  Solid state biodegradable 
microstructures (SSBMS) containing 5 and 10 %w/w FITC-BSA (66 kDa) and 2, 5 and 10 %
w/w 
recombinant protective antigen (rPA; 83 kDa) in a carbohydrate and polyvinyl alcohol (PVA) 
excipient solution were prepared by pressure micromoulding and drying at 32 °C (Wendorf et 
al. 2011).  These SSBMS stably incorporated both proteins for successful transdermal delivery 
(Wendorf et al. 2011).     
 
To fabricate biodegradable MNs from natural polymeric materials CMC, amylopectin and BSA, 
viscous hydrogel formulations were fabricated and model drug was added by hand.  The model 
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substances investigated were sulforhodamine B (SRB), BSA and lysozyme added at final weight 
concentrations of 0.15 – 30 %, 20 % and 5 % respectively (Lee et al. 2008).  In contrast to 
previous reports, this study found that the addition of 20 % BSA to CMC MNs increased the 
mechanical strength of the needles in comparison to pure CMC MNs; however, the authors 
acknowledged that this may not be the case with other model drugs (Lee et al. 2008).  
Furthermore, lysozyme retained almost 100 % activity within MN structures following 2 
months storage at room temperature (Lee et al. 2008).  Alternatively, CMC MNs were 
fabricated containing rhGH at 5 %w/w utilising a relatively low temperature casting 
methodology (Lee et al. 2011a).  When stored in air under ambient conditions, rhGH contained 
within the needles was shown to be stable over a 3 month period maintaining biological 
activity (Lee et al. 2011a).          
 
Further reports describe MNs fabricated from other synthetic polymeric materials.  
Polyvinylpyrrolidone (PVP) MNs formed by in situ photo polymerisation at ambient 
temperature demonstrated effective incorporation and delivery of BSA and functional β-gal in 
vitro and were shown to protect nearly 100 % β-gal activity following incorporation within MN 
structures (Sullivan et al. 2008).  This suggested that macromolecular drug incorporation 
within these MNs would be favourable.  Chu et al. investigated MN structures created from 
blends of PVA and PVP containing SRB incorporated within the needles either in a gradient 
fashion or as a homogeneous mix throughout the matrix (Chu et al. 2010).  The MNs contained 
2 – 8 % drug and were shown to reliably insert into excised porcine skin (Chu et al. 2010).  
Alternatively, MNs were fabricated from Gantrez® AN-139 polymer containing 1 %w/w 
theophylline.  It was found that loading above this concentration led to a highly flexible 
material that was unsuitable for MN manufacture (Donnelly et al. 2011).  However, at 1 %w/w 
loading, MNs possessed similar mechanical properties to their non-drug-loaded counterparts 
and were shown to successfully deliver drug across porcine skin in vitro (Donnelly et al. 2011).  
Further MNs were created from poly (methylvinylether maleic anhydride) containing insulin 
loaded at 2.5 and 10 mg per device.  Loading of MNs at both concentrations did not adversely 
affect MN morphology or robustness and only slight losses of insulin were incurred during 
fabrication (Migalska et al. 2011).  These studies suggested that if formulated correctly 
biodegradable MN structures could be produced to stably encapsulate a range of both small 
and large molecular weight substances.                              
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As described, there are many different approaches to biodegradable MN fabrication and 
incorporation of model compounds.  In this chapter the incorporation of a range of model 
substances will be investigated to determine the loading capacity and stability of SGMN arrays.     
 
4.1.2 Macromolecule incorporation within sugar glasses 
As described, glass forming sugars have great significance in nature as they are used to protect 
delicate biological tissues in the dehydrated state (Potts 1994).  Pharmaceutical processes such 
as heating, freeze-thawing and freeze-drying can potentially denature proteins (Uritani et al. 
1995) through stresses involved in removal of its hydration shell (Prestrelski et al. 1993).  
Subsequently, it has been shown that certain disaccharides, for example trehalose, maltose 
and sucrose protect these molecules in the dehydrated state (Carpenter and Crowe 1988).  It 
has been suggested that water molecules that surround polar residues within labile 
macromolecular assemblies, such as membranes and proteins, in the natural state are 
replaced by sugars.  Hence this maintains stability when the hydration shell is removed (Crowe 
and Clegg 1973).  It has been proposed that the mode of action of these sugars is to encourage 
the retention of the native structure of the protein and prevent unfolding in the dried state 
(Prestrelski et al. 1993).  Accordingly, it was hypothesised that these materials may be suitable 
for biodegradable MN fabrication and stable macromolecule incorporation.   
 
Although many workers have investigated carbohydrates for biodegradable MN manufacture, 
there are only a few instances of stable macromolecule incorporation within these structures.  
Limitations of this approach appear to be the utilisation of elevated temperatures to fabricate 
these structures.  However, as described in Chapter 2, sugar glasses can be produced by a 
variety of different techniques, which do not always require elevated temperature or force to 
cause vitrification.  A prominent area where the protective capacity of sugars has been 
explored is in the study of freeze-drying formulation and subsequent product storage.  For 
example, addition of trehalose or maltose to phosphofructokinase solution prior to freeze-
drying was shown to stabilise the enzyme to a minimum of 80 % of its original level (Carpenter 
et al. 1987a).  However, in the context of this work it was realised that freeze-drying would not 
be appropriate for filling micromoulds.  It was hypothesised that the low temperature 
dehydration process developed in Chapters 2 and 3 would be more appropriate to producing 
SGMNs containing model substances, which was the focus of this chapter.   
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4.2 Chapter objectives 
1. Incorporate a range of model substances within SGMN arrays and investigate limitations 
of the system. 
2. Assess the stability of model macromolecule contained within sugar glass material 
formed by low temperature dehydration. 
3. Investigate the long-term physical stability of sugar glasses (SGs) and SGMN arrays under 
varying storage conditions. 
4. Investigate the long-term stability of SGs containing model macromolecule under 
varying storage conditions.  
5. Investigate cutaneous delivery of model macromolecule by SGMN arrays.   
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4.3 Materials and methods 
4.3.1 Materials 
All reagents were obtained from Fisher Scientific Ltd. (Loughborough, UK) and were of 
analytical grade unless stated otherwise. 
β-galactosidase, product code G-6008, was obtained from Sigma - Aldrich (Poole, UK). 
Human breast skin was obtained from the Aneurin Bevan Health Board Royal Gwent Hospital 
(Newport, Wales, UK) following mastectomy or breast reduction surgery with full ethical 
committee approval and informed patient consent.  
 
4.3.2 Methods 
4.3.2.1 Incorporation of model drugs within sugar glass microneedle arrays 
A 20 %w/v solution of TRA/SUC 75:25 %
w/w in dH2O was prepared.  Model drugs ibuprofen 
sodium (IBU), propranolol hydrochloride (PHCl), bovine serum albumin (BSA), FITC-BSA and 
sulforhodamine B sodium (SRB) (Sigma - Aldrich, Poole, UK) were incorporated at 5, 1 – 10, 1 – 
10, 5 and 5 %w/w respectively, of final sugar glass weight.  Sugar solution containing drug was 
magnetically stirred to dissolve the powders.  Additionally, to dissolve 10 %w/w PHCl, solutions 
were heated to 50 °C for 10 mins.  Once formed, solutions were filtered through a cellulose 
acetate 0.2 µm filter and vacuum formed in PDMS micromoulds as described in section 3.3.2.5.  
All arrays were viewed under light microscopy (Olympus BH-2, Japan).  A one-way ANOVA with 
Dunnett’s multiple comparison post hoc test was performed on the experimental data using 
the GraphPad Prism 5 software package.  In all cases, statistical significance was determined by 
a value of P < 0.05 
 
4.3.2.2 Incorporation of model macromolecule within sugar glass microneedle arrays  
A 16.7 %w/v solution of TRA/SUC 75:25 %
w/w was prepared by dissolving the sugars in 100 mM 
sodium phosphate buffer (PB) (Sigma - Aldrich, Poole, UK).  A stock solution of β-gal was made 
up in PB solution at a concentration of 1 U/µL.  Stock solution was further diluted with PB to 
form a 5 U/10 µL solution.  10 µL of sugar PB solution was removed from a 1 mL aliquot and 
replaced with 10 µL of diluted β-gal stock solution, to form a solution with a final enzyme 
concentration of 5 U/mL.  200 µL of the solution was vacuum formed into a PDMS micromould, 
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as described in section 3.3.2.5.  Following 48 h dehydration, SGMN arrays were stored in a 
vacuum desiccator prior to use. 
 
4.3.2.3 Theoretical calculation of microneedle volume  
The theoretical volume of the MNs within a 6 x 6 SGMN array was calculated as follows to 
determine the potential drug loading within the MNs alone.  The geometry of the silicon MN 
master structures used in this work were approximated to a square based pyramid.  The 
volume of individual SGMNs fabricated in this study were calculated using Equation 1. 
Pyramid volume (µL) = base area (µm) x height (µm) x 1/3 (1) 
Utilising the volume calculated in (1) the mass of sugar contained within the SGMNs of the 
array was calculated as shown in equation 2. 
SGMN volume x Sugar density x 36 (2) 
The theoretical amount of drug contained within SGMNs was then calculated based on 
percentage incorporation.  
 
4.3.2.4 Formation of X-gal staining solution for qualitative β-galactosidase assay  
X-gal powder was dissolved in N,N-dimethylformamide at a concentration of 40 mg/mL.  2.42 g 
tris-hydrochloride buffer (Sigma - Aldrich, Poole, UK) was dissolved in 8 mL dH2O.  The pH was 
adjusted to pH 8.5 by adding hydrochloric acid (0.5 M) in a drop-wise manner.  The solution 
was then made up to a final volume of 100 mL using dH2O.   
Approximately 5 mL of X-gal staining solution was created using the following formula: 
X-gal solution               250µL 
K+ ferricyanide (III)       42µL 
K+ hexacyanoferrate      42µL 
1 M MgCl2 solution 10µL 
Tris-HCl buffer   2.5mL 
dH2O    2.15mL 
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4.3.2.5 Delivery of β-galactosidase to human skin via SGMN arrays 
A previously frozen full thickness human skin sample was defrosted and prepared as described 
in 3.3.2.9.  SGMN arrays containing β-gal, section 4.3.2.2, were mounted onto the flattened 
end of a syringe plunger and applied to defrosted human skin, as described in section 3.3.2.9.  
The arrays were left in situ for 30 mins before being removed.  Upon removal, treated skin 
sections were maintained at the air-liquid interface using a “Trowell-type” organ culture setup 
placed into an incubator at 37 °C for 1 h.  Following incubation, the samples were removed and 
rinsed in PBS containing 4 mmol MgCl2 before fixation in chilled 2 %
w/v glutaraldehyde in PBS / 
MgCl2 solution for 2 h.  Once fixed, skin sections were rinsed twice in PBS / MgCl2 solution for 
15 mins and transferred into X-gal staining solution.  Samples were maintained in an incubator 
at 37 °C for 18 h before removal and visualisation of the insoluble blue X-gal product.  
 
4.3.2.6 Quantitative ortho-nitrophenyl β-D-galactopyranoside assay for β-galactosidase 
β-gal activity was quantified by adding 100 µL of sample or standard enzyme solution to a 
reaction vessel, equilibrated to 37 °C, containing:- 
Ortho-nitrophenyl β-D-galactopyranoside (ONPG) 100 µL 
30 mM MgCl2 solution     100 µL 
3.36 M 2-mercaptoethanol solution   100 µL 
100 mM PB      2.6 mL 
Blanks for each sample contained the same reaction components including ONPG substrate, 
but no enzyme.  Samples were incubated in a water bath at 37 °C for 90 mins.    The reaction 
was stopped with 1.5 mL sodium carbonate solution (1 M) and 100 µL of enzyme sample was 
added to each blank solution.  300 µL aliquots of each sample were analysed by UV 
spectrophotometer (Fluostar Optima™, BMG Labtech, Aylesbury, UK), with absorbance at 405 
nm.  Residual enzyme activity was estimated by linear regression and correlation analysis of 
the calibration curve generated.  A one-way ANOVA with Bonferroni’s multiple comparison 
post hoc test was performed on the experimental data using the GraphPad Prism 5 software 
package.  In all cases, statistical significance was determined by a value of P < 0.05 
 
4.3.2.7 Effect of dehydration surface area on enzyme stability 
A 20 %w/v sugar solution TRA/SUC 75:25 %
w/w was created by dissolving the sugars in PB before 
filtering through a cellulose acetate 0.2 µm filter.  Stock solutions of 10-3 U/µL β-gal in PB and 
Chapter 4 
102 
sugar PB were created by diluting stock β-gal solution, section 4.3.2.2, in further PB.  Samples 
of 300 µL were pipetted into 96, 24 and 6 well plates (Fisher Scientific Ltd, Loughborough, UK) 
and dehydrated as described in section 2.3.2.1.  Dehydrated products were then re-hydrated 
with 300 µL dH2O and left for 10 mins to dissolve.  Samples were stirred with a 200 µL pipette 
tip and the remaining enzyme activity was quantified by ONPG assay, as described in section 
4.3.2.6.  All plates were weighed throughout the 48 h dehydration period using a balance 
(Sartorius, Goettingen, Germany).  Changes in sample weight were recorded and residual 
water content was inferred by subtracting the initial powder mass from sample weight.  
 
4.3.2.8 Investigation of β-galactosidase enzyme stability within sugar glasses 
A 16.7 %w/v solution of TRA/SUC 75:25 %
w/w was prepared as described in section 4.3.2.2.  
Solutions of PB and sugar PB containing 10-3 U/µL β-gal were created, as described in section 
4.3.2.7.   To form sugar glasses, 200 µL samples of solution were dehydrated within 24 well 
plates.  Samples were dehydrated as described in section 2.3.2.1, and negative controls were 
dehydrated for 24 h at ambient temperature followed by a further 24 h at 90 °C.  Control 
solution samples were pipetted into Eppendorf tubes and sealed to prevent evaporation.  
Following dehydration, samples were re-hydrated with 200 µL dH2O and assayed as described 
in section 4.3.2.7.  The enzyme was quantified by ONPG assay, section 4.3.2.6.   
 
4.3.2.9 Initial stability study of sugar glass formulation  
A 20 %w/v solution of TRA/SUC 75:25 %
w/w was created by dissolving sugars in PB.  The solution 
was filtered through a cellulose acetate 0.2 µm filter.  Solutions of PB and sugar PB containing 
10-3 U/µL β-gal enzyme were created and 300 µL samples were pipetted into 24 well plates 
(Fisher Scientific Ltd, Loughborough, UK).  The solutions were dehydrated to form a solid as 
described in section 2.3.2.1.  SGMN arrays were fabricated from a 20 %w/v solution of TRA/SUC 
75:25 %w/w, as described in section 3.3.2.5.  Dehydrated samples and SGMN arrays were 
stored for a period of 3 months under the following storage conditions:- 
1. At room temperature (20 ± 2 °C) under vacuum desiccation (silica gel) 
2. In a desiccator (silica gel) under refrigeration (4 ± 2 °C) 
3. At room temperature under 60 ± 5 % relative humidity (RH) 
4. At 40 ± 2 °C under 75 ± 5 % RH  
5. Under refrigeration (4 ± 2 °C) 
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Following time points 7 days, 28 days and 3 months solid products were re-hydrated with 
300 µL dH2O and assayed as described in section 4.3.2.7.  SGMN arrays were viewed at all time 
points under light microscopy to examine needle integrity. 
 
4.3.2.10 Long-term assessment of β-galactosidase stability within sugar glasses 
A 16.7 %w/v solution of TRA/SUC 75:25 %
w/w was prepared by dissolving the sugars in PB and a 
stock solution of β-gal enzyme was prepared as described in section 4.2.2.2.  To form sugar 
glasses, 300 µL samples were pipetted into 24 well plates (Fisher Scientific Ltd, Loughborough, 
UK).  The solutions were then dehydrated to form a solid as described in section 2.3.2.1.  
Following dehydration, samples were re-hydrated with 300 µL dH2O and assayed as described 
in section 4.3.2.7.  Further samples were stored under vacuum desiccation utilising Sorbsil® 
Chameleon® desiccant (VWR International Ltd, Leicestershire, UK) at 20 ± 2 °C or desiccation 
(Sorbsil® Chameleon®) at 4 ± 2 °C for up to 3 months.  Samples were re-hydrated as stated 
previously and residual enzyme activity was quantified at 7, 35 and 95 days following sugar 
glass formation.  
 
4.3.2.11 Sugar glass microneedle stability study 
SGMN arrays were formed from a filtered 20 %w/v solution of TRA/SUC 75:25 %
w/w, as 
described in section 3.3.2.5.  Blank sections of SG material were formed by pipetting 200 µL 
sugar solution onto flat sections of PDMS and dehydrating as described in section 2.3.2.1.  
Once fabricated, arrays and SGs were stored under one of the following conditions:- 
1. At room temperature (20 ± 2 °C ) under vacuum desiccation (Sorbsil® Chameleon®) 
2. In a desiccator (Sorbsil® Chameleon®) under refrigeration (4 ± 2 °C) 
3. At room temperature under 5.5 % RH  
4. At room temperature under 10 % RH  
5. At room temperature under 15 % RH  
6. At 37 °C under 10 % RH. 
Sugar glass MN arrays were viewed under light microscopy (Olympus BH-2, Japan) following 
7 days, 28 days and 3 months storage.  The water content of SGs were analysed by 
thermogravimetric analysis (TGA) (section 2.3.2.4) at the same time points. 
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4.4  Results and discussion 
4.4.1 Incorporation of model drugs within sugar glass microneedle arrays 
Previous data in Chapter 3 had shown that MB powder could be incorporated within SGMNs as 
a model drug compound.  Other workers have incorporated this compound within 
biodegradable MN structures as a model medicament (Xueqiu et al. 2010).  It was found that 
incorporation of this substance at a concentration of 2 %w/w dry weight had little effect on the 
structural integrity of SGMN arrays formed.  However, when incorporated at a concentration 
of 5 %w/w it was observed that SG material properties changed significantly and lost robustness 
(data not shown).  Sugar glass MN arrays became very difficult to remove from PDMS 
micromoulds and often cracked during the process.  To probe this behaviour further model 
substances with widely differing physicochemical properties were incorporated into SGMNs.  
Propranolol hydrochloride (PHCl) is a relatively small molecule, molecular weight (MW) 
approximately 296, whilst bovine serum albumin (BSA) is a large MW protein, approximately 
66 kDa in size, as shown in Figure 4.1. 
(A)  
(B) 
Figure 4.1  Structure of model drugs incorporated within SGMNs.   
Models incorporated included (A) propranolol hydrochloride and (B) bovine serum albumin.  Adapted 
from source, http://www.sigmaaldrich.com/catalog/ProductDetail.  Accessed 17/01/2012.    
    
Each model drug was incorporated into model sugar solution before being vacuum-formed 
into solid SGMN arrays.       
 
SGMN arrays containing PHCl are shown in Figure 4.2.  Visually, it was observed that there was 
little difference between each of the MN arrays formed.  Generally all of the SGMNs formed 
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had strong morphological fidelity to the silicon master MNs and increasing the content of PHCl 
appeared to have little effect on MN structure. 
 (A)  
 (B) 
 (C) 
Figure 4.2  Representative light photomicrographs of SGMN arrays containing propranolol 
hydrochloride.   
Arrays contain (A) 1 %w/w, (B) 5 %
w/w and (C) 10 %
w/w drug.  Images cross illuminated for visualisation 
(Bar = 100 µm) (representative of n=3). 
    
Although all individual MNs containing PHCl formed well, upon removal of arrays from the 
PDMS moulds it was found that SGMNs incorporating 10 %w/w PHCl were weaker than the 
arrays containing smaller quantities of PHCl.  It was observed that two thirds of the SGMN 
arrays incorporating 10 %w/w PHCl fractured during removal from the moulds, whereas none of 
the other arrays were affected during removal.  This behaviour was similar to the results 
obtained from SGMN arrays incorporating 5 %w/w MB powder.  Although these were only small 
datasets, it was reasoned that incorporation of 5 to 10 %w/w of a small MW model substance 
caused loss of gross structural integrity.  This correlated closely with previous findings by 
others where incorporation up to 10 %w/w within biodegradable MNs was feasible (Miyano et 
al. 2005; Park et al. 2006).  
 
In a similar manner, all SGMNs containing up to 10 %w/w BSA, Figure 4.3, appeared to have 
good morphological correlation to silicon MN master structures.       
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 (A)   
(B)   (C) 
Figure 4.3  Representative light photomicrographs of SGMN arrays containing bovine serum albumin. 
Arrays contain (A) 1 %w/w, (B) 5 %
w/w and (C) 10 %
w/w protein.  Images cross illuminated for visualisation 
(Bar = 100 µm) (representative of n=3).  
 
To further assess differences between the loaded SGMN arrays formed, the number of 
individual MNs formed on each of the arrays was counted, Figure 4.4.   
 
Figure 4.4  Comparison of the number of MNs fully formed on SGMN arrays containing model drugs.   
Data presented as mean ± S.D. 
 
As Figure 4.4 shows, there was no statistical difference (P=0.24) in MN formation between 
loaded SGMN arrays and control.  This correlated with the similarities in MN structure, 
regardless of substance loading, visualised previously (Figures 4.2 and 4.3).  Further, it 
appeared that incorporation of model fluorescent compounds at 5 %w/w had a negligible effect 
on SGMN structure, as Figure 4.5 shows.   
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 (A)   (B)   
Figure 4.5  Fluorescent photomicrographs of SGMN arrays containing fluorescent model substances.  
 Arrays contained 5 %w/w loading of (A) sulforhodamine B, and (B) FITC-BSA (Bar = 100 µm).   
   
Therefore, to maintain SGMN array integrity, a maximum of 5 %w/w model drug was 
incorporated within arrays in all future studies. 
 
4.4.2 Theoretical calculation of sugar glass microneedle volume 
Due to the relatively small dimensions of the SGMNs fabricated in this work, it was important 
to calculate the quantity of drug that could theoretically be loaded into the MNs alone.  Based 
upon MN dimensions of 200 µm base width and 250 µm height, the total volume occupied by 
36 SGMNs (Equation 1) was 0.12 µL.  The densities of trehalose and sucrose are approximately 
1.58 g/cm3 and hence using Equation 2, 36 SGMNs contain approximately 0.19 mg of sugar.  If 
drug were incorporated uniformly within these MNs at a concentration of 5 %w/w, theoretically 
9.5 µg drug would be contained within the needles.  If this were extrapolated to a patch 
measuring 50 x 50 mm containing 2500 SGMNs then the amount of drug contained within the 
MNs at 5 %w/w loading would be 650 µg.         
 
Others have calculated that a MN patch containing 100 – 1000 bevel-tip or tapered-cone 
needles, each with an individual mass of 10 µg, containing 10 %w/w drug could theoretically 
deliver 100 – 1000 µg (Park et al. 2006).  Further, Lee et al. calculated that 600 µm long 
pyramidal MNs formed from various natural polymeric materials contained 25 - 60 µg matrix 
material per needle (Lee et al. 2008).  Due to restrictions in the concentration of drug that 
could be incorporated within the matrix, the authors calculated that doses up to 1000 µg could 
be contained within a patch of a few hundred MNs.  This dose could be increased to between 
10 and 100 mg by loading drug throughout the entirety of the MN device however (Lee et al. 
2008).  Hence, this constrains the number of treatment applications for biodegradable MNs, 
but doses up to 1000 µg are appropriate for a number of drugs on the market.  These include 
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interferon α-2A for hepatitis C, interferon β-1A for multiple sclerosis and EPO for anaemia 
which have doses of 33 µg/week, 132 µg/week and 100 µg/day, respectively (PDR 2005).  Thus 
controlled release of drug would allow treatment for 30 weeks, 7 weeks and 10 days, 
respectively (Park et al. 2006).  Vaccine delivery presents another very attractive option, for 
example, hepatitis B vaccine and influenza vaccine require antigen doses of only 10 and 45 µg, 
respectively (Park et al. 2006).  Therefore, the SGMNs fabricated in this study could find utility 
in transdermal delivery of a number of medicaments.           
   
4.4.3 Delivery of β-galactosidase to human skin via SGMN arrays 
A model macromolecule, β-gal, was incorporated into sodium phosphate buffer (PB) solution 
containing TRA and SUC 75:25 %w/w.  The solution was vacuum-formed into a PDMS 
micromould and dehydrated to form a solid SGMN array containing enzyme, as described in 
section 4.3.2.2.  Sugar glass MN arrays containing β-gal were shown to have strong 
morphological fidelity to silicon MN master structures, as shown in Figure 4.6. 
 (A)   (B) 
Figure 4.6  Representative light photomicrographs of SGMN array containing β-galactosidase.  
(A) Entire array (Bar = 1000 µm) and (B) individual SGMN within array (Bar = 100 µm) (representative of 
n=3).   
 
The SGMN arrays shown in Figure 4.6 were mounted onto syringe plunger applicators, as 
described section 3.3.2.9, and inserted into human skin.  The arrays were maintained under an 
occluded environment throughout the experiment to aid dissolution and degradation.  Upon 
removal of the arrays and X-gal staining of treated skin sections, the following data were 
obtained, Figure 4.7. 
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 (A)   (B)   (C)   
Figure 4.7  En face light photomicrographs of human skin following β-galactosidase delivery via SGMN 
and X-gal post-staining.   
(Bar = 1000 µm) (n=3).  
 
 (A)   (B) 
Figure 4.8  Representative light photomicrographs of human skin sectioned transversely following β-
galactosidase delivery via SGMNs.   
(Bar = 100µm). 
 
As shown in Figure 4.7, each of the SGMN arrays containing β-gal punctured human stratum 
corneum (SC) to facilitate the delivery and deposition of enzyme within deeper skin layers.  
This was confirmed by the presence of oxidised blue X-gal staining product surrounding SGMN 
channels, Figure 4.8.  However, deposition of enzyme was not uniform in each case, for 
example, as Figure 4.8 (B) shows it appeared that a considerably smaller amount of enzyme 
was delivered into this MN channel compared to the channel in Figure 4.8 (A).  Although all 
SGMN arrays did penetrate human skin to deliver β-gal, under these conditions deposition of 
enzyme appeared to vary between individual treatments.  It was reasoned that the variations 
observed could be due to a number of issues.  Firstly, skin penetration by each array may not 
have been uniform which may have led to uneven protein deposition within the epidermis.  
Furthermore, the MN channels created may have re-sealed or become blocked during 
subsequent processing.  Consequently, there may have been variations in penetration of X-gal 
staining solution into the tissue for reaction and post-staining of the enzyme.  All these factors 
may have contributed to the variations in apparent β-gal activity observed.     
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Figure 4.9  Representative light photomicrograph of SGMN array containing β-galactosidase following 
insertion into human skin.   
All needles were observed to have completely dissolved on each array following 30 mins (Bar = 1000 
µm) (representative of n=3).    
 
In contrast to Figure 4.6, it was visually apparent that all of the MNs on each of the SGMN 
arrays had dissolved by the end of the study, as shown in Figure 4.9.  Subsequently it appeared 
logical that any viable enzyme contained within the MNs will have been deposited into the 
skin, providing that SC penetration occurred in each case.  Therefore, this further suggested an 
issue with enzyme post-staining within the skin tissue.  However, this experiment did 
demonstrate that β-gal remained viable in the sugar glass material throughout the process of 
SGMN array fabrication.       
 
4.4.4 Effect of dehydration surface area on enzyme stability   
Qualitative results utilising X-gal staining solution had demonstrated that β-gal was stable 
within SGMN arrays when maintained under vacuum desiccation (section 4.4.3).  However, 
quantitative assessment of β-gal dehydrated within PB and sugar PB solutions appeared to 
show that the enzyme lost significant activity under certain conditions, even when maintained 
within a sugar glass (SG), Figure 4.10.   
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 (A)  
 (B)   
Figure 4.10  Residual enzyme activity following solution dehydration within wells with differing 
volumes.   
Fresh enzyme solutions (t=90m) contained (A) β-gal in sodium phosphate buffer solution (PBSo) and (B) 
β-gal in sugar buffer solution (SugSo) dehydrated within 96, 24 and 6 well plates for 48 h (t=49.5 h) to 
form PB solid (PBGl) or sugar glass (SG).  Data presented as mean ± S.D. (n=3).      
 
Initially, enzyme solutions were dehydrated within 96 well plates and the enzyme was almost 
completely denatured under standard dehydration processing conditions, Figure 4.10.  This 
appeared to contradict previous qualitative data and it was hypothesised that the surface area 
to volume ratio of the well plates used for dehydration of enzyme solutions was a key 
determinant in residual enzyme activity.  This hypothesis was supported by data shown in 
Figure 4.10 (B) where the enzyme appeared to be more stable in plates with larger well 
dimensions.  It was reasoned that this may be due to the larger surface area provided for 
water evaporation.  This is likely to have facilitated more rapid water loss during the first 24 h, 
leading to enhanced protein stabilisation within a sugar matrix during the second 24 h 
dehydration at elevated temperature.   
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The data in Figure 4.10 (A) demonstrated that enzyme dehydrated in PB solution alone 
retained no residual activity following dehydration, regardless of well surface area.  This was 
expected as phosphate buffer solution alone is not known to protect biomolecules in the liquid 
(Leslie et al. 1995) or dehydrated state (Carpenter et al. 1987a).  During dehydration under 
elevated temperature conditions, enzymes, such as β-gal, can become deactivated by 
processes such as denaturation (unfolding) and thermal aggregation (Yoshioka et al. 2003).  
Thermal denaturation is defined as a first-order phase transition during which the native 
folded conformation of the protein is altered (Cordone et al. 1999), leading to inactivation.  
However, when the enzyme was dehydrated in the presence of sugars, Figure 4.10 (B), the 
volume of the wells appeared to play an important role in enzyme stabilisation.  As stated, 
when a 96 well plate was utilised the enzyme retained little activity following dehydration.  
Conversely, when the enzyme was dehydrated in sugar PB in 24 or 6 well plates the sugar 
provided significant protection and the enzyme retained 76 % and 54 % residual activity, 
respectively.  Similar levels of protein recovery following dehydration in the presence of 
amorphous stabilising mediums have been noted in other model systems, for example 
phosphofructokinase (Carpenter et al. 1987a; Carpenter et al. 1987b) and invertase (Schebor 
et al. 1996).   
 
It was speculated that the increased surface area provided by the wells in the 24 and 6 well 
plates permitted faster evaporation of the solution and hence a solid SG was formed more 
rapidly to stabilise the enzyme.  Surprisingly, the enzyme appeared to be slightly less stable 
when dehydrated within 6 well plates, the plate with the largest surface area, compared to 24 
well plates.  In all cases 300 µL of enzyme solution was used, and it was observed that only the 
6 well plates had a large enough surface area for the solution to form a distinct droplet in the 
centre of the well.  However, the reason for decreased protection afforded by SGs in these 
wells was not obvious.  Consequently, it appeared that the 24 well plates provided the optimal 
surface area to volume ratio for solution evaporation and enzyme stabilisation and hence were 
used in all future studies.   
  
To examine water evaporation kinetics, changes in enzyme solution weight were recorded 
throughout the experiment.  In comparison to the 24 and 6 well plates, it was found that there 
was considerably more water present in enzyme formulations contained within 96 well plates 
following the first 24 h of dehydration.  It was observed that approximately 60-70 % water 
remained within 96 well plates at 24 h, regardless of whether sugar was present or not.  
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Conversely, formulations dehydrated in 24 and 6 well plates contained much lower quantities 
of water at 24 h.  As more water was present within the 96 well plate formulations at 24 h, it 
was speculated that the enzyme was less likely to have been stabilised during subsequent 
temperature elevation.  This may have led to denaturation of the protein within 96 well plates, 
Figure 4.10.         
 
4.4.5 Investigation of β-galactosidase stability within sugar glasses 
To further explore the capacity of SG material to stabilise a functional macromolecule, β-gal 
was incorporated within PB and sugar PB solutions.  These solutions were exposed to the 
processing conditions developed to fabricate solid SGs with dehydration at ambient 
temperature for 24 h followed by dehydration at an elevated temperature of 50 °C for a 
further 24 h.  Enzyme activity at all time points was estimated by linear regression analysis of 
standard β-gal concentrations, as Figure 4.11 shows.    
(A)
 (B) 
Figure 4.11  Exemplar standard curves used in quantitative determination of β-galactosidase.   
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Curves represent (A) β-gal in PB solution and (B) β-gal in sugar PB solution.  Data presented as mean ± 
S.D. (n=3).  
It was found that the activity of β-gal was very similar regardless of whether it was formulated 
into a solution containing sugar or not.  This was indicated by the similarity in the slopes 
obtained for the calibration curves generated in Figure 4.11.  Utilising these curves sample 
enzyme concentrations were estimated following 48 h processing.  As stated, sample solutions 
were dehydrated over a 48 h period under standard dehydration conditions.  Control solutions 
were either maintained in sealed vials to prevent solvent evaporation or heated to 90 °C; a 
temperature known to denature β-gal (Ladero et al. 2006; Leslie et al. 1995).  The stability of 
the enzyme following processing is shown in Figure 4.12.   
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(A)  
   (B) 
Figure 4.12  Stability of β-galactosidase during dehydration processing and sugar glass formation.   
Treatments were as follows; fresh enzyme (t=90 m) in (A) phosphate buffer solution and (B) sugar buffer 
solution.  Enzyme in (A) phosphate buffer and (B) sugar buffer solution dehydrated under standard 
conditions (ambient temperature for 24 h followed by 24 h at 50 °C); Buffer solid 50oC and SG 50oC 
(t=49.5 h), respectively.  Enzyme in (A) phosphate buffer and (B) sugar buffer solutions maintained 
under standard conditions; Buffer soln. 50oC and Sugar soln. 50oC (t=49.5 h), respectively.  Enzyme in 
(A) phosphate buffer and (B) sugar buffer solution stored at ambient temperature (20 °C) for 48 h; 
Buffer soln. 20oC and Sugar soln. 20oC (t=49.5 h), respectively.  Enzyme in identical formulations as 
stated under standard conditions except with dehydration at 90 °C for 24 h; suffix 90oC.  Data presented 
as mean ± S.D. (n=3), * denotes statistical significance at P<0.05.   
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As Figure 4.12 shows, β-gal was denatured in all treatments processed at 90 °C.  This was 
expected as 90 °C is known to denature β-gal and because it is unlikely that a solid SG will have 
formed completely by 24 h to stabilise the enzyme prior to temperature elevation.  This 
temperature is also close to the Tg of TRA and SUC and hence they will have afforded little 
protection to the enzyme at this temperature (de Jonge et al. 2007).  Formation of a solid 
dehydrated product appeared to be critical to enzyme protection.  This was demonstrated by 
the samples heated to 50 °C, where the enzyme was completely denatured when maintained 
in PB (Buffer soln. 50oC) and sugar PB (Sugar soln. 50oC) solutions.  Similar observations were 
made by Mazzobre et al. where β-gal was denatured rapidly at 45 – 55 °C when maintained in 
liquid phosphate buffer (Leslie et al. 1995).  However, in the corresponding samples where a 
solid product was formed, Buffer solid 50oC and SG 50oC respectively, the enzyme retained 
residual activity following processing, Figure 4.12.  It was apparent that the residual enzyme 
activity remaining within the SG 50 °C product was significantly greater than that of the Buffer 
solid 50 °C product though.  It has been stated that during drying, the major stress that a 
protein must overcome is loss of its hydration shell.  This effect can cause irreversible 
inactivation upon rehydration (Carpenter and Crowe 1989) unless a carbohydrate is present 
(Carpenter et al. 1987a; Carpenter et al. 1987b; Prestrelski et al. 1993).  Accordingly, it was 
surprising that the enzyme retained any activity following dehydration within PB alone. 
 
It was speculated that the enhanced residual enzyme activity within the SG was due to 
replacement of evaporated water through hydrogen bonding of sugar to the protein to 
prevent dehydration-induced denaturation and inactivation (Carpenter and Crowe 1988, 
1989).  Additionally, there were only small decreases in enzyme activity between freshly 
prepared sugar PB solution (Sugar soln.) and enzyme left at ambient temperature for 48 h in 
sugar solution (Sugar soln. 20oC) or incorporated within SG at 50 °C.  These data together 
demonstrate the protective functionality of solid TRA/SUC 75:25 %w/w SG on β-gal when 
processed below the denaturation temperature of the enzyme.   
 
Furthermore, solutions maintained at ambient temperature for 48 h showed significantly 
greater enzyme stability in sugar PB solution compared to PB alone.  This result was 
unexpected as solid SG had not been formed.  However, similar effects have been noted by 
others where it has been shown that solutes in solution have a protective effect on proteins 
undergoing stresses, such as freezing (Koster and Leopold 1988).  In conclusion, it appeared 
that the enzyme was stable during dehydration processing when incorporated into the matrix 
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of a SG.  Although the quantity of enzyme that remained within the glass decreased slightly 
compared to the initial concentration, it appeared that the enzyme was protected to a far 
greater extent when sugar was present in the formulation.  This data demonstrated the utility 
of solid SGs to maintain β-gal viability during air-drying dehydration processes.    
 
4.4.6 Initial stability study of sugar glass formulation 
During the initial 7 days of the study it appeared that SGMNs maintained under refrigeration, 
elevated temperature and relative humidity (RH) conditions, as stated in section 4.3.2.9, were 
completely unstable.  Upon visual examination of SGMN arrays it was apparent that these 
devices would not be stable unless maintained in a low moisture environment.  Amorphous 
materials are known to be unstable under high humidity (Hageman 1992; Lai et al. 1999; 
Nowakowski and Hartel 2002) and elevated temperature environments (de Jonge et al. 2007; 
Hageman 1992) and the results observed here support these findings.  Further, maltose MNs 
were shown to be unstable when stored at a RH of 50 % and dissolved within hours (Miyano et 
al. 2005).  Additionally, galactose MNs were found to dissolve within 1 h at a RH of 75 % and 
within 6 h at a RH of 43 % (Donnelly et al. 2009a).  In a similar manner, the arrays stored at 4 
°C, Figure 4.13 (C), and at 60 %RH, Figure 4.13 (A), in this study were both found to be viscous 
semi-solids whilst the array stored at 75 %RH and elevated temperature had completely re-
crystallised, Figure 4.13 (B). 
 (A)   (B)   (C)   
Figure 4.13  Light photomicrographs of SGMN arrays within micromoulds following 7 days storage.   
Arrays were stored under (A) 20 ± 2 °C and 60 ± 5 %RH, (B) 40 ± 2 °C and 75 ± 5 %RH and (C) 4 ± 2 °C.  
Arrows indicate example areas of crystallisation (Bar = 1000 µm). 
 
It was hypothesised that the results observed in Figure 4.13 were due to moisture absorption 
from the environment by the SGMN arrays.  It was speculated that this may be due to the 
hygroscopic nature (Dittmar 1935) of the SG material being examined.  Additionally, the result 
observed with elevated temperature storage, Figure 4.13 (B), could have been due to 
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increased molecular mobility within the material (de Jonge et al. 2007) as these conditions 
were closer to the glass transition temperatures of the sugars studied.  As none of the storage 
conditions in Figure 4.13 yielded viable SGMN arrays following 7 days storage, these treatment 
groups were discontinued.  It was rationalised that β-gal was unlikely to be stable within the 
SG material under these conditions, as it has been shown that enzyme activity is significantly 
reduced upon sugar crystallisation at elevated humidity (Cardona et al. 1997).  It is likely that 
spatial constraints within the crystalline phase reduce the effectiveness of hydrogen bonding 
between protein and sugar leading to reduced stabilisation (Izutsu et al. 1994).  Furthermore, 
if MN structure could not be maintained then it would be impossible to deliver the protein 
across skin.     
 
In contrast, SGMN arrays maintained under a desiccated environment appeared to retain their 
amorphous structure at 7 days, as Figure 4.14 shows. 
 (A)   (B) 
Figure 4.14  Light photomicrographs of SGMN arrays following 7 days storage.   
Arrays were stored under (A) 20 ± 2 °C and vacuum desiccation and (B) 4 ± 2 °C and desiccation (Bar = 
1000 µm). 
 
It appeared that under desiccated storage environments at both 4 and 20 °C, SGMN arrays 
maintained their gross structure throughout the study duration.  Once more, this is supported 
by the work of Miyano et al. where it was found that maltose MNs maintained under an 
environment of less than 40 %RH retained their morphology over a 3 month period (Miyano et 
al. 2005).  Donnelly et al. made similar findings and observed that the morphology of galactose 
MNs stored at 0 %RH did not change throughout 3 weeks storage (Donnelly et al. 2009a).  
However, in this study there were differences noted between individual MNs within the arrays 
stored under each of the desiccated conditions.  This is shown in Figure 4.15. 
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 (A)   (B) 
 (C)  (D) 
Figure 4.15  Representative light photomicrographs of SGMNs following desiccated storage.   
Arrays were stored for 5 weeks under (A) 20 ± 2 °C and vacuum desiccation and (B) 4 ± 2 °C and 
desiccation, and (C) and (D) 3 months under the storage conditions stated in (A) and (B) respectively.  
Images cross illuminated for visualisation (Bar = 100 µm).  
 
As Figure 4.15 shows, SGMNs maintained under both desiccated storage conditions lost their 
pyramidal structure during the study duration.  It appeared that SGMNs maintained under 
20 ± 2 °C and vacuum desiccation, Figure 4.15 (A) and (C), retained their morphology to a 
greater extent than MNs stored under  4 ± 2 °C and desiccation, Figure 4.15 (B) and (D) 
however.  This study suggested that neither storage condition was optimal for maintaining 
SGMN geometry over a 3 month storage period.  The images in Figure 4.15 appeared to 
suggest that the SG material had flowed during the storage period.  Microneedles maintained 
under both conditions appeared to be more rounded and smooth than freshly prepared MNs.  
A similar phenomenon had been observed with the first SGMN array formed in Chapter 3.  This 
array was mounted onto a metallic stub and sputter coated with a thin layer of gold, for SEM 
viewing, before being left under ambient conditions for a period of 12 months.  The array was 
mounted at a 90 ° angle and, as Figure 4.16 shows, following this period the glassy material 
appeared to have flowed under the force of gravity in a similar manner to a liquid droplet.  
From these data, it was speculated that this phenomenon may have been due to the relatively 
unstable amorphous nature of SGs deforming during storage.   
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Figure 4.16  First SGMN array fabricated.   
Array was sputter coated with gold for SEM viewing and left under ambient conditions for 12 months at 
a 90 ° angle (Bar = 1000 µm).   
 
4.4.7 Assessment of β-galactosidase stability within sugar glasses 
To quantitatively explore the stability afforded by SGs a model macromolecule, β-gal, was 
incorporated into the matrix and its activity was assayed over a 3 month period.  In this study 
24 well plates were used as these had been shown to provide the most effective surface area 
to volume ratio for dehydration and stabilisation of enzyme in SGs (section 4.4.4).  The data 
presented in Figure 4.17 shows the residual enzyme activity remaining within dehydrated 
samples throughout the study.     
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(A) 
(B) 
Figure 4.17  Stability of β-galactosidase in dehydrated formulations stored over 3 months. 
Treatments were as follows; fresh enzyme (t=90 m) in (A) phosphate buffer solution (PBSo) and (B) 
sugar buffer solution (SugSo) and enzyme maintained within (A) dehydrated PB solid (PBGl) and (B) 
sugar glass (SG) stored under 4 ± 2 °C or 20 ± 2 °C and desiccation; 4oC and 20oC, respectively.  Enzyme 
activity was quantified in fresh solutions and in dehydrated formulations (t=49.5 h) and then at 7 days 
(t=217.5 h ), 5 weeks (t=889.5 h) and 3 months (t=2377.5 h) following dehydration.  Data presented as 
mean ± S.D. (n=3).  
 
As Figure 4.17 (A) shows, β-gal was denatured when dehydrated slowly within PB alone.  This 
supported previous findings where the enzyme lost activity when dehydrated within buffer 
solution only, Figure 4.12.  In contrast, to maintain enzyme activity in commercial formulations 
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the enzyme is supplied as a lyophilised powder containing Tris buffer salts and magnesium 
chloride (http://www.sigmaaldrich.com/catalog/product/sigma/g6008?lang=en&region=GB.  
Accessed 27/03/12) to maintain β-gal activity.  As hypothesised, when the enzyme was 
contained within a SG material, Figure 4.17 (B), the enzyme retained residual activity 
throughout the study duration.  During SG formation (t=49.5 h) there was a small but 
significant decrease in initial enzyme activity.  This correlated with previous data showing that 
dehydration processing in 24 well plates decreased enzyme activity to approximately 76 % of 
the freshly prepared stock solution, Figure 4.10.  Enzyme activity then decreased further 
during the first week of storage (up to 217.5 h).  This behaviour is not uncommon as it is 
known that chemical deterioration processes can still occur in SG systems stored below Tg, but 
at a reduced rate (Streefland et al. 1998).  Further, it was speculated that the reduction in β-gal 
activity during the first week of storage may have been due to annealing of the sugar glass.  
This process alters the material properties towards a lower energy state which is under meta-
stable equilibrium (Zhou et al. 2007).  From one week storage onwards, enzyme activity 
appeared to remain stable within the glass when maintained under vacuum or refrigeration 
desiccation, which supports this hypothesis.  This data indicated that as long as the SG material 
was maintained under a desiccated environment the amorphous material would be stable and 
protect the enzyme incorporated within the matrix (Fraenkel et al. 2006).  In this work β-gal 
enzyme was chosen as a model protein due to its ease of assay.  It seems likely that the 
protective SG effects observed here may be extrapolated to other proteins however.  β-
galactosidase is prone to loss of activity through increase in apparent size which may be due to 
covalent bond formation between molecules, aggregation without covalent bond formation or 
protein denaturation and unfolding (Guyot and Fawaz 2000).  Other proteins such as 
interferon, basic fibroblast growth factor, lactalbumin, and casein are known to undergo 
similar conformational changes during dehydration which leads to inactivation (Prestrelski et 
al. 1993).  It has been postulated that these changes maximise the intra- and inter-chain 
hydrogen bonds between polypeptides to replace those bonds lost to water (Prestrelski et al. 
1993).  Furthermore, lactate dehydrogenase in buffer solution was completely inactivated 
following freeze-drying, whereas it maintained approximately 100 % activity when dried in the 
presence of sucrose and various other sugars (Prestrelski et al. 1993).  Similarly, Lee et al. 
recently demonstrated only a 15 % loss of recombinant human growth hormone activity 
contained within CMC MNs stored under ambient conditions (Lee et al. 2011a).  This suggests 
that a number of proteins may behave in a similar manner to β-gal and hence further 
optimisation of the fabrication conditions of SGMN arrays may be required for enhanced 
macromolecule stabilisation.      
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4.4.8 Sugar glass microneedle stability study 
Previous findings had shown that SGMN arrays were physically unstable when stored under 
high RH conditions, under refrigeration or at elevated temperature (section 4.4.6).  To 
investigate the optimal storage conditions for SGMN arrays further, arrays were stored under 
the following conditions, vacuum desiccation at 20 °C, desiccation at 4 °C, 15 %RH at 20 °C, 
10 %RH at 20 °C, 5.5 %RH at 20 °C and 10 %RH at 37 °C.  Examples of SGMNs formed at the 
beginning of the study are shown in Figure 4.18.   
 (A)   (B) 
Figure 4.18  Representative light photomicrographs of freshly formed SGMNs.   
Images cross illuminated for visualisation (Bar = 100 µm). 
 
As Figure 4.18 demonstrates, SGMNs formed initially had a strong morphological correlation to 
silicon MN master structures.  This was important to establish as all SGMNs would be 
compared to these initial structures throughout the duration of the study.  Following storage 
of SGMNs for 7 days the arrays were viewed once more under light microscopy.  It was 
observed that SGMNs stored at ambient temperature under 5.5 %RH and 10 %RH or 37 °C and 
10 %RH were unstable and no MN structures remained on these arrays at 7 days (data not 
shown).  However, SGMN arrays stored under desiccation at 4 or 20 °C and 15 %RH at 20 °C 
did appear to be stable, Figure 4.19.            
 (A)   (B)   (C) 
Figure 4.19  Representative light photomicrographs of SGMNs stored for 7 days.   
Arrays were stored under (A) 4 ± 2 °C and desiccation (B) 20 ± 2 °C and 15 %RH, (C) 20 ± 2 °C and vacuum 
desiccation.  Images cross illuminated for visualisation (Bar = 100 µm). 
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It was apparent from the data presented in Figure 4.19 that the different storage conditions 
had distinctive effects on SGMN structure.  It appeared that the optimal storage condition at 
this time point was 15 %RH at 20 °C, Figure 4.19 (B), as the MNs within this array retained the 
strongest morphological fidelity to the master structures.  In support of previous findings, 
Figure 4.15, it appeared that SGMNs stored under a desiccated environment, Figure 4.19 (A) 
and (C), began to lose their initial morphology within 7 days.  It was speculated that there was 
an equilibrium relationship established between the moisture in the storage chamber and the 
residual water remaining within the SGMNs.  Furthermore, it has been shown that storage RH 
does not equate to moisture content of amorphous sugars maintained within the environment 
at equilibrium (Nowakowski and Hartel 2002).  For example, corn syrup and sucrose glasses 
with high surface to volume ratios equilibrated to 80 %RH for one week contained 
approximately 9 % total moisture (Nowakowski and Hartel 2002).  Therefore, it may have been 
that 15 %RH, which corresponds to an absolute humidity of 2 g/kg at 20 °C (Margetts and 
Sawyer 2007), provided the optimal storage humidity for stabilisation of the SGMN structure.  
When the environment contained a lower mass of water vapour at 5.5 or 10 %RH, this 
appeared to cause rapid MN degradation, and conversely when excess water was present in 
the environment this caused rapid water sorption and destabilisation of the amorphous glass, 
Figure 4.13.  
 
To assess the water content of SG material maintained under these conditions, TGA was 
performed on the glasses, Figure 4.20.
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(A) (B) (C)
(D) (E) (F) 
(G) 
Figure 4.20  Thermogravimetric analysis of sugar glasses under various storage conditions.   
Profiles indicate water content of SGs (A) at formation, and then following storage under (B) 4 ± 2 °C and desiccation, (C) 20 ± 2 °C and 15 %RH, (D) 20 ± 2 °C and vacuum 
desiccation, (E) 20 ± 2 °C and 5.5 %RH, (F) 20 ± 2 °C  and 10 %RH, (G) 37 °C  and 10 %RH.   
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As shown in Figure 4.20 (A), the SGs formed initially contained approximately 7 %w/w water.  
This correlated with previous findings in section 2.4.4, where combination SGs were shown to 
contain approximately 5 - 8 %w/w water.  However, once introduced into environments with 
differing RH the water content of the SGs appeared to change.  Variation in water content was 
not large under any of the storage conditions, but it may have had an effect on the subsequent 
stability of the SGMN arrays.  As stated, SGMNs appeared to be completely unstable following 
storage under ambient temperature at 5.5 %RH and 10 %RH or 37 °C and 10 %RH.  The profiles 
in Figures 4.20 (F) and (G) showed that both glasses maintained under 10 %RH showed an 
increase in water content following 7 days storage and a slight increase in water content was 
shown following storage at ambient temperature and 5.5 %RH, Figure 4.20 (E).  It was not 
apparent why these glasses may have increased in water content, and as the increases were 
only small, the differences may have been due to experimental variation.  Importantly, none of 
these storage conditions appeared to stabilise the SGMN structure and hence were 
disregarded. 
 
In contrast, it appeared that SGMN arrays remained stable when maintained under desiccation 
or 15 %RH at ambient temperature.  Sugar glasses maintained under ambient temperature and 
vacuum desiccation or 15 %RH, Figures 4.20 (C) and (D), appeared to show thermal profiles 
very similar to the initially fabricated SG, Figure 4.20 (A).  This data suggested that the material 
was stable under these environments and supported visual observations of SGMN stability, 
Figure 4.19.  The SG maintained at 4 °C under desiccation showed a slight decrease in water 
content following 7 days storage however.  Similar observations had been made previously, 
section 2.4.4, where it appeared that the water content of SGs had decreased following 
periods of desiccated storage.  This decrease in water content did not appear to be completely 
detrimental to the SGMN structure, Figure 4.19 (A), but the array was noted to have changed 
from being transparent to opaque.  It was speculated that this effect may have been due to 
the desiccated environment utilised and further removal of water from the SG structure.  From 
these data it was concluded that the nature and stability of SGMNs formed by low 
temperature dehydration was not straightforward.  Fabrication technique and thermal history 
are known to influence amorphous sugar properties (Surana et al. 2004) and hence it was 
speculated that the process developed for SGMN production may have led to the unusual 
material properties observed.   
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To observe how storage conditions affected SGMN properties over extended periods, arrays 
were maintained under these conditions for 3 months.  The images in Figure 4.21 depict 
SGMNs following 28 days storage.  As shown, the geometry of each of the SGMNs stored 
under each of the environments studied appeared to have changed little in comparison to 7 
days storage.  It was observed that all MNs on each of the arrays appeared to have taken on a 
more rounded appearance, but that they generally resembled the SGMNs shown in Figure 
4.19.  Once more, this supported previous findings following 5 weeks storage, Figure 4.15.                                       
 (A)   (B)   (C) 
Figure 4.21  Representative light photomicrographs of SGMNs following 28 days storage.   
Arrays were stored under (A) 4 ± 2 °C and desiccation (B) 20 ± 2 °C and 15 %RH, (C) 20 ± 2 °C and vacuum 
desiccation.  Images cross illuminated for visualisation (Bar = 100 µm).  
 
Further sections of SG were examined to determine water content at this time point, Figure 
4.22.  Again, it appeared that the water content of these glasses closely resembled those 
obtained at 7 days, Figure 4.19 (B) – (D).  However, it was noted that the content of the SG 
maintained at 4 °C under desiccation appeared to have decreased marginally once more, 
Figure 4.22 (A).  This is likely to have been due to the desiccated environment and further 
water loss over this period.       
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(A)
(B) 
(C) 
Figure 4.22  Thermogravimetric analysis of sugar glasses following 28 days storage.   
Profiles indicate water content of SGs following storage under (A) 4 ± 2 °C and desiccation, (B) 20 ± 2 °C 
and 15 % RH, (C) 20 ± 2 °C and vacuum desiccation.     
 
The data obtained following 3 months storage was disrupted prior to SGMN array visualisation.  
As Figure 4.23 shows, all of the arrays viewed at this time point retained no MN structures.  It 
was noted that each of the arrays had developed a “lustrous” appearance, and the surfaces 
had become viscous in nature.  According to reports on the day of assessment and 
visualisation, the ambient temperature was approximately 25 °C whilst the RH was 94 %.  As 
RH is a measure of the degree of water vapour saturation of air (Margetts and Sawyer 2007), 
and as it was a warm day, the air will have contained a relatively large mass of water vapour.  
From the results observed, it was speculated that due to the hygroscopic nature of SG material 
(Dittmar 1935) SGMN arrays had adsorbed and absorbed water from the environment prior to 
visualisation.  Moisture sorption processes are likely to have caused the rapid dissolution and 
change in material properties (Nowakowski and Hartel 2002) of the SGMNs observed.      
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(A)  (B)  (C)  (D)  
(E) 
Figure 4.23  Representative examples of SGMN arrays stored for 3 months.   
Macro images of arrays stored under (A) 4 ± 2 °C and desiccation (B) 20 ± 2 °C and 15 % RH, (D) 20 ± 2 °C 
and vacuum desiccation prior to visualisation(Bar = 100 µm).  (C) and (E) light photomicrographs of the 
surface of arrays (B) and (D), respectively, demonstrating the absence of discrete microneedle 
structures.  Images cross illuminated for visualisation purposes.        
 
Due to the suspected adverse effects of the ambient conditions on SGMN arrays, measures 
were taken to protect SG material from these conditions prior to thermal analysis.  As the 
profiles in Figure 4.24 show, there was little difference in water content noted at 3 months in 
comparison to samples examined at 28 days, Figure 4.22.  This suggested that the material was 
stable for up to 3 months under desiccation at 4 and 20 °C and at 20 °C under 15 %RH.  The 
small decrease in water content noted in samples stored under desiccation at 4 °C was 
speculated to be due to the mass of desiccant utilised.  As the quantity of desiccant was not 
standardised between different storage conditions this may have accounted for the decrease 
in water content observed in refrigerated samples only.     
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(A)
(B) 
(C) 
Figure 4.24  Thermogravimetric analysis of sugar glasses following 3 months storage.   
Profiles indicate water content of SGs following storage under (A) 4 ± 2 °C and desiccation, (B) 20 ± 2 °C 
and 15 % RH, (C) 20 ± 2 °C and vacuum desiccation.     
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4.5 Conclusion  
It was an important focus of this chapter to investigate incorporation of model substances 
within the structure of SGMN arrays.  In line with previous reports, loading of a range of 
different model molecules with varying physicochemical properties did not appear to affect 
MN stability up to approximately 5 %w/w.  Drug loading at a greater concentration than this, 
especially with small molecules, appeared to decrease SGMN array integrity however.  The 
activity of a functional model macromolecule, β-galactosidase, following incorporation within 
SGMNs was shown to be stable following vacuum processing and dehydration.  Sugar glass 
MNs containing enzyme demonstrated sufficient structural rigidity to puncture the human skin 
barrier to facilitate delivery of protein into deeper skin layers.  This finding was essential to the 
future utility of these devices to facilitate transdermal drug delivery of macromolecular drug 
substances.   
 
Furthermore, the enzyme was shown to retain activity when maintained within sugar glass 
material following storage at ambient or refrigerated temperature under desiccation over a 
period of months.  Storage conditions were shown to be critical to the physical stability of 
SGMN structure however.  Elevated temperature and humidity appeared to be extremely 
detrimental to MN morphology; although conversely a completely desiccated environment did 
not appear to be optimal either.  Preliminary studies indicated that a storage environment 
with a low relative humidity at ambient temperature may be optimal for prolonged SGMN 
stability.                         
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5 Optimisation of in vitro assays to assess sugar glass microneedle drug 
delivery 
5.1 Introduction 
5.1.1 In vitro transdermal drug delivery 
The gold standard for assessing the drug delivery capacity of any novel transdermal delivery 
device would be to evaluate its efficacy in human subjects.  However, there are many 
drawbacks to this form of investigation including cost, ethical approval and the potential for 
harm to be caused to the subject.  Therefore, a number of in vitro and in vivo techniques have 
been developed to estimate the drug delivery efficiency of transdermal formulations in model 
systems.   
 
In vitro methods are particularly interesting as they remove the necessity to use a living 
organism to assess transdermal drug delivery properties.  Typically, diffusion cells are used to 
assess potentially suitable transdermal formulations and devices.  In this set up a model 
membrane is sandwiched between the flanges of the donor and receptor chambers of the 
diffusion cell and a formulation is applied to the donor phase.  Different representative 
barriers are used in these experiments, each with their own advantages and disadvantages.  
One approach is to use a synthetic membrane that is not of animal origin, but one which 
retains certain characteristics of the human skin barrier.  For example, medical grade non-
porous Silastic® (polydimethylsiloxane) sheeting has been compared to heat separated human 
epidermal membranes in the assessment of oestradiol diffusion from saturated and 
supersaturated solutions of drug in various co-solvent systems (Megrab et al. 1995).  The 
rationale for the use of such a model is that the material represents a simple and inert 
membrane to investigate the permeation of drug from an unstable formulation.  Skin 
represents a heterogeneous and variable membrane in comparison to Silastic® and therefore 
the polymer provides a more predictable barrier in such permeation studies (Donnelly et al. 
2009a; Megrab et al. 1995).  It has also been shown previously that the permeability of silicone 
rubber membrane to a small molecular weight drug, such as salicylic acid, is comparable to 
that of human skin (Nakano and Patel 1970).  Other synthetic model membranes that have 
been investigated include hydrophilic, microporous polyethylene membrane for hormone drug 
release studies from transdermal patches (Schulz et al. 2010).  Once again, this material 
provides a more homogenous barrier for assessing drug release kinetics from a formulation.   
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Another model barrier that has been used is excised skin tissue of animal origin.  For example, 
Wang et al. investigated the iontophoretic delivery of hydrocortisone across full thickness 
hairless mouse skin (Wang et al. 1993).  Similarly, full thickness porcine skin was utilised by 
Karande et al. to assess the effect of chemical penetration enhancers on the permeation of 
inulin (Karande et al. 2005).  These are good models for transdermal permeation as all the 
various layers of the skin are present and have not been through harsh processing conditions.  
However, the precise skin structure of humans and animals does vary, for example the SC of 
mouse skin is much thinner, 5.8 ± 0.3 µm compared to 16.8 ± 0.7 µm (Bronaugh et al. 1982), 
and contains considerably more hair follicles, 658 ± 38 compared to 11 ± 1 (Bronaugh et al. 
1982) for human skin, and therefore it may be hard to extrapolate findings.     
 
It is apparent that both these model barriers bear no relation to the physiology and anatomy 
of genuine human skin.  The mechanical, hydration and overall barrier properties of all of the 
models discussed so far will never be precisely the same as those of human tissue.  This is 
particularly critical when assessing mechanical methods for disrupting the skin barrier to 
facilitate drug delivery.  Therefore, many workers have examined either split thickness human 
skin, where the epidermis and a portion of the dermis are utilised, or fully separated epidermal 
membrane as a model barrier for transdermal drug delivery studies (Akomeah et al. 2009; 
Prausnitz et al. 1993).  The rationale behind the use of these barriers is that the SC provides 
the primary barrier to drug transport (Brown and Langer 1988), in particular to hydrophilic and 
large molecular weight substances, and because the dermis provides an artefactual reservoir 
and binding site for drugs which have crossed the epidermal barrier and would be removed by 
capillaries found within the dermal-epidermal layer in vivo (Amsden and Goosen 1995).  
Accordingly, it was an important focus of this chapter to investigate a robust in vitro human 
skin model to predict SGMN facilitated drug delivery across skin.                 
 
5.1.2 Establishment of skin barrier integrity by electrical resistance measurement 
A critical aspect of assessing drug delivery across human skin in vitro is to determine initial 
barrier functionality.  Removal and processing of tissue prior to experimentation may all have 
damaging effects on barrier function and therefore it is vital to establish integrity prior to study 
initiation.   
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As stated in section 1.2.2.2 the SC barrier consists of protein rich corneocytes stacked within 
lipid bilayers.  The barrier characteristics of the SC have previously been studied by a number 
of methods including determination of the rate of tritiated water permeation (Dugard et al. 
1984; Scott et al. 1991) and measurement of transepidermal water loss (Heylings et al. 2003; 
Zhao and Singh 1999).  An alternative technique that has been receiving increasing interest is 
measurement and variation in electrical properties of the barrier.  The ordered structure and 
low permeability of SC lipids are responsible for the high electrical impedance or resistance of 
the SC as it forms a relatively non-conductive, semi-permeable membrane to ions (Lackermeier 
et al. 1999).  Therefore, electrical impedance measurement across skin is strongly related to its 
barrier function (Karande et al. 2006).  As a corollary, damage to the lipids of the SC, for 
example from chemical irritants, will enable an electrical current to pass through the skin 
barrier more easily (Heylings et al. 2003).  Hence, skin impedance in the context of this work 
was used in its simplest form, by measuring the resistance of electrons to move from the 
donor to the receptor compartment in the presence of an AC current (Karande et al. 2006). 
 
It has been shown previously that the electrical resistance (ER) of intact epidermal barriers 
from various biological organisms vary.  For example, a value of 5 - 20 kΩ for full thickness 
mouse skin (Heylings et al. 2003) represented the normal range for this skin type and a similar 
range of 6 - 20 kΩ was observed for rat epidermal skin (Oliver et al. 1988).  Other workers have 
examined human skin samples from various anatomical sites and found that ER greater than 
20 kΩ/cm2 was indicative of an intact barrier (Chilcott et al. 1996; Lawrence 1997).  However, 
Davies et al. found that human whole and epidermal membranes both had mean resistance 
values of approximately 10 kΩ (Davies et al. 2004) and Fasano et al. found that epidermal 
membrane values ranged from 12 - 62 kΩ (Fasano et al. 2002).  The differences reported are 
likely to be due in part to variations in experimental methodology and setup, for example it 
has been shown that ER decreases with an increase in cell area (Fasano et al. 2002) and ion 
concentration in skin (Oh et al. 1993).  What has been suggested is that ER measurement is a 
suitable and robust methodology for evaluating skin integrity; there being a strong association 
between high water flux and low ER across different species (Davies et al. 2004; Fasano et al. 
2002; Oliver et al. 1988).  Importantly, skin storage conditions can be a potential issue when 
investigating barrier properties of skin membranes, especially following storage under frozen 
conditions.  However, it is generally accepted that the integrity of both full thickness human 
skin and epidermal membranes is unaffected by storage at -20 ºC for up to one year (Davies et 
al. 2004).   
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The broad aim of this chapter of work was to establish and validate a robust in vitro 
methodology for the estimation of percutaneous drug delivery from SGMN array devices.  
Selection of the most appropriate barrier, and establishment of barrier integrity, were critical 
factors in assessing the utility of this methodology.      
         
5.1.3 Transdermal drug delivery systems                   
The transdermal drug delivery system (TDDS), or patch, is an attractive, non-invasive option 
(Sullivan et al. 2008) for delivering small molecular weight, lipophilic drugs at low flux rates 
(Langer 1998) through the skin for systemic therapeutic effect (Brown and Langer 1988).  
There are numerous advantages associated with transdermal delivery.  These include 
controlled release of drug into the patient, thus potentially enabling a steady blood-level 
profile resulting in reduced systemic adverse effects, and the possibility of improved efficacy 
over other dosage forms (Chong and Fung 1989).  Importantly, drugs administered via this 
route are not subject to hepatic first-pass metabolism.  Improved patient compliance arises 
from the convenience of application and dose flexibility (Audet et al. 2001).  Examples of drugs 
currently delivered transdermally include nicotine, fentanyl, ethinylestradiol, norethisterone 
acetate, testosterone, clonidine, scopolamine, buprenorphine, norelgestromin and oxybutynin 
(Hadgraft and Lane 2006).  However, most drugs investigated for transdermal drug delivery do 
not cross the skin at therapeutically relevant rates (Guyot and Fawaz 2000) due to the 
extraordinary barrier function of the SC. 
 
Transdermal patches have broadly been developed into three different categories, namely the 
reservoir system, matrix diffusion-controlled system, and multiple polymer system.  The 
reservoir system is a diffusion-controlled system that contains a drug reservoir with a rate-
controlling polymer membrane (Margetts and Sawyer 2007).  In this device, the membrane 
that lies between the drug reservoir and the skin controls the rate of release from the drug 
reservoir to the skin surface and zero order drug release is achievable (Hadgraft and Lane 
2006).   Conversely, in matrix diffusion-controlled systems the active drug is contained within 
an adhesive polymer matrix and the drug is released at a rate governed by the components in 
the matrix (Margetts and Sawyer 2007).  However, matrix patches in themselves are not 
designed to provide true zero-order release because as the drug closest to the skin is released, 
the drug deeper within the patch must travel a longer distance to reach the skin. The longer 
diffusional path slows the rate of absorption from the patch over time.  For most well designed 
matrix patches this is not an issue as the decrease in release rate is so small that it does not 
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significantly affect the rate of drug absorption (Hadgraft and Lane 2006).  Inter-patient 
variability in drug absorption in both patch systems is minimised by a slow rate of release from 
the patch; either by the rate controlling membrane or the adhesive matrix (Margetts and 
Sawyer 2007).  However, in conventional drug-in-adhesive patches, the dual functionality of 
the adhesive and reservoir may pose a problem for patch size.  A small patch needs high drug 
concentrations, but loading the polymer adhesive with drug can compromise its adhesive 
properties (Hadgraft and Lane 2006) and lead to drug crystallisation.    
 
 
Conventional drug delivery from passive diffusion controlled TDDSs remains limited because 
the barrier properties of the skin are not fundamentally changed.  The SC barrier remains 
intact and therefore permits diffusion of only specific exogenous materials with appropriate 
properties.  For example, patch-type transdermal products on the market are employed to 
deliver only a small number of drugs, as mentioned previously.  These drugs tend to have 
similar physicochemical properties including a molecular weight less than 500 Da, sufficient 
aqueous and lipid solubility (LogP between 1 - 3) and high potency, for example, 10 - 30 ng/mL 
for nicotine.  Although patch systems do not overcome the physicochemical restrictions 
discussed, they offer an improvement in dose control, patient acceptance, and compliance 
compared with semisolid formulations (Brown et al. 2006). 
 
It was hypothesised that SGMNs could be integrated into an adhesive patch system to provide 
controlled release of model substances.  In Chapter 3 it had was found that SGMNs dissolve 
rapidly in situ in skin and therefore it was unlikely that control of drug release would be 
feasible in these systems.  It was envisaged that an integrated SGMN adhesive patch may 
provide controlled delivery of relatively impermeable molecules across skin.        
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5.2 Chapter objectives 
1. Investigate the potential for model hydrophilic compound incorporation within adhesive 
patch systems. 
2. Fabricate integrated transdermal adhesive SGMN array patches for percutaneous drug 
delivery applications. 
3. Assess the stability of SGMN arrays attached to a range of adhesive backing layers. 
4. Develop the classical static type Franz diffusion cell set up for MN penetration and 
diffusion studies. 
5. Explore the percutaneous drug delivery efficacy of MN arrays across a number of 
different model barriers utilising Franz diffusion cells. 
6. Assessment and validation of ER measurement as a determinant of human skin barrier 
integrity. 
Chapter 5 
138 
5.3 Materials and methods 
5.3.1 Materials 
All reagents were obtained from Fisher Scientific Ltd. (Loughborough, UK) and were of 
analytical grade unless stated otherwise. 
All films and adhesive films were kindly obtained from 3M Drug Delivery Systems (St Paul, MN, 
USA). 
Acrylate adhesives were generously supplied by Henkel Limited (Berkshire, UK).  
Silicone adhesives were generously supplied by Dow Corning (MI, USA).   
Human breast skin was obtained from the Aneurin Bevan Health Board Royal Gwent Hospital 
(Newport, Wales, UK) following mastectomy or breast reduction surgery with full ethical 
committee approval and informed patient consent.  
 
5.3.2 Methods 
5.3.2.1 Fabrication and stability assessment of SGMN arrays with adhesive backings 
A 20 %w/v solution of TRA and SUC 75:25 %
w/w was prepared and MB powder was incorporated 
at 1 %w/w of final sugar glass weight.  The solution was filtered using a 0.2 µm filter and 
vacuum formed into PDMS micromoulds.  200 µL of sugar solution was injected onto the 
mould surface under vacuum using the methodology described in section 3.3.2.7 (A).  Upon 
removal from the vacuum chamber, 170 - 180 µL of the solution was pipetted off the surface 
of the mould and the solution was dehydrated for 48 h as described in section 2.3.2.1 to form 
SGMN arrays with a thin backing layer.  Once dried, SGMN arrays were removed using a 
cuboidal shaped rod, dimensions 5 x 5 x 100 mm, with double-sided adhesive tape attached to 
the square end.  A variety of SGMN backing materials were attached to the adhesive tape 
including:- 
 fabric plaster 
 waterproof plaster 
 Micropore™ tape  
 CoTran™ 9699  
 foam 9733  
 polyurethane 9832F  
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The SGMN array adhesive patches were viewed under light microscope to observe patch and 
needle integrity prior to storage under vacuum desiccation.   
 
5.3.2.2 Fabrication and optimisation of drug loaded adhesive patches 
Silicone soft skin adhesive (SSA; MG 7-9800) and amine compatible silicone BIO-pressure 
sensitive adhesive (BIO-PSA 7-4302) were used to create 500 mg samples of blank adhesives 
and adhesives containing 1 %w/w ketoprofen (KFA) and propranolol hydrochloride (PHCl).  To 
create drug loaded adhesives two approaches were used:- 
a) KFA was dissolved in acetone or ethyl acetate and mixed by hand into part A of the 
adhesive kit for 60 secs  
b) KFA or PHCl powder was mixed by hand into part A for 60 secs. 
An equal mass of part B was added to the mixtures and thoroughly mixed by hand for another 
3 mins.  Blank adhesives were fabricated by adding equal quantities of part A and B and mixing 
thoroughly for 3 mins.  All adhesive mixtures were mixed on Scotchpak™ 1022 release liner in a 
square base dish (approximately 5 x 5 cm).  Once mixed, SSAs were cured at 95 ºC for 1 h and 
BIO-PSAs were placed into a fume hood at ambient temperature for 2 h. 
 
5.3.2.3 Fabrication of integrated sugar glass microneedle transdermal patches containing 
sulforhodamine B 
Sulforhodamine B sodium salt (SRB) was loaded into the adhesives Duro-Tak® 87202-A 
(acrylate adhesive) and BIO-PSA® 7-4302 (silicone adhesive) at a concentraion of 5 %w/w.  A 
known amount of dry adhesive was dissolved in ethyl acetate and the drug powder was added.  
The resulting suspension was magnetically stirred for 30 mins to uniformly disperse the drug.  
Once dispersed, the formulation was pipetted onto Scotchpak™ 1022 release liner and placed 
on a flat bed shaker overnight (18 h) to evaporate the solvent.  To ensure removal of residual 
solvent, the adhesive was then dried for 1 h in an oven at 60 oC (Schulz et al. 2010).  Once the 
adhesive layer had formed, Scotchpak™ 9733 backing layer was placed onto the adhesive and 
pressure was applied in a rolling motion.  Patches were formed using a biopsy punch with a 
diameter of 0.8 cm.  This technique yielded patches containing approximately 5 mg of adhesive 
and 250 µg SRB.   
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SGMN arrays with a thin backing layer (formed from 40 µL of 20 %w/v TRA:SUC 75:25 %
w/w 
solution) were formed as described in section 5.3.2.1.  Release liner was removed from the 
adhesive patches and they were placed adhesive side down onto the PDMS moulds.  SGMN 
arrays were removed using a cuboid shaped rod as described in section 5.3.2.1.   
     
5.3.2.4 Investigation of model membranes to assess microneedle facilitated drug delivery 
capabilities 
Silastic® (Dow Corning, MI, USA) and plasticised PVC film membranes (Saran™ premium wrap) 
were mounted onto semi-circular cork board wrapped in tissue paper and treated with a single 
silicon MN array application.  Membranes were then mounted between the greased donor and 
receptor chambers of static Franz type diffusion cells of known receptor volume (mean volume 
3.58 mL) and internal diffusional area (diameter approximately 1 cm).  The receptor 
compartment was filled with degassed de-ionised water (dH2O) for PHCl studies or phosphate 
buffered saline (pH 7.4) (PBS) (Sigma - Aldrich, Poole, UK) for IBU studies.  Positive control cells 
in both experiments were treated with a single hypodermic needle (26 G) application.  To 
assess Silastic® as a model membrane barrier, 0.5 mL of a solution of PHCl 0.5 mg/mL dissolved 
in dH2O (1.7 mM) (Coulman et al. 2009) was applied to the donor compartment of each cell 
and occluded with a section of Parafilm®.   
 
Blank sugar glasses (SGs) and SGs containing 5 %w/w IBU were prepared by pipetting 150 µL 
sugar or drug-sugar solutions, respectively, onto a flat sheet of PDMS and dehydrating as 
described in section 2.3.2.1.  To assess model plasticised PVC film barrier, blank or drug loaded 
SGs were applied to the donor compartment of each cell and occluded with intact plasticised 
PVC film.  Cells were placed on top of a multipoint magnetic stirrer in a water bath and 
equilibrated to 37 ºC for at least 30 mins.  A small magnetic follower was added to each cell 
providing a membrane surface temperature of approximately 32 ºC and continuous agitation 
of the receptor solution (Chabri et al. 2004).  200 µL samples were removed from the receptor 
phase at time points 1, 2, 4, 6, 12 and 24 h and the receptor compartment was replenished 
with an equal volume of dH2O or PBS pre-equilibrated to 37 ºC; a dilution factor which was 
accounted for in subsequent data analysis.  Samples were stored at -20 ºC until required for 
high performance liquid chromatography (HPLC) analysis.   
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For comparisons of multiple treatment groups, a one-way ANOVA with Bonferroni’s multiple 
comparison post hoc test was performed on the experimental data using the GraphPad Prism 5 
software package.  In all cases, statistical significance was determined by a value of P ≤ 0.05.    
  
5.3.2.5 Investigation of heat separated epidermal membrane to assess microneedle 
facilitated drug delivery 
A saturated solution of IBU (1871.8 mM) was created by adding excess IBU to continuously 
agitated dH2O heated to 37 ºC.  A 20 %
w/v solution of TRA and SUC 75:25 %
w/w was prepared 
and IBU powder was incorporated at 5 %w/w of final sugar glass weight.  Previously frozen full 
thickness human skin from a female donor, age 58 years, was defrosted at room temperature 
for approximately 1 h before underlying subcutaneous fat was removed by blunt dissection.  
The epidermis was isolated by immersion into a water bath at 60 ºC for 55 secs followed by 
membrane removal with forceps.  Samples were stored at -20 ºC until required and used 
within 2 months of preparation.  Before use, membranes were defrosted for up to 20 mins, 
and mounted dermal side down between the greased donor and receptor chambers of static 
Franz type diffusion cells.  The receptor compartment was filled with degassed PBS and 
equilibrated to 37 ºC in a water bath.  Treated membranes were punctured with a single 
hypodermic needle (26 G) application and 0.5 mL of IBU saturated solution was applied to the 
donor compartment of each cell and occluded with Parafilm® to prevent evaporation.  In a 
separate experiment, epidermal membranes isolated from female donors aged 47 and 80 
years, were mounted dermal side down onto a section of Whatman no. 1 filter paper (1.5 x 1.5 
cm).  Membranes were mounted in Franz cells and treated with a single silicon MN array 
puncture before 150 µL of the 5 %w/w IBU sugar solution was applied to the donor 
compartment.  Cells were placed into a water bath and 200 µL samples were removed from 
the receptor phase at defined time points, as described in section 5.3.2.4 and stored at -20 ºC 
until required for HPLC analysis.    
 
5.3.2.6 Quantitative analysis of small molecule model drug substances 
Samples containing the analyte PHCl were analysed by fluorescence spectrophotometry 
(Fluostar Optima™, BMG Labtech, Aylesbury, UK) using a 96 well plate methodology with 
excitation and emission filters set at 280 and 330 nm respectively.  Drug quantities were 
estimated by linear regression and correlation analysis of the calibration curve generated with 
a LOD of 1 x 10-3 mM.  IBU sample analysis was performed using reversed-phase HPLC 
apparatus with the following instrumentation: SCM 1000, pump P2000 and auto-sampler 
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AS3000 equipped with a UV2000 detector (Spectra System®, Thermo Fisher Scientific, 
Hertfordshire, UK).  The GraceSmart™ RP C18 5 µ column (250 x 4.6 mm) and an isocratic 
eluent (pH 3.4) of 75 % methanol, 24 % water and 1 % glacial acetic acid were used in this 
study.  The flow rate was set at 1.5 mL/min and 20 µL samples were injected onto the column.  
The elution time was set for 6 mins and absorbance detection was at a wavelength of 272 nm.  
Drug quantities were estimated by linear regression and correlation analysis of the calibration 
curve generated with a LOD of 5 x 10-3 mM.  Error bars shown on permeation profiles in all 
studies relate to the standard error of the mean to take into account sample size. 
     
5.3.2.7 Development and optimisation of static type Franz diffusion cells for microneedle 
facilitated penetration / permeation studies 
SGMN arrays were fabricated from a 20 %w/v solution of TRA and SUC 75:25 %
w/w as described 
in section 3.3.2.5.  The following modifications were made to the classical setup of the Franz 
diffusion cell to assess optimal membrane penetration capabilities of SGMN arrays.   
5.3.2.7.1 Inverted method   
A cylindrical shaped metal rod with diameter approximately 1 cm was placed into an upturned 
donor chamber.  SGMN arrays were placed with their needles facing upwards onto a circular 
section (1 cm diameter) of plasticised PVC film and placed onto the end of the rod.  A section 
of epidermal membrane, mounted dermal side down onto a section of Whatman no. 1 filter 
paper (1.5 x 1.5 cm) was then placed SC side down on top of the SGMN array.  Pressure was 
applied to the membrane for 10 secs using a syringe plunger covered with a section of foam 
9773 tape.  The receptor compartment was filled with degassed PBS and the donor 
compartment and SGMN assembly were clamped in place, as shown in Figure 5.1. 
 
Figure 5.1  Schematic of inverted SGMN application methodology. 
Finally, cells were inverted to displace any residual water bubbles beneath the membrane. 
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5.3.2.7.2 Gauze method   
A Franz cell was assembled with a disc of polytetrafluoroethylene (PTFE) material, 
(approximately 2 cm diameter, 0.4 cm depth), between the flanges of the donor and receptor 
chambers.  A circular hole of 1 cm diameter was punched in the centre of the disc with a 
slightly larger hole on one side only to create a step.  A section of stainless steel gauze 
(Goodfellow Cambridge Ltd., Huntingdon, UK) with a nominal aperture of 0.38 mm, was 
fashioned to fit inside the stepped hole.  A section of filter paper was placed on top of the 
gauze and the epidermal membrane was placed dermal side down onto the filter paper.  The 
donor chamber was clamped in place and the receptor was filled with degassed PBS.  A SGMN 
array was mounted onto the flattened end of a syringe plunger and inserted into the donor 
compartment and pressed down for 10 secs into the membrane, as shown in Figure 5.2.   
 
Figure 5.2  Schematic of SGMN application methodology utilising gauze Franz cell insert. 
Once inserted, a 1 cm disc of plasticised PVC film was placed on top of the array. 
5.3.2.7.3 PTFE disc method   
The same assembly as in 5.3.2.7 (2) was utilised, except that the PTFE disc had 4 holes, 
diameter 2 mm, drilled into the centre rather than a section of gauze material. 
 
All membranes were observed by light microscope, Leica Zoom 2000 (Leica, Scotts Valley, CA, 
USA) prior to and following SGMN insertion to determine the penetration profile for each 
method. 
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5.3.2.8 Assessment and validation of electrical resistance as a measure of epidermal barrier 
integrity 
Modified static type Franz diffusion cells were assembled with a PTFE ring containing gauze 
insert as described in section 5.3.2.7 (2).  Heat separated epidermis was prepared as described 
in section 5.3.2.5 and mounted onto the modified cells.  The donor chamber was secured, and 
the receptor and donor compartments were filled with physiological saline (0.9 % NaCl in 
water) pre-equilibrated to 37 ºC.  Once assembled, the electrical resistance (ER) of each 
membrane was measured with an Agilent U1731A™ dual display handheld LCR meter (Agilent 
Technologies UK Ltd, Edinburgh, UK) using a testing frequency of 1 kHz.  Measurements were 
taken by inserting the stainless steel cathode probe into the side arm of the receptor chamber 
and then inserting the anode probe into the donor chamber, taking care not to touch the 
membrane.  Following stabilisation of the reading, the resistance value was recorded for each 
cell.  Once the ER assessment for each cell had been completed the contents of the donor and 
receptor compartments was discarded and the skin allowed to air dry (Heylings et al. 2003).       
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5.4 Results and discussion 
5.4.1 Fabrication of SGMN arrays with alternative backings  
As described in section 3.4.9, SGMN arrays dissolved rapidly in situ in ex vivo human skin.  
Therefore, it was concluded that they were unlikely to be suitable as controlled release drug 
delivery devices.  The solid SGMN array bases had also demonstrated poor structural rigidity 
upon skin insertion and it was envisaged that end-user application of arrays may be difficult.  
Using a traditional transdermal patch device as a template, it was hypothesised that SGMNs 
could be attached to a different base material.  This material would be a completely different 
material to rigid sugar glass that may confer desirable properties upon the SGMN arrays.  It 
was envisaged that possible benefits may include increased drug loading within the backing 
layer, potential for controlled release of medicament and ease of application for end-user.  
However, to fabricate stable SGMN arrays with flexible adhesive backings, it was critical to find 
a patch system that would not adversely affect SGMNs attached to it.      
 
A variety of base materials were investigated including generic fabric plaster and waterproof 
plaster, Micropore™ tape and various 3M adhesive films.  Each material was chosen for its 
adhesive properties and proven compatibility with human skin.   
 (A)   (B) 
 (C)   (D) 
Figure 5.3  SGMN arrays with alternative backings.   
Digital images of SGMNs incorporating 1 %w/w MB attached to (A) waterproof plaster and (C) 
Micropore™ tape backings.  (B) and (D) light photomicrographs of SGMNs depicted in (A) and (C) 
respectively (Bar = 100 µm). 
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Although SGMNs were successfully attached to a fabric plaster backing the plaster did not 
have the desired properties of a SGMN base.  It was envisaged that the base material would be 
flexible, with a smooth and flat adhesive side that would not adversely affect the morphology 
of the SGMN array.  The fabric plaster fulfilled some of these criteria, but critically the material 
was not smooth enough and MNs were observed to be positioned at many different angles 
(data not shown).  It was hypothesised that such an array would not be effective at 
penetrating human SC.  As shown in Figure 5.3 however, SGMN arrays with flexible backings 
made from waterproof plaster and Micropore™ tape fulfilled the above criteria to a much 
greater extent.  Both backing materials were much smoother than the fabric plaster and hence 
individual MNs were orientated in approximately the same direction.  However, the 
waterproof plaster backing appeared to cause rapid degradation of the SGMN morphology.  
Within 15 mins of creation, the MNs were observed to have changed shape and become 
rounder and less pyramidal, as shown in Figure 5.4. 
 
Figure 5.4  Light photomicrograph of SGMNs with a waterproof plaster backing.   
Image shows the rapid alteration in MN morphology observed. 
 
The rapid alteration in SGMN morphology was attributed to the waterproof nature of the 
plaster and it was speculated that it may be causing hydration and degradation of the needles.  
In contrast, SGMN arrays attached to Micropore™ tape appeared to be much more stable and 
SGMNs attached to this backing, Figure 5.3 (D), retained a much closer morphology to the 
silicon master structure.  
 
Another factor that became apparent through this study was that SGMN arrays fabricated 
from 20 µL of sugar solution did not always contain a sufficient quantity of material to form a 
continuous base layer once dehydrated.  Micromould invaginations were full of sugar glass 
material, but this did not extend to the entire surface of the mould.  It was found that removal 
of all 36 MNs formed became problematic, as shown in Figure 5.5 (A). 
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 (A)   (B) 
 (C) 
Figure 5.5  Light photomicrographs of SGMN array with a CoTran™ 9699 backing.   
(A) En face of entire SGMN array and, (B and C) individual SGMNs contained within array (Bar = 100 µm). 
 
As shown in Figure 5.5 (A) a number of MNs near the centre of the array were not removed by 
the adhesive backing layer.  This data appeared to suggest that a residual continuous base 
layer was required for successful removal of all SGMNs from the PDMS micromould.  Further, 
this study highlighted that CoTran™ 9699 adhesive tape was not an ideal backing material.  As 
shown in Figure 5.5 (B) and (C), SGMNs degraded when attached to this adhesive, and this 
process happened rapidly, within 14 days of fabrication and subsequent storage under vacuum 
desiccation. 
 
Figures 5.6 (A) and 5.7 (A) support Figure 5.5 (A) indicating that a continuous base layer was 
required for successful SGMN array attachment.  In both examples, very few of the SGMNs 
formed were removed by the backing layer adhesive.  However, the individual MNs remaining 
appeared to be stable on each of the adhesive backings, Figure 5.6 (C) and 5.7 (E).       
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 (A)   (B)  
 (C) 
Figure 5.6  Light photomicrographs of SGMN array with a polyurethane 9832F backing.   
(A) En face view of SGMN array and (B) transverse view of SGMNs (Bar = 1000 µm) and (C) individual 
SGMN contained within array (Bar = 100 µm).         
  
(A)  (B)  
(C)  (D)  (E) 
Figure 5.7  Light photomicrographs of SGMN array with a foam 9773 backing.   
(A) and (C) en face view of SGMN array, (B) and (D) transverse view of SGMNs (Bar = 1000 µm), (E) 
individual SGMN contained within array (Bar = 100 µm).   
  
This data appeared to show that SGMNs could be successfully attached to the correct adhesive 
backing layer and that they would remain stable under desiccated storage conditions, Figure 
5.7 (D) and (E).  To overcome the issue of incomplete SGMN array removal from micromoulds, 
the process was adapted and 30 µL rather than 20 µL was left on the mould surface before 
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dehydration.  This quantity of material generally formed an array with a complete base, and 
facilitated removal of all MNs from the mould, as shown in Figure 5.8.     
 (A)   (B) 
Figure 5.8  Light photomicrographs of SGMN array with a foam 9773 backing.   
(A) En face view of SGMN array and (B) transverse view of SGMNs (Bar = 1000 µm). 
 
From this study, it appeared that SGMN arrays formed from at least 30 µL of sugar solution 
could reliably and stably be attached to 3M polyolefin foam 9773 tape to form SGMN arrays 
with an alternative flexible backing. 
  
In conclusion, it was determined that the stability of SGMN arrays mounted onto a flexible 
backing would be a critical issue.  The utility of such a device would depend on the ability to 
successfully attach a plurality of SGMNs onto an adhesive backing layer that would not 
adversely affect the delicate and hygroscopic nature of the sugar glass material.  These pilot 
studies indicated that this concept may be feasible with the correct backing material and they 
led the way for further studies to optimise the system by fabrication of transdermal patches 
from basic principles, as detailed in section 5.4.3. 
 
5.4.2 Fabrication and optimisation of drug loaded adhesive patches 
Soft skin adhesives (SSAs) are intended for adhesion to skin and include a range of products 
such as over-the-counter bandages and scar therapies (Van Damme et al. 2009).  Conversely, 
BIO-pressure sensitive adhesives (PSAs) are intended for transdermal drug delivery products 
owing to good chemical stability of the adhesive in the presence of amine-functional drugs, 
excipients and enhancers (Laurent et al. 2007).  Two model drugs, with differing 
physicochemical properties, were incorporated into the two different adhesives at a 
concentration of 1 %w/w.  When KFA was incorporated within the SSA and heated to cure at 
100 ºC, dishes containing the adhesive dissolved and the adhesive did not cure fully (data not 
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shown).  This led to modification of the initial processing conditions and the use of a lower 
curing temperature of 95 ºC.           
 (A)   (B) 
Figure 5.9  Images of soft skin adhesives.   
(A) Blank adhesive and (B) 1 %w/w PHCl powder loaded SSA. 
 
As shown in Figure 5.9 (A), blank SSA formed a uniform transparent adhesive once cured.  
When PHCl powder was incorporated at 1 %w/w, the drug initially appeared to dissolve within 
the adhesive.  Upon curing of the adhesive however, the drug appeared to re-crystallise and an 
adhesive was formed that had an opaque nature, Figure 5.9 (B).  This was expected as PHCl is a 
water soluble salt of a basic drug and SSA does not contain amine compatible functionality in 
its structure.        
(A)  (B)  (C) 
Figure 5.10  Images of BIO-pressure sensitive adhesives.   
(A) Blank adhesive, (B) 1 %w/w KFA and (C) 1 %
w/w PHCl loaded adhesive samples. 
 
Blank BIO-PSA adhesive, like blank SSA, formed a transparent adhesive once cured, Figure 
5.10 (A).  The properties of the two adhesives varied significantly however, and the BIO-PSA 
adhesive formed a much more rigid material than the SSA.  The BIO-PSA had a lower tack than 
the SSA also and this made it easier to handle once cured.  It was hypothesised that this 
property may be useful in future applications when attaching SGMN arrays to the adhesives.  
As shown in Figure 5.10 (B), when 1 %w/w KFA was incorporated within the adhesive the drug 
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did not mix well within the matrix and re-crystallised rapidly as the solvent evaporated.  Again 
this was expected as KFA is a weak acid and contains no amine functionality.   It was 
rationalised that the PHCl may integrate better within the BIO-PSA matrix due to its basic 
nature.  This outcome was partially observed, as shown in Figure 5.10 (C), where no obvious 
crystallisation appeared in the adhesive; in contrast to the KFA adhesive, Figure 5.10 (B).  
However, it appeared that the drug remained in a suspended state, as shown by the opaque 
nature of this adhesive.   
 
The aim of these preliminary studies was to investigate the suitability of various commercial 
adhesives for incorporation of model medicaments.  These studies suggested that although 
drug appeared to crystallise within the cured adhesives, regardless of the physicochemical 
nature of the medicament, it may be possible in future work to incorporate a variety of model 
drug substances within these adhesives.  It was shown that thin adhesive layers containing 
medicament could be fabricated and it was hypothesised that these could be utilised as the 
basis of an integrated adhesive backed SGMN array patch.  This approach would potentially 
allow increased drug loading of the patch system and facilitate controlled drug release and skin 
adhesion. 
 
5.4.3 Fabrication of integrated sugar glass microneedle transdermal patches containing 
sulforhodamine B 
Sulforhodamine B (SRB) was chosen as a model compound to assess SGMN facilitated 
transdermal drug delivery.  This molecule has a MW of approximately 600 and a LogP of -0.45 
(Kushner et al. 2007) and is widely used as a model hydrophilic permeant when assessing 
active enhancement methods of drug delivery across the SC (Kushner et al. 2007; Sullivan et al. 
2008).  As demonstrated in section 4.4.1, SRB can successfully be incorporated within the 
matrix of SGMN arrays.  Therefore, it was chosen as an ideal model compound for comparison 
with SGMN adhesive patches in terms of transdermal drug delivery potential.  A loading 
concentration of 5 %w/w was chosen as percutaneous drug delivery systems are often 
formulated containing 5 – 10 %w/w drug.  It had also been shown that 5 %
w/w was an 
appropriate concentration of drug to incorporate within the matrix of SGMN arrays, section 
4.4.1, and therefore it seemed a logical concentration to work with.  The images in Figure 5.11 
show the nature of the novel integrated SGMN transdermal patch.      
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 (A)   (B)  
 (C)   (D)     
Figure 5.11  Images of novel integrated SGMN transdermal patch.   
(A) Blank Duro-Tak® 87202-A adhesive patch incorporating 5 %w/w SRB.  Light photomicrographs of (B) 
en face view and (C) transverse view of SGMN patch, (D) transverse view of SGMN patch following 6 
days storage under vacuum desiccation (Bar = 1000 µm).      
 
The dimensions of the patch, 0.8 cm diameter, were chosen for two reasons.  Firstly, the 
adhesive backing required a greater surface area than the square 6 x 6 mm dimensions of the 
SGMN attached to it.  Secondly, the patch had to be small enough to be applied to the donor 
phase of a Franz diffusion cell with a nominal diffusional surface area of 1 cm.  As shown in 
Figure 5.11 (B) the SGMN array sat well in the centre of the adhesive backing layer leaving a 
small area of unoccluded adhesive for skin adhesion.  Figure 5.11 (B) shows that the SRB 
formed discrete particles within the adhesive layer once formed.  This suggested that the 
solubility of SRB within the adhesive was low and it was speculated that this may provide a 
higher thermodynamic potential for transdermal drug delivery from the patch (Higuchi 1960).   
 
As Figure 5.11 (C) shows, SGMN arrays adhered to acrylate adhesive patches and appeared to 
retain their morphological structure.  This was expected as acrylate adhesives are hydrophobic 
materials and because the SGMN arrays were formed from 40 µL solution.  Therefore, the 
arrays had a slightly thicker base layer which may have improved the stability of the SGMNs 
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attached.  The SGMNs also appeared to be relatively stable under vacuum desiccation storage, 
Figure 5.11 (D).  Due to the flexible nature of the backing material and adhesive layer, the base 
of the SGMN array was often observed to crack in places, Figure 5.11 (C) and (D), but this did 
not appear to adversely affect the structure of individual MNs.  This data suggested the utility 
of this adhesive to formulate an integrated SGMN transdermal patch system.          
 
5.4.4 Investigation of different model membranes to assess microneedle facilitated drug 
delivery 
Various different methodologies for assessing the transdermal drug delivery potential of 
topical formulations have been described in the literature.  The Franz diffusion cell is a 
commonly used tool for assessing such parameters and a number of different model skin 
membranes have been utilised.  The aim of this section of work was to determine the most 
appropriate model membrane for examining the drug delivery potential of MN arrays.   
    
As shown in Figure 5.12 there was no significant difference (P=0.08) between untreated 
Silastic® membrane and membrane punctured with a hypodermic needle or silicon MN array.  
It appeared that penetrating the membrane decreased barrier integrity initially, as 
demonstrated by the absence of a lag phase in these treatment groups.  However, by the end 
of the study it was apparent that even Silastic® membrane treated with a hypodermic needle 
demonstrated little enhancement on total PHCl permeation compared to control.  There was 
also large variation in PHCl flux across the membrane, particularly following silicon MN 
treatment.  This result was not unexpected as although the MNs were applied to the 
membrane in the same manner each time, and visually inspected to observe membrane 
puncture, it may have been possible that not all of the MNs on the array fully punctured the 
membrane each time.  Also, as Silastic® membrane was used, any channels made within the 
membrane could potentially have closed up during the study. 
Chapter 5 
154 
 
Figure 5.12  Cumulative permeation of PHCl across Silastic® membrane.   
The square denotes data obtained following no membrane treatment (n=4), the triangle denotes data 
from hypodermic needle (26 G) treatment (n=4) and the circle from silicon MN treatment (n=4), the 
diamond denotes data from dH2O (n=3) application.  Data presented as mean ± S.D. 
 
To further investigate this membrane, a follow up study was performed in which Silastic® 
membranes were treated with one, five or ten hypodermic needle (26 G) punctures, Figure 
5.13.  As shown, there was no significant difference between each treatment group compared 
to untreated membrane.  From these studies, it appeared that puncturing Silastic® membrane 
had little effect on diffusion of the small molecule PHCl across the membrane.  Therefore, it 
was concluded that this model membrane would not be optimal for assessing MN facilitated 
drug delivery.    
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Figure 5.13  Permeation profiles of PHCl across hypodermic needle treated Silastic® membrane.   
The data represent permeation following no membrane treatment (diamonds) and after hypodermic 
needle (26 G) puncture 1x (squares), 5x (triangles) and 10x (circles).  Data presented as mean ± S.D. 
(n=4).   
 
Initial penetration studies suggested that Silastic® membrane may not be appropriate for 
assessing MN facilitated drug delivery.  Instead another synthetic model barrier, plasticised 
PVC film, was investigated.  In comparison, this membrane displayed quite different properties 
to Silastic®, as shown in Figure 5.15.  This set of experiments utilised an alternative water 
soluble analyte, IBU, and analysis was performed by HPLC.  A model standard curve is shown in 
Figure 5.14.   
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Figure 5.14  Exemplar standard curve used in quantitative determination of ibuprofen sodium flux 
across model barrier.   
Data presented as mean ± S.D. (n=3). 
 
 
Figure 5.15  Permeation profile of ibuprofen from 5 %w/w sugar glasses across plasticised PVC film. 
The square denotes data obtained following no membrane treatment and the diamond denotes data 
following silicon MN array application.  Data presented as mean ± S.E. (n=10).  
 
As shown in Figures 5.12 and 5.15, it appeared that treatment of model membranes with a 
silicon MN array was not always reproducible.  This was shown by the relatively large standard 
error values of ibuprofen flux across the membranes following MN treatment.  From this 
Chapter 5 
157 
study, it was speculated that the plasticised PVC membrane may suffer from the same 
penetration and resealing issues as the  Silastic® membrane used in previous studies. 
 
This study did show however, that intact plasticised PVC film formed an impenetrable barrier 
to the permeation of ibuprofen from SGs.  By 24 h significantly more ibuprofen had diffused 
across the membrane treated with a MN array in comparison to untreated membrane.  As a 
positive control plasticised PVC membranes were punctured with a single 26 G hypodermic 
needle puncture, Figure 5.16.  As shown, following both hypodermic and silicon MN 
treatments, there was an initial lag phase up to 1 h, before ibuprofen began to diffuse across 
the punctured membranes.  By 4 h however, significantly more ibuprofen had permeated 
across the hypodermic treated membrane containing the IBU loaded SG, Figure 5.16, 
compared to the silicon MN treated membrane, Figure 5.15.   
 
Interestingly, it appeared that there was no significant difference in permeation between drug 
loaded SG formulation compared to sugar solution containing the same drug concentration, 
Figure 5.16.  This behaviour was not unexpected as it is known that amorphous systems are in 
a higher energy state relative to crystalline materials (Zhou et al. 2007) and hence that they 
demonstrate similar properties to a liquid phase.   
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Figure 5.16  Permeation profile of ibuprofen across plasticised PVC film treated with a single 
hypodermic needle (26 G) puncture.   
The square denotes data obtained following application of 5 %w/w SGs to the donor chamber.  Controls 
were a blank SG (diamond) and stock IBU sugar solution used to create 5 %w/w SGs (triangles).  Data 
presented as mean ± S.E. (n=10). 
 
The final model barrier system investigated was heat separated human epidermis.  It had been 
shown that neither Silastic® or plasticised PVC membranes were ideal models for assessing 
penetration and delivery studies, and therefore it was hypothesised that epidermal membrane 
would be the most appropriate model for this investigation.             
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As shown in Figure 5.17, after an initial lag phase of approximately 1 h, ibuprofen began to 
permeate the epidermal membrane from a saturated solution.  By 12 h a mean cumulative 
total of 864.4 μg ibuprofen had diffused across the membrane, providing a mean maximal flux 
rate of approximately 104 μg / cm2 / h by 24 h.  This correlated with previous literature values 
for permeation of ibuprofen from saturated aqueous solutions across human epidermis of 
approximately 35 – 332 μg / cm2 / h (Al-Saidan 2004) and 11.8 μg / cm2 / h (Stott et al. 1998); in 
the latter paper the SC had been fully hydrated prior to study initiation.       
 
Mean flux (μg / 
cm2 / h) ± S.D.   
Permeability 
coefficient 
(cm / h) ± S.D.   
Mean cumulative 
amount 
permeated at 6 h 
(Q6) (μg / cm
2) ± 
S.E. 
Lag time (Lt) 
(h) 
Percentage 
formulation 
permeated at Q6 
(%) ± S.E. 
104 ± 11.4 5.4  x 10-4 ± 0.6 254.3 ± 99.0  1.4 0.13 ± 0.05 
Figure 5.17  Permeation profile of ibuprofen across epidermal membrane.   
The square denotes data obtained after application of a saturated IBU solution and the diamond 
denotes data for blank dH2O.  Data presented as mean ± S.E. (n=4). 
 
To observe the effect of membrane penetration, other sections of membrane were treated 
with a single hypodermic puncture and a saturated solution was applied to the donor 
chamber.  As shown in Figure 5.18, significantly more (P<0.0001) ibuprofen permeated across 
epidermal membranes treated with a hypodermic needle compared to intact membranes.  
This was demonstrated by a mean Q6 of approximately 84435 µg / cm
2 (Figure 5.18) compared 
to approximately 254 µg / cm2 for untreated membrane (Figure 5.17).  Unlike Silastic® 
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membranes, it appeared that penetrating epidermal membrane would lead to a significant 
increase in drug permeation, confirming the utility of this membrane for future MN 
penetration studies.  A plateau in ibuprofen permeation was noted from 12 h onwards which 
correlated with depletion of the donor formulation (containing approximately 192,000 µg IBU). 
Furthermore, although the solubility of ibuprofen in aqueous solution is low (0.12 mg / mL) 
(Iervolino et al. 2000), ibuprofen sodium salt has been incorporated at 16 % w/v (160 mg / mL) 
within water-in-oil liquid microemulsions (Sintov and Botner 2006).  Therefore, sink conditions 
(<10 % of saturation concentration) (Ng et al. 2010) were violated within this study, which may 
also account for the plateau in permeation observed.            
 
Treatment  Mean Q6 (µg / cm
2) ± S.E. Percentage formulation 
permeated at Q6 (%) ± S.E. 
Hypodermic needle 84434.9 ± 16521.1 43.8 ± 8.6 
Figure 5.18  Permeation profile of ibuprofen from saturated solution across epidermal membrane. 
The triangle denotes data following hypodermic needle (26 G) treatment and the square denotes data 
obtained for no membrane treatment (patient age 58 years).  Data presented as mean ± S.E. (n=4). 
 
However, when a finite dose and silicon MN array penetration was used as a positive control 
treatment to enhance ibuprofen flux, the results deviated from hypothesis.  As Figure 5.19 
shows, there was no significant difference (P=0.29) at 24 h in the quantity of ibuprofen 
permeation across intact and silicon MN treated membranes.   
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Treatment  Mean Q6 (µg / cm
2) ± S.E. Percentage formulation 
permeated at Q6 (%) ± S.E. 
Silicon MN array 561.9 ± 116.8 37.5 ± 7.8 
Untreated membrane 716.9 ± 112.4  47.8 ± 7.5  
Figure 5.19  Permeation profile of ibuprofen from 5 %w/w IBU loaded stock sugar solution across 
epidermal membrane.   
The square denotes data following silicon MN treatment and the diamond denotes data obtained for no 
membrane treatment (patient ages 47 and 80 years).  Data represented as mean ± S.E. (n=6). 
 
This result was not expected, and suggested that either the classical Franz cell experimental 
setup or the model permeant may not be optimal for assessing MN facilitated drug delivery.  If 
the silicon MNs did not reliably penetrate the membrane this may account for the similarities 
in drug flux observed.  Alternatively, the membrane could have been compromised prior to the 
beginning of the study, possibly due to prolonged periods under frozen storage conditions.  
Finally, due to favourable physicochemical properties, it may have been that ibuprofen 
permeated the membrane easily without physical disruption of the epidermal barrier (Stott et 
al. 1998).  Furthermore, as noted previously in Figure 5.18, as the donor concentration became 
depleted, permeation of ibuprofen decreased and a plateau in delivery was observed.      
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It also became apparent that standardisation of the initial epidermal barrier properties was 
essential to permeation studies.  As Figure 5.20 (B) shows, even though silicon MNs decreased 
ER of the epidermal barrier by appearing to penetrate the membrane, Figure 5.20 (D), 
impedance measurement of the untreated epidermal membranes in each treatment group 
varied significantly (P=0.03).  It is known that if skin integrity is compromised prior to in vitro 
percutaneous absorption studies this will affect the permeability of the membrane to test 
substances (Scott et al. 1991).  Therefore, to make comparisons between treatment groups, 
baseline ER measurements would need to be established to ensure standardisation of barrier 
integrity.      
(A)  (B) 
 (C)   (D) 
Figure 5.20  Estimation of epidermal membrane penetration.   
The black bars represent electrical resistance measurement prior to treatment and the white bars 
represent data following (A) no treatment or (B) silicon MN treatment.  Data presented as mean ± S.D. 
(n=6).  (C) and (D) representative sections of filter paper supporting untreated and silicon MN treated 
membranes respectively.  
 
It has been well characterised that silicon MN arrays reliably puncture human skin to facilitate 
drug delivery (Coulman et al. 2009; Henry et al. 1998; McAllister et al. 2003).  In this study a 
significant increase in drug flux following MN treatment was not observed.  It was speculated 
that this may have been due to inefficient puncture of the membrane, limitations of the 
experimental setup, or that ibuprofen was not the optimal model permeant due to high 
passive permeation of the molecule across skin.    
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5.4.5 Development and optimisation of static type Franz diffusion cells for microneedle 
facilitated penetration / permeation studies 
Initial membrane screening studies, section 5.4.4, highlighted that the classical setup of Franz 
diffusion cells may not be optimal for assessing MN facilitated percutaneous drug delivery.  
Preliminary studies highlighted that without any support beneath the epidermal membrane 
within a diffusion cell, penetration of the barrier by MN arrays may be variable.  Therefore, 
various adaptations of the classical setup were investigated to provide a platform for the 
assessment of SGMN arrays.   
 
Three different modifications were investigated; the inverted method whereby the epidermal 
membrane was applied SC down on top of mounted MNs prior to cell assembly, the gauze 
method where a PTFE ring with a gauze section in the centre was fashioned and the PTFE disc 
method whereby small holes were drilled into the disc and clamped between the donor and 
receptor flanges.  Sugar glass MN arrays were then applied in situ into the donor chamber.  
Each setup was investigated by the insertion of SGMN arrays into the SC side of the epidermal 
membrane.  As Figure 5.21 shows, it was not visually obvious which setup provided the most 
reliable method for insertion of SGMN arrays.   
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 (A)   (B)   (C) 
 (D)   (E) 
Figure 5.21  En face light photomicroscopy images of epidermal membranes.   
(A) Untreated membrane and membrane following SGMN insertion using (B) and (C) inverted method, 
(D) gauze method, (E) PTFE ring method (representative of n=2).  Bar = 1000 µm (black bar) or 500 µm 
(white bar).  
    
Disregarding the large hole present in Figure 5.21 (B) (black arrow), reasoned to be an artefact 
formed during the dismantaling of the Franz cell process, and the remnants of hair follicles / 
sweat ducts, Figure 5.21 (C), there were no obvious signs of MN channels within any of the 
membranes.  Various reasons for this outcome were proposed.  It could have been that the 
SGMN arrays did not penetrate the membrane in any of the modified setups, or it could have 
been that the holes generated were too small to visualise at this magnification.  Otherwise, it 
could have been that any microchannels formed simply resealed rapidly following MN 
insertion; although this seems unlikely as the treated areas were occluded during the study.      
 
To probe the SGMN penetration properties of each method, MB dye solution was applied to 
the SC side of the membrane.  The aim was to observe any channels created in the epidermis 
by the SGMN arrays.  However, as the images in Figure 5.22 show, there was no evidence of 
discrete membrane puncture sites which would indicate that the SGMNs had inserted into the 
membrane.  This result was even observed in positive control samples following silicon MN 
treatment of the membrane, Figure 5.22 (A).    
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 (A)   (B) 
 (C)   (D) 
Figure 5.22  En face light photomicroscopy images of epidermal membranes following methylene blue 
dye staining.  
The data show membrane following (A) silicon MN on corkboard treatment, (B) PTFE ring method, (C) 
inverted method and (D) gauze method (n=2) (Bar = 1000 µm).     
 
These investigations demonstrated that it would not be possible to precisely assess the 
membrane penetration capabilities of MN arrays by membrane staining and light microscopy 
and therefore that more detailed analyses would be required. 
 
A variety of strategies were used to investigate the penetration efficiency of epidermal 
membranes via MN arrays.  These included fixing of treated membranes with glutaraldehyde 
solution and visualisation under fluorescence microscopy and environmental SEM imaging 
(data not shown).  Both these techniques provided some evidence of membrane puncture, 
however there was still no obvious pattern of MN penetration.  It was concluded that it would 
not be possible to observe a distinct penetration profile pattern within the membrane using 
MN arrays of these dimensions.  Following a number of repeat experiments, it was determined 
that the gauze method, section 5.3.2.7 (2), provided the best Franz cell modification to assess 
SGMN epidermal membrane penetration.  This conclusion was based on the relative ease of 
assembly of this modified cell and because the setup appeared to provide the best support for 
application of MNs in situ.  
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5.4.6 Assessment and validation of electrical resistance as a measure of epidermal barrier 
integrity 
As the data in Figures 5.20 and 5.23 demonstrate, the methodology described in this work was 
appropriate for the assessment of ER of heat separated epidermis.  However, it became 
apparent that some of the skin tissue used in early experiments was not fit for purpose and 
had impaired barrier function.  This was demonstrated by some of the low initial ER 
measurements of intact membrane prior to MN insertion, for example Figures 5.20 (A) and 
5.23.  A correlation was observed between a low intact membrane resistance value and a 
tendency of the membrane to rapidly allow passage of the donor compartment NaCl solution 
into the receptor compartment.  This “leaky” behaviour further suggested that the integrity of 
the membrane was poor and therefore visual inspection of the Franz cell became a secondary 
marker of skin barrier functionality.  One possible reason for these observations may have 
been due to the duration of tissue storage under frozen conditions, as it is known that these 
conditions can disrupt barrier function if maintained for longer than 12 months (Davies et al. 
2004). 
 
Figure 5.23  Electrical resistance measurement of epidermal membranes.  
(Patient ages archived, 58 and 93 years).  Treatments were as follows, intact skin (black bar, n=4), silicon 
MN treated (white bar, n=9), 5 %
w
/w IBU loaded SGs (grey bar, n=9) and 5 %
w
/w IBU loaded SGMN 
treated (hashed bar, n=11).  Data presented as mean ± S.D., * denotes significance (P=0.0017). 
 
It was noted that impedance measurements of membranes varied greatly between donors and 
also within samples from the same donor.  For example, the impedance of membranes treated 
with flat SGs, Figure 5.23, were greater than intact membranes measured at the beginning of 
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the study, although they all came from the same donor population.  Variation in ER 
measurement of untreated membrane has been noted previously by other workers (Fasano et 
al. 2002; Lawrence 1997) and therefore this was not unexpected.  To address this issue, an 
initial screening methodology involving ER measurement combined with visual observation of 
test cells was developed to determine barrier integrity.  
 
5.5 Conclusion 
In summary, this chapter suggests that adhesive layers containing a variety of suspended 
model drug substances can be reliably produced.  Subsequently, it has been shown that SGMN 
arrays fabricated with a thin base layer can be attached to a transdermal adhesive patch 
system for potential percutaneous drug delivery applications.  Importantly, the morphology of 
the SGMNs appeared to be relatively stable when the array was attached to model drug 
loaded adhesive backings and stored under vacuum desiccation.   
 
A range of model membranes were assessed for their applicability to SGMN penetration and 
diffusion studies.  It was shown that human heat separated epidermis was superior to 
synthetic membranes in these studies.  However, it was found that the classical setup of the 
Franz diffusion cell was not optimal for investigating MN facilitated transdermal drug delivery.  
Although not conclusive, modifications to the classical setup appeared to provide an 
enhancement of the application and penetration capabilities of MN arrays.  In addition, a 
reliable methodology for assessing initial epidermal barrier integrity was developed utilising a 
combination of visual assessment and electrical resistance measurement.  It was envisaged 
that these tools together would provide a robust platform for future investigation of SGMN 
array percutaneous drug delivery potential.   
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6 Transdermal drug delivery using sugar glass microneedles 
6.1 Introduction 
6.1.1 Microneedle facilitated transdermal drug delivery methods 
As discussed previously, there are many examples of different biodegradable MN systems in 
the literature.  The delivery of various drugs has been investigated utilising these systems and 
studies have been conducted to determine their potential for transdermal drug delivery.  
These studies have been conducted using both in vitro and in vivo models depending upon the 
properties of the drug under investigation.  Accordingly, the main focus of this chapter was to 
investigate the drug delivery potential of SGMN arrays utilising an in vitro human skin model.   
 
Early MN facilitated delivery studies conducted by Henry et al. utilised heat separated 
epidermal membrane as a model barrier (Henry et al. 1998) as it is known to provide the 
predominant mechanical barrier (Van Duzee 1978) to needle insertion.  The epidermis was 
mounted within static Franz type diffusion cells with the SC facing the donor compartment and 
the lower epidermis facing the receptor compartment (Henry et al. 1998).  Permeabilities for 
MN treated skin were determined for the surface area treated with the MN array only.  This 
was justified as it was reasoned that, once treated with a MN array, drug transport of 
impermeable substances would only occur over the area where the needles have been 
inserted (Henry et al. 1998).  Subsequently, this approach to permeation data analysis was 
utilised in all diffusion studies conducted in this chapter.   
 
The work of McAllister et al. utilised heat separated epidermis which was removed from the 
diffusion cell and placed on a supported surface prior to MN application (McAllister et al. 
2003).  The rationale behind using epidermal membrane was further developed in this work as 
mathematical modelling was carried out by the authors.  It was determined that removing the 
dermal barrier above the capillaries of the dermal-epidermal junction may overestimate skin 
permeability by a factor of 2, however the use of full thickness skin may underestimate 
permeability by a factor of 5 (McAllister et al. 2003) and hence this is why the epidermis alone 
was used.  This rationale has been supported by others who have suggested that the dermis 
may provide an artefactual reservoir and binding site in vitro for drugs that would have been 
removed by capillaries in the dermal-epidermal layer in vivo (Amsden and Goosen 1995).  
Furthermore, shorter lag times across full thickness skin have been observed in vivo compared 
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to in vitro following MN insertion.  It has been speculated that the increased lag time in vitro 
may be due to diffusion of the permeant through the entire thickness of the skin before 
detection in the receptor phase.  In vivo, the drug is picked up by the microcirculation as soon 
as it traverses the epidermis (Kolli and Banga 2008) and hence displays a shorter lag time.     
 
Park et al. utilised a similar methodology whereby cadaver heat separated epidermis was used 
as the barrier and was mounted onto layers of tissue paper to act as a mechanical support 
before polymer MN treatment.  Once treated, the epidermis was placed onto a support mesh 
and loaded into the diffusion cells (Park et al. 2005).  Coulman et al. used a similar approach in 
which separated epidermal sheets were replaced onto the dermis from which they had been 
separated.  Silicon MN arrays were mounted onto metal applicators and applied to the 
membrane 5 times before they were mounted into Franz diffusion cells (Coulman et al. 2009).  
In both these experiments, donor solutions containing drug were applied following cell 
assemblage.       
 
More recently, workers have investigated drug delivery from biodegradable MNs where the 
drug is incorporated within the MN structure itself.  Solid state biodegradable microstructures 
(SSBMS) containing fluorescein isothiocyanate-tagged BSA (FITC-BSA) have been evaluated in 
vitro using split thickness human cadaver skin (Wendorf et al. 2011).  Synthetic dissolving MNs 
containing insulin have been examined in vitro by analysing diffusion of the drug across 
dermatomed neonatal porcine skin using modified Franz diffusion cells.  Here the skin was 
affixed to the donor flanges of the donor compartment before MNs were inserted (Migalska et 
al. 2011).  In a similar set of experiments Donnelly et al. incorporated theophylline into 
polymeric MNs and assessed its permeation across dermatomed neonatal porcine skin.  The 
skin was glued, SC side up, to the donor flanges and supported underneath by dental wax 
whilst MNs were inserted; the MN device was secured in place and the donor and receptor 
chambers were assembled (Donnelly et al. 2011).   
 
In this work a novel adaptation of the classical Franz diffusion cell setup, as described in 
Chapter 5, was utilised to assess the drug delivery potential of SGMN arrays.  To date there 
does not appear to be a single optimised methodology to investigate MN facilitated 
permeation of model substances across skin barrier in vitro.  In this work a ring of PTFE was 
fashioned to fit between the flanges of the donor and receptor compartments of the Franz 
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cell.  In the centre of the ring there was a 1 cm2 hole with a section of steel gauze placed into 
it.  In this way the cell could be greased and assembled, complete with the epidermal 
membrane, prior to SGMN insertion in situ.  It was envisioned that this methodology may 
provide a promising alternative to evaluate the transdermal drug delivery potential of MN 
devices, and in particular rapidly dissolving biodegradable MNs containing drug.  Previous 
methodologies have generally focussed on MN insertion prior to assembly of the Franz cell.  
This may lead to more complex assembly of the cell and give rise to the potential for MN 
devices to become dislodged during the process leading to inaccurate initial permeation 
measurements.  To assess the efficacy of MNs to enhance permeation of a substance across 
skin the enhancement ratio has been calculated.  In this study the enhancement ratio was 
based on the ratio of ibuprofen flux through SGMN treated skin compared to the flux across 
untreated skin, using the following equation (Donnelly et al. 2008; Stott et al. 1998). 
Enhancement ratio = ibuprofen flux through SGMN treated skin / ibuprofen flux through 
untreated skin   
 
Together, the studies detailed here highlight the different approaches to assessing the 
transdermal drug delivery efficiency of a number of MN enhancement techniques in vitro.  In 
this work a novel methodology was developed, as described in Chapter 5, to investigate the 
transdermal drug delivery potential of SGMN arrays across human skin barrier. 
 
6.1.2 Drug delivery from transdermal drug delivery systems 
As discussed in Chapter 5, there are now a number of different TDDSs available.  The benefit of 
delivering drugs transdermally across skin is that in certain systems zero-order drug kinetics 
may be achieved, that is, a constant amount of drug is delivered per unit time.  This situation is 
most likely to lead to a stable level of drug in the plasma which is of benefit in treating chronic 
conditions.  In contrast, first-order kinetics, whereby a fixed proportion of the total drug is 
delivered per unit time, as in conventional dosage forms, leads to initial peaks followed by 
potentially subtherapeutic troughs in drug concentration within the body (Lee and Robinson 
2000).   Reservoir patches are capable of providing zero-order delivery kinetics, whereas matrix 
patches are not designed to provide true zero-order release.  In these systems, as drug closest 
to the skin is released, drug contained within the remainder of the patch must travel a further 
distance before permeation occurs.  With time this gradually increases the diffusional pathway 
for drug within the patch and slows release (Hadgraft and Lane 2006).  Well-designed matrix 
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patches circumvent this problem by minimising the reduction in release rate so that 
absorption is not affected (Hadgraft and Lane 2006).  Typically this is achieved by high drug 
loading within the patch, and often 20 times the drug to be absorbed is contained within the 
patch to create a stable concentration gradient (Nitti et al. 2006).   
 
Although drug release from matrix patches has potential limitations, in general these patches 
are the preferred formulation due to their enhanced clinical safety profile over the reservoir 
system (Margetts and Sawyer 2007).  Accordingly, depending upon the adhesive polymer 
utilised and the physicochemical properties of the model drug within the patch, in vitro 
permeation has been shown to vary.  For example, relatively high fluxes of primaquine base 
across human skin, approximately 57 µg/cm2/h and 49 µg/cm2/h, have been noted from two 
different acrylate adhesive matrices containing 10 mg/cm2 (Jeans and Heard 1999).  
Alternatively, the permeation of fentanyl base across human skin from silicone-2920 and 
polyisobutylene adhesives, loaded at 2 %, were approximately 6 and 3 µg/cm2/h, respectively 
(Roy et al. 1996).  Duro-Tak® 2516 acrylate adhesive patches containing 1.5 % levonorgestrel 
and 21 % captopril, both stabilised by PVP, facilitated drug fluxes across hairless rat skin of 
approximately 0.6 and 105 µg/cm2/h, respectively (Jain and Banga 2010).  As these studies 
show, some variations in drug permeation from adhesive patches have been demonstrated in 
vitro; dependent upon the system under investigation.  In general, maximal drug flux values 
are in the range of micrograms per centimetre squared per hour.   
 
Accordingly, it was of interest in this chapter to investigate the permeation of large molecular 
weight model substances from integrated transdermal SGMN patches in vitro.  Furthermore, it 
was an aim of this chapter to compare permeation of model substances across human 
epidermal membrane from drug loaded SGMN arrays and integrated SGMN patches.                    
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6.2 Chapter objectives 
1. Quantitative assessment of in vitro percutaneous drug delivery potential of SGMN arrays 
containing a small molecule across heat separated epidermis. 
2. Quantitative assessment of in vitro percutaneous drug delivery potential of SGMN arrays 
containing larger molecular weight moieties across heat separated epidermis. 
3. Investigate in vitro percutaneous drug delivery potential of integrated transdermal 
SGMN array patches containing model drug substance across heat separated epidermis. 
4. Assess dissolution kinetics of SGMN arrays in situ in full thickness human skin in vitro. 
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6.3 Materials and methods  
6.3.1 Materials 
All reagents were obtained from Fisher Scientific Ltd. (Loughborough, UK) and were of 
analytical grade unless stated otherwise. 
Human breast skin was obtained from the Aneurin Bevan Health Board Royal Gwent Hospital 
(Newport, Wales, UK) following mastectomy or breast reduction surgery with full ethical 
committee approval and informed patient consent.  
 
6.3.2 Methods 
6.3.2.1 Sugar glass microneedle facilitated diffusion studies across human epidermal 
membrane 
6.3.2.1.1 SGMN arrays containing ibuprofen sodium 
SGMN arrays containing 5 %w/w ibuprofen sodium (IBU) were prepared as described in section 
4.3.2.1.  Flat sections of blank SG and SG containing 5 %w/w IBU were prepared as described in 
section 5.3.2.4.  Modified static type Franz diffusion cells were assembled (section 5.3.2.7.2) 
with heat separated epidermis from female donors aged 47, 80, 93 and 58 years and ER 
measurements were taken, as described in section 5.3.2.8.  Drug loaded SGMNs and SGs were 
mounted onto the flattened end of syringe plunger and applied to the membrane as described 
in section 5.3.2.7.2.  Control cells were assembled and the membrane was treated with a 
silicon MN array, applied in the same manner, before a section of SG was placed into the 
donor.   
 
In this method the receptor compartment was filled with degassed PBS (pH 7.4) equilibrated to 
37 ºC only once the MNs had been applied to the membrane.  Formulations were covered with 
a plasticised PVC film backing disc and cells were placed into a water bath on top of a magnetic 
plate as described in section 5.3.2.4.  Cells were occluded and samples were taken as described 
in section 5.3.2.4.  At the end of the study, the donor and receptor contents were removed 
and final ER measurement readings taken.  Ibuprofen sample analysis was performed using 
reversed-phase HPLC as described in section 5.3.2.6.  The flux of ibuprofen from SGMN arrays 
was compared to flat sections of SG and a mean enhancement ratio for SGMNs was obtained.  
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6.3.2.1.2 SGMN arrays containing sulforhodamine B sodium 
SGMN arrays containing 5 %w/w SRB were prepared as described in section 4.3.2.1.  Flat 
sections of SG containing 5 %w/w SRB were prepared as described in section 5.3.2.4.  Initial ER 
measurements were taken, as described in section 5.3.2.8, before positive control membranes 
were treated with a single hypodermic needle puncture and a section of SG was placed into 
the donor chamber.  150 µL 5 %w/w drug loaded sugar solution was pipetted onto the surface 
of untreated skin sections as a negative control.  Modified static Franz diffusion cells were 
assembled with heat separated epidermis from female donors aged 49 and 82 years, as 
described in section 6.3.2.1.1 and the same processes were carried out with these SGMNs.  
SRB sample analysis was performed by fluorescence spectrophotometry (Fluostar Optima™, 
BMG Labtech, Aylesbury, UK) using Greiner black polypropylene 96 well plates with excitation 
and emission filters set at 544 and 590 nm respectively.  Sulforhodamine B quantities were 
estimated by linear regression and correlation analysis of the calibration curves generated 
(LOD 5 x 10-5 mM) in each method.   
 
6.3.2.1.3 SGMN arrays containing fluorescein isothiocyanate conjugated bovine serum 
albumin 
SGMN arrays containing 5 %w/w FITC-BSA were prepared as described in section 4.3.2.1.  Flat 
sections of SG containing 5 %w/w IBU were prepared as described in section 5.3.2.4.  Initial ER 
measurements were taken, as described in section 5.3.2.8, before positive and negative 
control membranes were treated as described in section 6.3.2.1.2.  Modified static Franz 
diffusion cells were assembled with heat separated epidermis from female donors (archived 
tissue and those aged 49 and 82 years), as described in section 6.3.2.1.1, and the same 
processes were carried out with these SGMNs.  FITC-BSA sample analysis was performed by 
fluorescence spectrophotometry (Fluostar Optima™, BMG Labtech, Aylesbury, UK) using 
Greiner black polypropylene 96 well plates with excitation and emission filters set at 485 and 
520 nm respectively.  FITC-BSA quantities were estimated by linear regression and correlation 
analysis of the calibration curves generated (LOD 5 x 10-5 mM) in each method.      
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6.3.2.2 SDS-PAGE electrophoresis 
Running buffer concentrate (10x) was prepared with the following formula. 
Glycine         144 g 
Tris base        30.3 g 
Sodium dodecyl sulphate (SDS)      10 g  
(Biorad Laboratories Ltd., Hertfordshire, UK)  
dH2O         up to 1000 mL  
A 10 % resolving gel was prepared using the following components. 
40 % Acrylamide/Bis-acrylamide (Sigma - Aldrich, Poole, UK)  5.0 mL  
3M Tris base pH 8.8       2.5 mL 
10 % SDS        0.2 mL 
dH2O         12.2 mL 
Temed (Biorad Laboratories Ltd.)     15 µL (added just 
before pouring cassette) 
Ammonium persulphate 10 % (Sigma - Aldrich, Poole, UK)  150 µL   
The resolving gel was loaded into two 1.5 mm gel plate cassettes attached to a casting stand 
on the gasket of a casting clamp.  Once loaded, the gel was kept moisturised with dH2O and 
maintained at room temperature for approximately 40 mins until solidified.   
 
A 4 % stack gel was prepared using the following components. 
 40 % Acrylamide/Bis-acrylamide  1.0 mL  
1M Tris HCl pH 6.8    1.3 mL 
10 % SDS     0.1 mL 
dH2O      7.6 mL 
Temed      10 µL  (added just before pouring cassette) 
Ammonium persulphate 10 %   75 µL 
Once the resolving gel had solidified, excess water was removed and the stacking gel was 
loaded into the cassette on top of the resolving gel.  A comb was immediately inserted into the 
stacking gel and the gel was kept moisturised for approximately 40 mins until solidified.  Once 
set, the comb was removed and 5 µL of molecular weight marker (GE Healthcare) was loaded 
into 2 wells.  20 µL aliquots of samples and BSA and FITC-BSA standards were loaded into 
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separate wells within the gel.  The cassettes were then placed into an electrophoresis chamber 
filled with chilled diluted running buffer (1x).  Electrophoresis of the samples was carried out at 
110 V for approximately 60 mins to resolve samples.   
 
6.3.2.3 Silver staining of gels 
Once run, the gels were removed from the cassettes and rinsed twice in dH2O for 10 mins 
each.  They were then transferred into 10 % glutaraldehyde solution for 30 mins before being 
rinsed 3 times in dH2O for 20 mins each.  A staining solution was prepared as follows. 
0.36 % NaOH   21 mL 
dH2O    74 mL         
NH4OH    1.4 mL 
2 % silver nitrate solution 4 mL  
The gel was transferred to a fresh container and the staining solution was added.  The 
container was placed onto a flat bed rocker at 35 rpm and left for 30 mins.  Following this, the 
gel was rinsed 3 times in dH2O for 5 mins. 
 
A developing solution was prepared as follows. 
Formaldehyde  260 µL 
1 % citric acid  2.5 mL 
dH2O     up to 500 mL  
The developing solution was added and maintained at room temperature until the bands 
within the gel turned brown.  Once the bands were well developed, the gels were transferred 
into stopping solution, consisting of the following. 
Ethanol  40 mL 
Acetic acid 10 mL 
 dH2O  up to 100 mL  
The gels were maintained in stopping solution until no further colour change was observed 
and then rinsed twice in dH2O for 15 min each.  Gels were analysed using Image Lab 3.0 (Bio-
Rad Laboratories, Inc.) using the ChemiDoc™ XRS+ system software.      
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6.3.2.4 Bicinchoninic acid protein assay 
A protein assay solution was prepared containing 49 parts bicinchoninic acid (BCA) (Sigma - 
Aldrich, Poole, UK) and 1 part copper sulphate solution.  Fresh stock solutions of FITC-BSA in 
PBS (pH 7.4), concentration 1 mg/mL, were prepared and varying volumes from 2 – 20 µL were 
pipetted into 96 well plate wells.  Standards were made up to 20 µL with PBS.  20 µL samples 
were taken from the 24 h time point samples of FITC-BSA studies and pipetted into the well 
plate.  200 µL protein assay solution was then added to all wells.  Well contents were gently 
mixed and incubated at 37 ºC for 30 mins before cooling to room temperature.  Plates were 
analysed by UV spectrophotometer (Sunrise™, Tecan Group Ltd., Switzerland) with absorbance 
at 562 nm and BSA masses were estimated by linear regression and correlation analysis of the 
calibration curve generated. 
 
6.3.2.5 Bradford protein assay 
Fresh stock solutions of FITC-BSA in PBS (pH 7.4), concentration 1 mg/mL, were prepared and 
standards ranging between 0.05 – 1.0 mg/mL were formulated.  10 µL of standard or samples 
from the FITC-BSA 24 h time point studies were pipetted into 96 well plate wells.  200 µL of 
Bradford dye reagent (Sigma - Aldrich, Poole, UK) was then pipetted into each well and mixed 
thoroughly.  Plates were maintained at room temperature for 45 mins before analysis by UV 
spectrophotometer (Sunrise™, Tecan Group Ltd., Germany) with absorbance at 595 nm.  BSA 
quantities were estimated by linear regression and correlation analysis of the calibration curve 
generated. 
 
6.3.2.6 Integrated transdermal sugar glass microneedle patch facilitated diffusion studies 
across human epidermal membrane      
SRB was loaded into one of three backing layers at a concentraion of 5 %w/w as described in 
section 5.3.2.3.  Backings included the adhesives Duro-Tak®  87202-A (an acrylate), BIO-PSA® 
7-4302 (a pressure-sensitive silicone) and sugar glass (TRA:SUC 75:25 %w/w).  SGMN arrays with 
a thinner base were formed as described in section 5.3.2.3.  SGMN patches with a diameter of 
0.8 cm were formed by attaching the adhesive patch to the base of the microneedle array as 
detailed in section 5.3.2.3.  Blank SGs were prepared from 40 µL sugar solution as described in 
section 5.3.2.4, and the same approach was utilised to fabricate patches without needles for 
control samples.        
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Modified static Franz diffusion cells were assembled with heat separated epidermis from 
female donors aged 49, 82 and 73 years and ER measurements were taken, as detailed in 
section 6.3.2.1.1.  Positive control membranes were treated with 3 hypodermic needle 
punctures and patches were applied to the SC of each membrane by mounting them onto the 
flattened end of a syringe plunger and applying them for 10 secs each.  Cells were occluded 
and samples were removed from each cell as described in section 5.3.2.4 up to 48 h.  At the 
end of the study, the donor and receptor contents were removed and final ER measurement 
readings were taken as described in section 5.3.2.8.    
 
6.3.2.7 Full thickness skin sugar glass microneedle dissolution study  
A 20 %w/v solution of TRA and SUC 75:25 %
w/w was prepared and MB powder was incorporated 
at 1 %w/w of final sugar glass weight.  SGMN arrays and flat sheets of SG material were 
fabricated as described in section 3.3.2.5 and 5.3.2.4 respectively.  Previously prepared frozen 
full thickness human skin sections (2 x 2 cm) from a female donor, age 73 years, with 
subcutaneous fat removed, were removed and equilibrated for approximately 1 h.  Once 
defrosted, skin sections were pinned dermal side down onto curved corkboard covered in tin 
foil.  SGMNs were applied onto the SC of the skin using the flattened end of a syringe plunger 
using a rolling motion.  Arrays were applied for 10 secs and the skin was assembled into Franz 
diffusion cells, as described in section 5.3.2.5.  A 0.8 cm diameter cling film disc was placed 
over the sugar formulations in the donor chamber to provide an occlusive backing.  Cells were 
filled with equilibrated PBS and a section of Parafilm® was placed over the donor phase.  A 
small magnetic bar was added to each cell and then placed into a water bath, as described in 
section 5.3.2.4, for 24 h.  At 24 h, skin sections were removed from cells and the residual mass 
on the skin surface was weighed.  Excess dye was removed with tissue paper soaked in ethanol 
prior to viewing under light microscopy.  Finally, skin sections were snap frozen, cryosectioned 
and visualised under light microscopy, as described in section 3.3.2.11.  
 
6.3.2.8 Statistical analysis 
For direct comparisons, a one-tailed student’s T-test was performed on the experimental data 
using the Microsoft Excel software package.  For comparisons of multiple treatment groups, a 
one-way ANOVA with Bonferroni’s multiple comparison post hoc test was performed on the 
experimental data using the GraphPad Prism 5 software package.  In all cases, statistical 
significance was determined by a value of P ≤ 0.05. 
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6.4 Results and discussion 
6.4.1 Sugar glass microneedle facilitated diffusion studies across human epidermal 
membrane 
6.4.1.1 SGMN arrays containing ibuprofen sodium 
To assess the capability of SGMNs to facilitate transdermal drug delivery of model 
medicaments, a number of different molecules were incorporated within SGMN arrays.  
Ibuprofen was chosen as a model low molecular weight molecule due to its proven efficacy as 
a topically applied anti-inflammatory.  The parent drug molecule has a MW of 206 and logP of 
around 4 (Herkenne et al. 2007) whereas the sodium salt has a MW of 229 and a lower logP of 
0.92 (Patel et al. 2009) making it much more water soluble.  In this work, ibuprofen sodium salt 
(IBU) was incorporated within SGMNs and flat sections of SG at a concentration of 5 %w/w.  The 
rationale behind this concentration was that topically applied ibuprofen is typically supplied as 
a 5 %w/w formulation and because it had been shown that increasing the mass of drug within a 
SGMN above 5 %w/w disrupted the robustness of the array, section 4.4.1.  It was hypothesised 
that SGMNs would dissolve rapidly in situ to release incorporated drug cargo.  Accordingly, a 
high initial permeation rate would be observed, followed by a gradual decrease in permeation 
as the sugar formulation depletes around the aqueous channels.        
 
Figure 6.1  Exemplar standard curve used in quantitative determination of ibuprofen sodium flux 
across human epidermis.   
Data presented as mean (n=2).   
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Using the standard curve generated in Figure 6.1, the quantity of ibuprofen permeated was 
estimated.  As Figure 6.2 shows, there was a significant difference (P=0.03) in ibuprofen 
diffusion across epidermal membrane from loaded SGMNs at 24 h in comparison to flat SG 
sections.  As observed previously, Figure 5.19, permeation of ibuprofen from a sugar 
formulation following MN treatment of epidermal membrane was initially rapid before 
reaching a plateau by 12 h.  In both experiments, permeation reached a plateau at 
approximately 700 – 800 micrograms corresponding to approximately half of the total dose 
contained within the donor formulation (Figure 6.2).  This further suggested that depletion of 
the donor phase, of greater than 10 % of the total dose, led to a reduction in concentration 
gradient across the membrane and hence violated sink conditions (Ng et al. 2010; Williams 
2003).             
 
Treatment  Mean Q6 (µg / cm
2) ± S.E. Percentage formulation 
permeated at Q6 (%) ± S.E. 
SGMN array 713.9 ± 95.4 47.6 ± 6.4 
SG section 462.3 ± 99.7 30.8 ± 6.6 
Figure 6.2  Permeation profiles of ibuprofen from sugar glass formulations across human epidermal 
membrane.   
Formulations included 5 %w/w SGMN arrays (diamonds) and flat sugar glasses (squares).  Data presented 
as mean ± S.E. (n = 12).  
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This result was expected, as it was hypothesised that the SGMNs were able to puncture the 
stratum corneum (SC) to facilitate permeation of ibuprofen across the membrane.  
Accordingly, a large mean Q6 of 713.9 ± 95.4 µg / cm
2 (Figure 6.2) was measured immediately 
following SGMN treatment of the membrane.  Previous in vitro studies have shown that 
biodegradable polymer MNs demonstrate an initial burst release of approximately 50 % of the 
drug contained within the MNs (Migalska et al. 2011) which supports this data.  However, in 
both treatment groups in this study, it was observed that only approximately half of the Franz 
cells contained residual sugar glass formulations within the donor chamber at 24 h.  This 
suggested that water from the receptor phase may be causing dissolution of the entire dosage 
form during the study.  This did not fit with our earlier hypothesis, and it was speculated that 
the results obtained may be due to formation of a concentrated sugar solution on the skin 
surface.  This may have led to the generation of a hyperosmotic gradient across the 
membrane.   
 
Furthermore, it appeared that ibuprofen permeated the membrane rapidly from SG 
formulations also.  Subsequently, a small enhancement ratio of 1.4 was obtained.  This was not 
expected and it was speculated that this could have been due to a number of reasons.  It was 
shown in Chapter 5 that ibuprofen permeation across untreated epidermis from sugar solution 
was relatively high, (mean Q6 = 716.9 ± 112.4 µg / cm
2), and that pre-treating membranes with 
a silicon MN array did not enhance permeation compared to untreated control, Figure 5.19.  
Therefore, it appeared that MN treatment of the membrane did not significantly enhance 
ibuprofen permeation.  Alternatively, the high drug permeation observed from SG treated 
samples, Figure 6.2, could have been due to membrane damage caused by cracking of the 
brittle, glassy material under the force applied.        
 
As a further control, cells were pre-treated with silicon MN arrays prior to application of 
ibuprofen loaded SGs to the donor chamber.  Permeation of drug across these membranes 
showed an initial burst effect followed by a plateau from approximately 6 h onwards, (data not 
shown), which correlated with results observed previously (Figure 6.2).  However, the results 
of this study were highly variable and hard to to draw definitive conclusions from.  This 
behaviour was attributed to a high degree of experimental error due to lack of optimisation of 
the Franz diffusion cell setup for MN facilitated drug delivery prior to this study.     
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As the schematic in Figure 6.3 shows, it was speculated that following initial membrane 
penetration with silicon MNs the SG formulation was rapidly wetted and began dissolution, 
Figure 6.3 (A).   
 (A) 
(B)
(C) 
Figure 6.3  Schematic of ibuprofen diffusion from 5 %
w
/w loaded sugar formulations across MN treated 
epidermis.   
Formulations shown are (A) silicon MN application plus sugar glass, (B) SGMN array and (C) silicon MN 
application plus sugar solution.    
 
Within 4 h this effect had become limited and little further ibuprofen permeated the 
membrane after this time.  It was speculated that the microchannels formed may have re-
sealed or become blocked with sugar or lipid during the study thereby preventing further drug 
permeation.  Similar observations have been made by other workers where permeation from 
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biodegradable polymer MNs rapidly reached a plateau.  The authors attributed this effect to 
blockage of microchannels by dissolved polymeric matrix material and pore closure (Migalska 
et al. 2011).  Figures 6.3 (B) and (C) suggest explanations for the permeation profiles observed 
in SGMN, Figure 6.2, and control silicon MN / sugar solution treated cells.   
 
Additionally, as stated, there was large variation in drug flux throughout the control study 
investigating silicon MN arrays, which suggested that membrane penetration may not have 
been uniform.  This was supported by visual observation of MNs following the study which 
indicated extensive damage of individual MNs (data not shown).  In combination, these studies 
demonstrated that ibuprofen flux across MN treated skin was not enhanced to a great extent.  
This was not surprising as the drug is found widely in many topically applied drug delivery 
systems, such as gels, and hence passively diffuses across the SC without significant barrier 
disruption.  Therefore, the potential for enhanced ibuprofen permeation from SGMN arrays 
was potentially low, as it has been shown that the drug pentrates the SC well due to its high 
lipophilicity (Stott et al. 1998).   
 
Alternative hypotheses for the similarity in data observed in this study was that there were 
inadequacies in the experimental set up or that epidermal barrier function was comprimised.  
Workers have found previously that a force of 0.1 – 3 N (Davis et al. 2004) is required for MN 
insertion into skin and hence this may not have been achieved in this study.  Furthermore, skin 
samples used in this experiment had been frozen at -20 ºC for over 3 years and therefore the 
barrier integrity of each may have been disrupted, as discussed in section 5.4.6.  This will have 
influenced the flux of ibuprofen across each membrane and hence may account for the 
similarities in flux observed between SGs and SGMNs.  This hypothesis was supported 
experimentally by electrical resistance measurement of the epidermal membranes at the end 
of the study, Figure 6.4.    
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Figure 6.4  Electrical resistance measurement of epidermal membranes following treatment.   
Membranes were treated with SGMN arrays (black bar) and flat SG sections (white bar).  Data presented 
as mean ± S.D. (n = 6). 
 
As Figure 6.4 shows, there was a small difference (P=0.03) between membranes treated by SGs 
and SGMN arrays.  Although significantly different, all resistance measurements were very 
similar, and all relatively low, indicating that the barrier functionality in control samples may 
have been compromised.  To attempt to overcome these deficiencies in experimental setup, 
enhanced membrane screening prior to diffusion study initiation was proposed, as described 
in section 5.4.6.   
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6.4.1.2 SGMN arrays containing sulforhodamine B sodium 
As an alternative to ibuprofen, a model hydrophilic substance with a larger molecular weight, 
sulforhodamine B (SRB) was selected as a model permeant.  Utilising the standard curve 
generated in Figure 6.5, it appeared that SRB permeation from various sugar formulations 
behaved quite differently to IBU loaded formulations, as shown in Figure 6.6. 
 
Figure 6.5  Exemplar standard curve used in quantitative determination of SRB sodium flux across 
human epidermis.   
Data presented as mean ± S.D. (n=3). 
Chapter 6 
186 
 
Treatment Mean Q6 (µg / cm
2) ± S.E. Percentage formulation 
permeated at Q6 (%) ± S.E. 
SGMN array 64.1 ± 17.3   4.3 ± 1.2 
Hypodermic + SG 43.0 ± 12.8  2.9 ± 0.9 
Figure 6.6  Permeation profiles of SRB from sugar glass formulations across human epidermal 
membrane.   
Treatments included glass sections loaded with 5 %w/w SRB across untreated (triangles) and hypodermic 
needle (26 G) treated (squares) or SGMN treated (diamonds) membranes.  Data presented as mean ± 
S.E. (n=4). 
 
To confirm that the SC of each membrane investigated was intact prior to the study, ER 
measurements were taken.  The data in Figure 6.7 show how the membrane resistance 
changed throughout the study. 
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(A) 
(B)
(C) 
Figure 6.7  Electrical resistance measurement of epidermal membranes.   
Bars denote resistance prior to treatment (black) and following (A) SGMN array treatment, (B) 
hypodermic needle (26 G) treatment or (C) no treatment (white).  Data presented as mean ± S.D. (n=4).  
 
In contrast to previous studies utilising IBU as a model permeant, it was apparent that no SRB 
permeated across untreated membrane when applied topically in a sugar solution, Figure 6.6.  
In support of this observation, ER measurement indicated that the SC remained intact 
throughout the study, Figure 6.7 (C), as there was no significant decrease in impedance 
(P=0.4).  This result supported the hypothesis that due to its size and physicochemical 
properties, SRB would not passively permeate the SC.  As with the IBU loaded formulation 
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studies, there was no lag phase shown in the permeation of SRB across either of the needle 
treated membranes.  In support, it was suggested by ER measurement, Figures 6.7 (A) and (B), 
that SGMN arrays and hypodermic needles significantly decreased impedance of the epidermal 
barrier, P=0.0007 and 0.003 respectively.  However, with this model substance there was no 
rapid plateau in permeation, as shown with ibuprofen permeation (Figure 6.2), and the 
percentage of permeant delivered by Q6 was approximately 10 fold lower.  This further 
suggested that ibuprofen passively permeated the membrane without enhancement.   
 
Throughout the study there was a strong correlation between the permeation of SRB across 
membranes treated with a hypodermic needle or SGMN array.  The mean Q6 in each treatment 
arm were very similar (Figure 6.6) and this suggested that the SGMN array punctured the 
membrane with a similar efficacy to a hypodermic needle.  Furthermore, by 24 h there was no 
significant difference between the cumulative amount permeated in each treatment arm 
(P=0.32).  This suggested that microchannels generated within the epidermal membrane 
caused barrier disruption to a similar extent as hypodermic needle treated membranes.  The 
permeation of SRB across SGMN treated membrane was also 2 orders of magnitude greater 
than across untreated membrane.  These results confirmed the utility of a SGMN array to 
facilitate the delivery of a model hydrophilic substance across human SC.  However, relatively 
large standard error values indicated that the rate of permeation continued to vary between 
diffusion cells.  This effect has been noted by other workers where it was reasoned that the 
variability may be due to inconsistent penetration of the membrane by MNs and minor 
differences in the thickness of the separated membranes (Coulman et al. 2009).   
 
It was observed that approximately 10 and 14 % of the theoretical total amount of drug 
(1500 µg) contained within SG and SGMN formulations respectively, permeated the 
membrane by 24 h.  Therefore, much of the drug had not diffused across the membrane.  In 
support of this, it was found that residual masses remained within each of the donor chambers 
at the conclusion of the study, Figure 6.8. 
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Figure 6.8  Mass of sugar glass formulations containing SRB during human epidermal study.    
Bars denote mass of SG material before (black, n=3) and at 24 h (white, n=4) and SGMN array mass 
before (grey, n=3) and at 24 h (hashed, n=4).  Data represented as mean ± S.D., * denotes significance 
(P=0.0005).   
 
In contrast to the ibuprofen SGMN study, there was a residual mass of material left within 
each of the donor compartments at 24 h, Figure 6.8.  Therefore, residual drug will have 
remained within the formulation at the end of the study, which suggests why no plateau was 
observed in permeation at 24 h in Figure 6.6.  In addition, it was visually apparent that SRB had 
diffused into the epidermal membrane during the study, Figure 6.9. 
 (A)   (B)   (C) 
Figure 6.9  En face images of epidermal membranes during SRB diffusion study.   
Images show membrane (A) immediately after SGMN application to donor chamber and (B) and (C) at 
24 h following SGMN and hypodermic needle (26 G) application, respectively (figures representative of 
all treated membranes n=4). 
 
As the arrows in Figure 6.9 (B) show, it was still possible to observe discrete SGMN channels 
created within the membrane at 24 h.  However, in comparison to freshly treated membrane, 
Figure 6.9 (A), the channels were not as obvious due to partitioning of SRB throughout the 
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entire membrane.  The same effect was observed in positive control membranes treated with 
a hypodermic needle, Figure 6.9 (C), where the needle channel (black arrow) stained more 
intensely than the surrounding tissue at 24 h.  This suggested that channels created within the 
epidermis under these occluded patch formulations remained open throughout the study.  
Similar results have been observed by others investigating skin occlusion and MN channel 
lifetime (Kalluri and Banga 2011; Kalluri et al. 2011).  
 
Taken together, the data in this section indicate the utility of SGMNs of these dimensions to 
incorporate a model hydrophilic drug molecule and to successfully deliver it across the SC 
barrier of human skin.  Biodegradable MN structures have previously been shown to facilitate 
delivery of such molecules across porcine skin (Lee et al. 2008; Sullivan et al. 2008).  However, 
Sullivan et al. investigated MNs of 750 µm length whilst Lee et al. utilised MNs measuring 
600 µm; so the MNs used in this study were of a considerably shorter nature.  As previously 
discussed, biodegradable MNs with a length of 500 µm have been shown to facilitate delivery 
of macromolecules more efficiently than 200 µm long needles, possibly due to ineffective skin 
penetration by the shorter needles (Li et al. 2009).  Importantly, this study suggests that 
SGMNs with a pyramidal geometry and 250 µm length can successfully negate human skin 
barrier to facilitate cutaneous delivery of a model hydrophilic drug incorporated within the 
array matrix.      
 
6.4.1.3 SGMN arrays containing fluorescein isothiocyanate conjugated bovine serum 
albumin    
To further investigate the potential of SGMN arrays to facilitate transdermal delivery of model 
macromolecules, FITC-BSA was incorporated into the array matrix.  Bovine serum albumin is a 
hydrophilic protein with a large molecular weight of approximately 66 kDa and it has widely 
been studied as a model macromolecular permeant in MN facilitated transdermal drug 
delivery studies (Lee et al. 2008; McAllister et al. 2003; Wendorf et al. 2011).   
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Figure 6.10  Exemplar standard curve used in quantitative determination of FITC-BSA flux across 
human epidermis.   
Data presented as mean ± S.D. (n=3).   
 
Utilising the standard curve in Figure 6.10, Figure 6.11 shows the estimated diffusion of FITC-
BSA across epidermal membrane.  As shown, two membranes in the untreated control group 
were discarded from the analysis.  These membranes appeared to be compromised and 
demonstrated no initial lag phase.  It was speculated that this may have been due to prolonged 
tissue storage at -20 ºC, as discussed in section 5.4.6.   
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Treatment Mean Q6 (µg / cm
2) ± S.E. Percentage formulation 
permeated at Q6 (%) ± S.E. 
SGMN array 436.1 ± 113.3 29.1 ± 8.6 
Hypodermic + SG 623.3 ± 264.7 24.0 ± 16.2 
Figure 6.11  Permeation profiles of FITC-BSA from 5 %w/w loaded sugar formulations across human 
epidermal membrane.   
Membranes were left untreated with application of sugar solution containing FITC-BSA (triangles, n=2) 
or treated with a single hypodermic needle (26 G) puncture and solid SG application (squares, n=4) or 
SGMN array application (diamonds, n=4).  Data presented as mean ± S.E.   
 
The permeation profiles of these 2 membranes correlated with positive control data following 
hypodermic needle puncture of the membrane to completely negate the skin barrier, Figure 
6.11.  This observation was supported by SDS-PAGE which confirmed protein presence in the 
untreated samples (see Appendix 1).  Even a small hydrophilic molecule would not be expected 
to permeate intact skin immediately and the diffusion profile would demonstrate an initial lag 
time, as demonstrated in Figure 6.12.   
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(A)   
(B) 
Figure 6.12  Exemplar permeation profiles obtained from (A) infinite dose and (B) finite dose 
application to human skin.   
Adapted from source (Williams 2003).  
  
Another feature of this experiment was that a large proportion of the total dose applied 
appeared to be delivered into the receptor compartment by 24 h following membrane 
treatment.  This was a surprising result as typically 0 - 20 % of the applied dose is delivered 
utilising the classical Franz diffusion cell and a finite dose (Birchall et al. 2006; Coulman et al. 
2009; Jeans and Heard 1999).  It is generally accepted that permeation across intact skin 
occurs by passive diffusion (Scheuplein and Blank 1971) in accordance with Fick’s Law (Flynn et 
al. 1974) as the permeant moves along its concentration gradient; as long as sink conditions 
are maintained.  If the study duration permits, equal concentrations of the permeant will 
eventually be found in both the donor and receptor compartments, dependent upon their 
volume ratio.  In this experiment however, a solid formulation was applied to the donor and it 
was found that approximately 30 % of the payload had permeated by 6 h increasing to 
approximately 66 % by 24 h, Figure 6.11.  It was noted that permeation of FITC-BSA appeared 
to be reaching a plateau and hence that the amount of the permeant in the donor was 
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becoming depleted.  This correlated well with the diffusion profile from a finite dosage form 
with holes created in the membrane, Figure 6.12 (B).   
 
High levels of permeation from biodegradable MN structures in vitro have been found 
previously.  For example, various workers have showed 100 % delivery of rhodamine from 
CMC and amylopectin MNs (Kim et al. 2012; Lee et al. 2008) following dissolution in situ and 
Donnelly et al. noted 83 % delivery of theophylline from polymer MNs (Donnelly et al. 2011).  
Hence, it appears that these observations are not entirely anomalous and it was speculated 
that there could have been a number of possible explanations for this result.  Firstly, the drug 
loaded SGMN system is a novel transdermal drug delivery methodology with a finite dosage in 
a hydrophilic solid formulation maintained under an occlusive backing; a situation known to 
enhance the diffusion of drug through skin (Blank 1985).  Also, it was hypothesised that once 
the SGMNs penetrated the SC they would dissolve rapidly within the epithelial cell layer 
creating aqueous channels, as shown in Figure 6.3 (B).  This would allow “back diffusion” of 
water from the receptor compartment (Herkenne et al. 2007) to wet the main dosage 
reservoir of the SGMN array base.  As the array was occluded, this could have created a highly 
concentrated environment on the skin surface therefore driving further drug diffusion from 
the base layer.  Further studies in this chapter were conducted to observe whether the fate of 
SGMN arrays would be replicated in a full thickness skin model.       
 
In a similar manner to the membranes investigated in Figure 6.4, it was noted from ER 
measurement, Figure 6.13, that the initial barrier properties of membranes appeared to vary 
greatly.  Even though the same donor membrane was used in all treatment arms, it was 
apparent that the initial impedance in the SGMN and hypodermic treatment groups, Figure 
6.13 (A) and (B) respectively, were lower than in the untreated group at the start of the study.  
This further highlighted the importance of establishing baseline membrane impedance prior to 
study initiation.   
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(A) (no significant difference P=0.08) 
(B) (no significant difference P=0.32) 
(C) (no significant difference P=0.44) 
Figure 6.13  Electrical resistance measurement of epidermal membranes.   
Bars denote resistance prior to treatment (black) and following (A) SGMN array treatment, (B) 
hypodermic needle (26 G) treatment or (C) no treatment (white).  Data presented as mean ± S.D. (n=4).  
 
Due to the unusual nature of these results, the experiment was repeated using skin tissue from 
different donors, Figure 6.14, combined with the standardised approach (section 5.4.6) to 
assessment of initial membrane barrier integrity, Figure 6.16.     
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Figure 6.14  Permeation profiles of FITC-BSA from 5 %
w
/w loaded sugar formulations across human 
epidermal membrane.   
Membranes were left untreated with application of stock sugar solution containing FITC-BSA (triangles) 
or treated with a single hypodermic needle (26 G) puncture and solid SG application (squares) or SGMN 
array application (diamonds).  Data presented as mean ± S.E. (n=4).  
 
As the data in Figure 6.14 show this experiment did not make the analysis any clearer.  
Immediately it appeared that the actual numerical data was not logical; the theoretical total 
dose of FITC-BSA contained within SGMN arrays was 1500 µg, therefore it would be impossible 
to deliver nearly three times this amount.  The permeation profiles also appeared to be 
distinctly different to those shown in Figure 6.11.  In this study there did not appear to be a 
pronounced plateau of the delivery of FITC-BSA from 12 h onwards, indicating that there was 
still excess drug in the donor compartment.  The difference in permeation profile could be 
reasoned by utilisation of skin from different donors, however again the profile does not 
correlate with the numerical data obtained.  As Figure 6.15 shows, the residual mass of 
formulation remaining in the donor chamber at the end of each study varied also. 
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Figure 6.15  Residual mass of FITC-BSA formulation remaining in donor chamber at 24 h.   
Bars indicate residues from 1
st
 experiment; hypodermic (white bar, n=4), SGMN (black bar, n=1) and 2
nd
 
experiment; hypodermic (striped bar, n=4), SGMN (grey bar, n=2).  Data presented as mean ± S.E.  
 
As shown in Figure 6.15 there was considerable variation in the amount of residual 
formulation remaining in the donor chambers following 24 h.  However, it was apparent that 
there were a greater number of residues remaining after the second experiment, and hence 
that it was likely that a greater proportion of FITC-BSA remained in the donor chamber.  This 
evidence correlated with the permeation profiles observed in Figure 6.14, but further 
indicated that the numerical values were non-sensical. 
  
From these observations it appeared that there must have been flaws in the experimental 
technique in this study.  It was hypothesised that the FITC probe may have detached from the 
protein during the experiment and hence caused the spurious results observed.  However, a 
positive outcome of this study was that no FITC-BSA permeated across untreated membranes, 
Figure 6.16.  This correlated with the hypothesis that a protein would not passively diffuse 
across intact epidermal membrane.  Electrical resistance data confirmed that the initial 
measurements of untreated membrane, Figure 6.16 (C), did not vary significantly from those in 
other treatment groups and that they remained intact throughout the study.  Where 
membranes were treated with SGMNs or hypodermic needle, significant decreases in 
impedance were measured after the study, Figure 6.16 (A) and (B) respectively.  This 
correlated with previous ER findings shown in Figure 6.7.   
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(A) (* denotes significance P=0.003) 
(B) (* denotes significance P=0.002) 
(C) (no significant difference P=0.42) 
Figure 6.16  Electrical resistance measurement of epidermal membranes.   
Bars denote resistance prior to treatment (black) and following (A) SGMN array treatment, (B) 
hypodermic needle (26 G) treatment or (C) no treatment (white).  Data presented as mean ± S.D. (n=4).  
 
To probe the spurious-looking results obtained in the FITC-BSA diffusion studies, analyses 
based on direct protein quantification were attempted.  These studies relied upon interaction 
of protein and reagent and hence would not be affected by the fluorescent probe.  Figure 6.18 
shows the estimation of total protein in samples using the BCA assay using the standard curve 
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in Figure 6.17.  Where the number of repeats is less than 4, the protein quantity was below the 
limit of quantification of the assay.   
 
Figure 6.17  Exemplar standard curve used in quantitative determination of FITC-BSA by BCA assay.   
(n=1). 
 
Figure 6.18  Bicinchoninic assay quantification of FITC-BSA permeated across human epidermis at 
24 h.   
Data from 1st experiment; hypodermic needle (26 G) treated (black bar, n=3), SGMN array treated (dark 
grey bar, n=3) and untreated (light grey bar, n=4).  Data from 2nd experiment; SGMN array treated 
(white bar, n=4), hypodermic needle (26 G) treated (hatched bar, n=2) and untreated (striped bar, n=4).  
Data presented as mean ± S.E.     
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As Figure 6.18 shows, the total quantity of protein permeated in both experiments was much 
closer to the theoretical total amount of drug incorporated.  This further indicated that the 
data obtained in Figure 6.14 were not logical.  However, it was observed that the BCA assay 
was not sensitive enough to accurately quantify every treatment sample obtained.  Therefore, 
the samples were further analysed using the Bradford assay, Figure 6.20.         
 
Figure 6.19  Exemplar standard curve used in quantitative determination of FITC-BSA by Bradford 
assay.   
Data presented as mean ± S.D. (n=3). 
 
Figure 6.20  Bradford assay quantification of FITC-BSA permeated across human epidermis at 24 h. 
Data from 1st experiment; hypodermic needle (26 G) treated (black bar), SGMN array treated (dark grey 
bar) and untreated (light grey bar).  Data from 2
nd
 experiment; SGMN array treated (white bar), 
hypodermic needle (26 G) treated (hatched bar) and untreated (hashed bar).  Data presented as mean ± 
S.E. (n=4).     
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As shown, the Bradford assay was more sensitive than the BCA assay and all treated samples 
were quantifiable.  Generally, it was observed that the results of the Bradford assay correlated 
with the BCA assay data, Figure 6.18.  Importantly, both assays suggested that no more than 
approximately 1500 µg of protein was present within the receptor compartment at 24 h.  
Additionally, only a small amount of total protein was present in the untreated samples from 
the second experiment.   
 
In summary, these data further suggest the utility of SGMN arrays of these dimensions to 
facilitate the delivery of a range of model substances, including hydrophilic macromolecular 
compounds, across human SC barrier.       
 
6.4.2 Integrated transdermal sugar glass microneedle patch facilitated diffusion studies 
across human epidermal membrane    
6.4.2.1 Acrylate adhesive backing 
This section of the chapter aimed to assess the drug delivery potential of novel integrated 
transdermal SGMN patches fabricated in section 5.3.2.3.  The basis for the design of these 
patches was a drug in adhesive, monolithic style (Tan and Pfister 1999) with a SGMN array 
attached to the adhesive layer.  Previous data, section 6.4.1, demonstrated that large 
molecular weight hydrophilic drugs incorporated within the matrix of a SGMN array could 
successfully be delivered across human epidermal barrier.  However, potential limitations of 
this device include the total amount of drug that can be loaded into the array matrix, the 
physical stability of the material, lack of controlled delivery and poor adhesion to skin.  To 
attempt to overcome these issues it was conceived that SGMNs could be directly attached to 
adhesive backing layers containing drug. 
   
Sulforhodamine B sodium was chosen as a model drug substance in this work due to the 
reasons stated in section 6.4.1.2 and due to its ease of assay.  The delivery of SRB from an 
integrated Duro-Tak® (acrylate) adhesive SGMN patch is shown in Figure 6.21.    
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Treatment Mean Q12 (µg / cm
2) ± S.E. Percentage formulation 
permeated at Q12 (%) ± S.E. 
Integrated SGMN adhesive patch 2.3 ± 0.7 0.9 ± 0.3 
Hypodermic + patch 2.4 ± 1.0  1.0 ± 0.4 
Figure 6.21  Permeation profiles of SRB from 5 %w/w loaded Duro-Tak® adhesive patches across human 
epidermal membrane.   
Membranes were left untreated (triangles), or treated with 3 hypodermic needle (26 G) punctures 
(squares) or an integrated SGMN adhesive patch (diamonds).  Data presented as mean ± S.E. (n=4).    
 
As shown, the flux of SRB from an integrated SGMN adhesive patch was very different to that 
of the SGMN array alone, Figure 6.6.  In contrast to the SRB loaded SGMN array, this patch 
system demonstrated a distinct lag phase, until 2 h, before a rapid increase in permeation up 
to 24 h.  Lag times have been noted previously in passive transdermal adhesive systems  (Jain 
and Banga 2010; Jeans and Heard 1999; Roy et al. 1996) before a steady-state flux was 
observed.  In this sytem there was no permeant contained within the SGMNs and it was 
hypothesised that the lag time may have been due to the time required for needle and backing 
dissolution prior to wetting of the adhesive layer and SRB diffusion.      
                 
In this study, it was observed that the permeation profile obtained from an integrated SGMN 
adhesive patch correlated with a conventional transdermal patch that does not cause physical 
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disruption of the barrier (Jeans and Heard 1999).  However, in this system, approximately 2 % 
of the total drug contained within the adhesive was delivered by 24 h, and only 3 % by 48 h.  
As stated, SRB appeared to be completely saturated within the adhesive matrix due to crystal 
presence, Figure 5.11.  It has been found that if the solubility of a permeant is low in a 
particular vehicle this will increase its “leaving ability” via passive diffusion (Higuchi 1960).  
Hence, this should have provided maximal thermodynamic activity within the patch.  However, 
it has been shown that increasing drug loading within adhesive patches above saturation does 
not significantly enhance flux across skin  (Jain and Banga 2010; Roy et al. 1996).  As the salt 
form of SRB was incorporated within the adhesive, the soluble drug concentration within the 
patch was likely to have been low.  Other workers have incorporated drugs within acrylate 
adhesives in the free base form (Jain and Banga 2010; Jeans and Heard 1999; Roy et al. 1996) 
and hence this may explain the low total permeation of SRB from the integrated SGMN patch 
system over 48 h.  Additionally, due to its size and physicochemical properties, SRB will only 
have diffused from the patch where it was in contact with an aqueous channel in the 
membrane.  This hypothesis was supported by the permeation profile shown by hypodermic 
needle membrane treatment, Figure 6.21.  In this treatment arm the drug flux up to 6 h was 
rapid, but began to decrease after this time point.  This suggested that crystalline SRB in the 
patch immediately in contact with aqueous channels dissolved rapidly showing an initial burst 
effect, as noted in other similar adhesive systems (Guyot and Fawaz 2000; Roy et al. 1996).   
Following this initial burst, drug release slowed and followed a more linear profile, which could 
have been due to slow diffusion of SRB through the polymer (Guyot and Fawaz 2000).  In 
contrast, the MNs and backing of the SGMN arrays, section 6.4.1, both consisted of sugar glass 
in which SRB was fully dissolved.  Therefore, the base layer will have wetted rapidly once 
aqueous channels were created within the epidermis, as demonstrated in Figure 6.3 (B).  This 
hypothesis would explain the higher flux value of SRB from SGMNs observed in 6.4.1 compared 
to the relatively low flux observed here, Figure 6.21.      
 
To investigate epidermal membrane integrity, ER was measured prior to and following the 
study.  In agreement with previous findings, section 6.4.1.3, membranes treated with a 
hypodermic needle or integrated transdermal SGMN patch demonstrated significant decreases 
in barrier impedance, P = 0.02 and 0.02 respectively.  Membranes treated with an adhesive 
patch only did not show a significant change in ER throughout the study, P=0.46.  This 
indicated the utility of integrated transdermal SGMN patches to effectively puncture the SC of 
human skin.        
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Upon conclusion of the study, transdermal patches were removed from the epidermal surface 
prior to en face observation, Figure 6.22.  As shown, there were greater SRB residues found in 
the donor chambers of hypodermic and SGMN patch treated membranes, Figures 6.22 (A) and 
(B) respectively, compared to untreated membrane, Figure 6.22 (C).  Although no discrete 
puncture sites were observed, this data further supported the hypothesis that SGMNs created 
aqueous pathways across the SC to facilitate wetting of the adhesive layer.    
 (A)   (B)   (C) 
Figure 6.22  En face view of epidermal membranes from representative donor chambers at 48 h.   
Cells were treated with (A) hypodermic (26 G) needle and patch, (B) integrated SGMN patch, (C) 
untreated and patch.  (n=4). 
 
6.4.2.2 Silicone adhesive backing 
To investigate whether drug delivery from integrated transdermal SGMN patches could be 
enhanced a silicone adhesive, BIO-PSA® 7-4302, was utilised.  In a manner analogous to the 
acrylate adhesive patch, the drug formed a solid suspension within the backing.  However, the 
silicone is formulated to be amine-compatible and therefore it was thought that SRB may 
demonstrate a different release profile from the adhesive.  The delivery of SRB from these 
adhesive patches is shown in Figure 6.23. 
Chapter 6 
205 
 
Treatment Mean Q12 (µg / cm
2) ± S.E. Percentage formulation 
permeated at Q12 (%) ± S.E. 
Integrated SGMN adhesive patch 11.1 ± 3.4 4.4 ± 1.3 
Hypodermic + patch 4.4 ± 1.3 1.8 ± 0.5 
Figure 6.23  Permeation profiles of SRB from 5 %w/w loaded BIO-PSA® 7-4302 adhesive patches across 
human epidermal membrane.   
Membranes were left untreated (triangles), or treated with 3 hypodermic needle (26 G) punctures 
(diamonds) or an integrated SGMN adhesive patch (squares).  Data presented as mean ± S.E. (n=4).  
 
As the data in Figure 6.23 show, permeation of SRB from silicone patches appeared to be 
biphasic.  A sharp increase in permeation was observed at 24 h.  This behaviour is unusual and 
suggests that the membrane may have deteriorated during the study.  Additionally, by 24 h 
approximately 3 times the quantity of drug had permeated from the silicone adhesive patches 
compared to the acrylate adhesive, Figure 6.21.  As the rate of drug release from an adhesive 
is determined by drug solubility and diffusion coefficient within the polymer (Roy et al. 1996), 
this data indicated that either SRB had a greater solubility limit in the silicone adhesive, or that 
the adhesive wetted better once the SGMNs had dissolved to allow more rapid drug release.  
Furthermore, it was noted that there was no lag phase shown in permeation of the drug from 
these SGMN patches.  This suggested that the SGMNs penetrated the epidermal membrane 
and rapidly dissolved to allow drug diffusion from the patch backing.  Logically, the SGMN 
array in the integrated acrylate adhesive patch will have dissolved rapidly too, therefore the 
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lag time observed with this patch, Figure 6.21, is likely to have been due to a lower solubility 
and poor diffusion of SRB within the adhesive.  This suggested that the release of SRB from an 
acrylate backing was not optimal.   
 
Electrical resistance measurement once again suggested that all epidermal membranes were 
intact prior to initiation of the study and that both hypodermic and SGMN array treatment 
caused significant decreases in impedance.   The data in Figure 6.23 combined with ER 
measurement of untreated membranes suggested that there was no significant disruption of 
SC when patches without SGMNs were applied to the skin.  Thus, there was no detectable 
permeation of SRB across these membranes throughout the study.  This further suggested the 
utility of SGMNs to facilitate hydrophilic drug delivery across human skin. 
 
6.4.2.3 Sugar glass backing 
As a positive control study for the adhesive patch studies, a patch was designed with a 
hydrophilic backing layer composed of SG material.  In this patch the drug was fully dissolved 
within the backing layer and no crystallisation was observed.     
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Treatment Mean Q12 (µg / cm
2) ± S.E. Percentage formulation 
permeated at Q12 (%) ± S.E. 
Integrated SGMN adhesive patch 99.7 ± 44.1 39.9 ± 17.7 
Hypodermic + patch 90.7 ± 50.4 36.3 ± 20.2 
Figure 6.24  Permeation profiles of SRB from 5 %w/w loaded sugar glass patches across human 
epidermal membrane.   
Membranes were left untreated (triangles), or treated with 3 hypodermic needle (26 G) punctures 
(diamonds) or an integrated SGMN adhesive patch (squares).  Data presented as mean ± S.E. (n=4). 
  
As Figure 6.24 demonstrates, when the drug was fully dissolved within a hydrophilic backing 
layer, permeation from the patch was much greater than from either of the more hydrophobic 
adhesive layers.  There was no evidence of a lag phase in either of the needle treated groups in 
this study, and the amount of permeant delivered by 12 h was approximately 100 and 10 fold 
greater than with acrylate and silicone adhesive backing layers respectively.  Electrical 
resistance measurement again suggested that hypodermic and SGMN array treatment of 
epidermal membranes significantly decreased impedance compared to untreated membrane.  
This data indicated that the SGMNs punctured the SC and dissolved rapidly to facilitate SRB 
permeation from the backing.  This further suggested that the lag phase observed with the 
acrylate patch system was likely to be due to the poor solubility of SRB within the adhesive 
matrix.  Furthermore, total permeation at 12 h was approximatley 40 %, rising to  
approximatley 80 % of the dose applied by 48 h.  This was much greater than that observed 
Chapter 6 
208 
when using SGMNs with drug loaded throughout the entirety of the array, Figure 6.6.  It was 
hypothesised that as a much smaller quantity of drug was contained within the integrated 
SGMN patch, this potentially provided a larger surface area to volume ratio for wetting and 
dissolution of the dosage formulation.   
 
In summary, the combined data from the integrated transdermal SGMN patch diffusion studies 
is shown in Figure 6.25.     
 
Figure 6.25  Permeation profiles of SRB from 5 %w/w loaded integrated SGMN patches across human 
epidermal membrane.   
Profiles show diffusion from from BIO-PSA® 7-4302 (triangles), Duro-Tak® (diamonds) or SG (squares) 
backing layers.  Data presented as mean ± S.E. (n=4).    
 
As shown, the total permeation of SRB from both adhesive backing layers at 48 h was 
considerably less than from the SG backing layer.  In clinical practice, a wafer of SG would not 
be the ideal backing layer as it is brittle and non-adhesive.  However, the data suggested that 
varying the properties of the adhesive backing would alter the delivery of hydrophilic 
substances contained within the patch.  Other workers have found that plasticisers, for 
example polyvinylpyrrolidone, can decrease the crystallisation tendency of drugs within 
adhesives and improve transdermal delivery (Jain and Banga 2010).  Alternatively, more 
Chapter 6 
209 
hydrophilic adhesive layers have been utilised, for example hydroxypropylmethylcellulose 
(Guyot and Fawaz 2000), which may provide more stable incorporation of larger 
concentrations of hydrophilic drug entities.  Therefore, with adhesive and drug loading 
optimisation, it is possible that the delivery of large molecular weight, hydrophilic drugs from 
integrated transdermal SGMN patches may be enhanced. 
     
6.4.3 Full thickness skin sugar glass microneedle dissolution study 
As stated in section 6.4.1.3, it was surprising that such a large quantity of the dose applied to 
the donor compartment permeated across the membrane during diffusion studies.  It was 
speculated that this may be an artefact of the experimental set up and the epidermal 
membrane utilised.  As epidermal membrane supported on filter paper was used as the model 
barrier membrane, and there was a large reservoir of PBS in the receptor chamber, it was 
hypothesised that this may be creating an unrealistically hydrated environment within the 
tissue.  This may have accelerated the dissolution of SGMNs in situ and hence facilitated drug 
permeation from the drug reservoir. 
 
To probe this theory further, a qualitative Franz diffusion cell study utilising full thickness 
human skin was designed.  The aim of this study was to mimic the in vivo situation of human 
skin more closely.          
 (A) 
 (B) 
Figure 6.26  En face images of full thickness skin at 24 h following Franz diffusion cell study.   
Skin samples were treated by (A) SGMN arrays and (B) flat SG sections, both containing 1 %
w
/w MB. 
 
As Figure 6.26 (A) shows, all the SGMN arrays punctured the SC to permit delivery of MB dye 
into the epidermal layer.  This was demonstrated by a square shaped delivery pattern which 
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correlated precisely with the area treated by the MNs.  Delivery and diffusion of the dye was 
confirmed by subsequent transverse section of the skin tissue, Figure 6.27, where all skin 
sections demonstrated penetration of the SC and deposition of blue dye into the epidermis.  
Once again, it was apparent that these MNs did not penetrate deep into the epidermal layer 
and that delivery varied between samples.  However, it further confirmed that SGMNs of these 
dimensions are robust enough to reliably disrupt the SC to provide an aqueous pathway across 
the barrier.  It was speculated that these issues may be addressed by increasing the length of 
SGMNs and standardising the method and force of MN application in future work.   
(A) (B) 
(C)   (D) 
(E)    (F) 
Figure 6.27  Transverse sections of skin samples shown in Figure 6.27 (A).   
Sites stained blue indicate SGMN penetration of the membrane (Bar = 100 µm). 
 
Importantly, it was noted that flat SG sections were capable of puncturing the SC when applied 
in this manner, Figure 6.26 (B).  Two of the SG treated samples appeared to show evidence of 
SC penetration, although this was not present in every repeat and appeared to be a random 
occurrence.  This result demonstrated that the rigid but brittle nature of the glassy material 
may potentially disrupt skin barrier properties when applied under force.  However, it was 
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visually apparent that SGMN arrays penetrated the skin more reliably when applied in the 
same manner. 
To explore whether the permeation efficacy observed in the FITC-BSA SGMN and SG-backed 
patch diffusion studies were artefactual, the mass of residues remaining in the donor chamber 
were recorded at the end of the study, Figure 6.28.                  
 
Figure 6.28  Mass of sugar formulations during full thickness skin study.   
Bars represent mass of SGMN (black bar) and SG (white bar) prior to the study and at 24 h, SGMN (grey 
bar), SG (hashed bar).  Data presented as mean ± S.D. (n=3).  
 
As Figure 6.28 shows, there was very little change in weight of the SG formulations following 
the study.  This indicated that when using full thickness human skin as the model barrier in 
vitro, the formulations did not wet as well in comparison to using epidermal membrane, and 
hence did not dissolve so rapidly.  It was shown that SGMNs penetrated the barrier in this 
experiment, Figure 6.27, to create aqueous channels in the SC.  However, it appeared that 
hydration of the membrane was lower in this setup due to the increased tissue depth provided 
by the dermis.  As McAllister et al. predicted, the use of full thickness skin in diffusion studies 
may underestimate permeability by a factor of 5, whereas use of epidermal membrane may 
overestimate delivery by a factor of 2 (McAllister et al. 2003).  Therefore, it is likely that the 
actual delivery of medicaments via SGMN arrays in vivo may be up to two times less than 
predicted in these diffusion studies, but would certainly be greater than that observed in this 
final study.  Further in vivo experiments would be useful to determine the transdermal delivery 
potential of SGMN arrays.    
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6.5 Conclusion 
The focus of this chapter was to quantitatively assess the transdermal drug delivery potential 
of biodegradable SGMN array devices.  It has been demonstrated that various model 
molecules with differing physicochemical properties can successfully be loaded into these 
devices and delivered across human skin at therapeutically relevant doses.  However, 
limitations of the modified in vitro Franz cell methodology developed in Chapter 5 appear likely 
to have caused an overestimation of the drug delivery potential of SGMNs.  Due to 
experimental limitations it would not be appropriate to extrapolate these findings to delivery 
of medicaments in vivo as it appears that the actual permeation in vivo would be smaller than 
that observed in these diffusion studies.  However, it has been shown that a range of model 
substances can successfully be delivered across human skin barrier using SGMN arrays.  
Importantly, it has been demonstrated that large molecular weight molecules, that would not 
normally permeate the skin passively, can be delivered across the SC barrier.  This suggests 
that molecules such as peptides, antibodies, proteins and DNA may be delivered via the 
transdermal route using these devices.   
 
In pursuit of developing a more commercially viable device, it has been shown that SGMN 
arrays can be successfully integrated into a transdermal patch type system to facilitate delivery 
of a hydrophilic molecule from the adhesive backing layer.  Once more, it was shown that the 
molecule would not permeate the skin barrier passively from the adhesive layer unless the SC 
was disrupted.  Slower rates of delivery from these patches were observed, but they provided 
the potential for controlled drug release, optimisation of drug thermodynamic activity within 
the patch and skin adhesion.  Therefore, it is speculated that these devices may provide a 
realistic, patient-friendly drug delivery system.  Additionally, it appears that if the drug 
molecule is incorporated within a hydrophilic adhesive type matrix, then delivery from the 
patch may be enhanced due to improved wetting of the drug layer.  Hence, these studies 
suggest the utility of biodegradable SGMN arrays to facilitate transdermal drug delivery of a 
range of molecules, potentially including macromolecules, from integrated adhesive systems. 
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7 General discussion 
Despite the many perceived benefits of MNs for transdermal drug delivery applications, the 
number of clinical trials conducted with these devices to date has been limited.  Although MNs 
have demonstrated efficacy at increasing the permeation of model drug molecules across skin 
within the laboratory, there may be significant hurdles to translating this into clinical practice.  
Issues surrounding which medicines are appropriate for MN facilitated delivery, chemical 
stability of medicaments within devices, safety of MN materials, reliability of dosing and 
practical patient application of the device are all potential barriers to this form of drug 
delivery.  These problems have often been associated with solid MN devices and it is envisaged 
that biodegradable MNs may provide solutions to many of these.  Subsequently, this study was 
motivated by the opportunity to develop an optimised system for stable drug delivery utilising 
dissolvable biodegradable MNs.   
 
The aim of this thesis was to evaluate the feasibility of creating biodegradable MN arrays from 
amorphous sugar glass material.  It was envisaged that sugar glasses may be a suitable 
material for MN fabrication due to the many different routes to formation of a molecular glass 
(Surana et al. 2004) providing flexibility in formulation and micromoulding fabrication.  To 
date, a variety of biodegradable MN permutations have been reported which have been 
fabricated from a number of different materials.  These materials have included natural 
substances, for example the disaccharides maltose (Lee et al. 2011b; Miyano et al. 2005) and 
galactose (Donnelly et al. 2009a), the polymeric carbohydrates carboxymethylcellulose (Lee et 
al. 2011a; Lee et al. 2008) and amylopectin (Lee et al. 2008) and thread-forming polymers 
including chondroitin sulphate, dextrin and albumin (Ito et al. 2006).  Alternatively, others have 
investigated synthetic materials for biodegradable MN fabrication, such as 
polyvinylpyrrolidone (Sullivan et al. 2008), poly lactic acid (Chu et al. 2010; Park et al. 2005), 
poly lactide-co-glycolic acid (Park et al. 2005) and polyvinyl alcohol (Chu et al. 2010).  
Fabrication of these MN arrays has often focused upon a micromoulding methodology coupled 
with a variety of techniques to load material into the moulds.  Initial efforts frequently 
concentrated on the use of elevated temperature to aid filling of micromoulds which often 
resulted in inactivation of delicate molecules, such as proteins (Donnelly et al. 2009a; Park et 
al. 2006), incorporated within the matrix.  Subsequently, this led to a scenario involving 
insertion of solid biodegradable MN structures followed by application of a drug formulation in 
a two-step process (Kolli and Banga 2008; Miyano et al. 2005; Park et al. 2005).  This 
methodology was similar to the original “poke and apply” methodology utilised in early solid 
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MN studies (Donnelly et al. 2008; Henry et al. 1998; McAllister et al. 2003) and was 
undesirable. 
 
To overcome these limitations there has been significant interest in fabrication of 
biodegradable MN structures utilising low temperature methodologies.  These have included 
drying of viscous drug formulations under centrifugation and low temperature (Lee et al. 
2011a; Lee et al. 2008) or the pressure of a metallic plate (Fukushima et al. 2011; Ito Y. et al. 
2010a).  Alternatively, liquid pre-polymer solutions have been formed into micromoulds and 
polymerised in situ, for example vinyl pyrrolidone (Sullivan et al. 2008) and eShell 200 
monomer (Gittard et al. 2009).  These efforts have facilitated the stable incorporation of a 
range of macromolecules within MN structures for percutaneous delivery.  Macromolecular 
drugs now represent an increasing proportion of all new medicines on the market, although it 
is widely accepted that their stable delivery to the body is associated with significant 
challenges (Brown et al. 2006).   
 
Accordingly, the utilisation of sugar glasses to fabricate biodegradable MNs for labile 
medicament incorporation and stabilisation appeared attractive.  Sugar glasses are utilised in 
nature to protect delicate biological molecules in the dehydrated state (Potts 1994).  
Subsequently, it was realised that these materials may find utility in the pharmaceutical 
sciences to stabilise biomolecules during processing and storage (Uritani et al. 1995).  To date, 
there have been many reports of different methodologies utilised to formulate amorphous 
sugar glasses.  Typically, the route to amorphisation has been chosen based upon the intended 
application of the glass.  Many of these techniques have involved the use of mechanical 
processes, involving elevated temperature or shear force, to vitrify the sugar (Willart et al. 
2001).  However, other techniques have involved utilisation of solution evaporation (Wright et 
al. 2002) and it was speculated that these methodologies may be suitable for SGMN 
fabrication and stable molecule incorporation.  In Chapter 2 a number of different solutions 
containing individual sugars and sugar alcohols, and binary combinations of these, were 
examined during a low temperature dehydration process.  Subsequently, it was shown that 
non-crystalline sugars could be produced from solutions containing a combination of the 
disaccharides trehalose and sucrose.  This finding was vital to the future utility of sugar glasses 
to fabricate MN arrays utilising a micromould based filling technique.  Physical characterisation 
of the material suggested that although these sugars appeared to be non-crystalline they had a 
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complex nature, which may have been due to the low temperature (non-thermal) 
methodology utilised to form them (Willart et al. 2002).   
 
The critical question arising over many biodegradable MN structures is whether the material is 
robust enough for reliable skin insertion.  In comparison to silicon or metal, biodegradable 
materials, by their nature, tend to have poorer structural rigidity and hence may be prone to 
failure upon insertion (Lee et al. 2008).  Sugar glasses, in particular, are an amorphous solid 
generally exhibiting decreased physical stability (Zhou et al. 2007) compared to the crystalline 
state.  Furthermore, it has been shown that maltose MNs with a length of 500 µm are more 
effective at penetrating human skin than those with a shorter length of 200 µm (Li et al. 2009).  
Therefore, it was an important aspect of this work to investigate the stability and skin 
penetration capabilities of SGMNs of the dimensions fabricated in this study.     
 
Due to restrictions imposed by the geometry of silicon MN master structures, it was important 
to investigate and establish the skin puncture capacity of SGMNs with the same pyramidal-
shaped dimensions, and small aspect ratio, early in this work.  As demonstrated in Chapter 3, 
SGMNs formed by a novel low temperature vacuum-forming technique had suitable structural 
robustness to reliably insert into human skin.  This was a critical finding which suggested the 
utility of SGMN arrays as a platform for facilitating transdermal drug delivery.  In addition, it 
was found throughout Chapters 3 to 6 that it was possible to incorporate a range of different 
model substances within SGMN arrays and to deliver them across the human SC barrier.  These 
model substances included small molecular weight entities, such as methylene blue dye and 
ibuprofen, a larger hydrophilic moiety, sulforhodamine B, and the macromolecules FITC-BSA 
and β-galactosidase.  Significant increases in permeation of these model substances across 
human skin were noted following SGMN facilitated delivery.  However, due to the short length 
of these MNs, it was found that they only punctured the epidermis superficially and 
penetrated only a short way into the viable tissue.  It is speculated that SGMNs with a longer 
needle shaft, and an increased aspect ratio, may penetrate deeper into the aqueous skin layers 
which may be advantageous for needle dissolution and drug delivery in vivo.    
 
As discussed previously, the physical stability of sugar glasses is a key issue regarding their 
utilisation as pharmaceuticals.  Accordingly, it was an important aspect of this work to assess 
both the stability of the SGMNs themselves and also model substances incorporated within the 
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MN matrix.  In Chapter 4 it was found that a functional protein, β-galactosidase, retained 
activity over a period of months following dehydration and inclusion within a glassy matrix; 
when stored under desiccated conditions.  However, significant reductions in enzyme activity 
were found during the dehydration process compared to freshly prepared enzyme solutions.  
In this system, it appeared that once a vitrified solid had been produced, and annealed at room 
temperature, the protein remained stable throughout a 3 month storage period.  It is now well 
characterised that sugar glass material becomes unstable when stored under elevated 
humidity (Hageman 1992) or temperature (Zhou et al. 2007) conditions due to its hygroscopic 
(Dittmar 1935) and meta-stable (Zhou et al. 2007) nature, which was supported in this study.  
Surprisingly, it was found that SGMNs appeared to be most stable when maintained within a 
low moisture environment at ambient temperature rather than under a completely desiccated 
environment however.  This was not expected and suggested that an equilibrium relationship 
may be involved between the residual water content contained within the sugar glass material 
and the moisture in the environment.  From a practical perspective, it was found that 
manipulation and utilisation of SGMNs under humid environmental conditions was 
problematic and led to rapid MN degradation.  Once again, this may limit the use of this 
material for MN fabrication and utilisation in practice.                             
 
To investigate the delivery of model substances from SGMN arrays in vitro a modified 
arrangement of the well described Franz diffusion cell set up was developed.  Many groups 
investigating MN facilitated drug delivery have utilised human skin membranes and have 
treated the tissue prior to loading within the diffusion cell (Coulman et al. 2009; McAllister et 
al. 2003).  The modification proposed in Chapter 5 allowed SGMNs to be applied in situ within 
the donor chamber, which was of particular benefit due to the rapid dissolution kinetics of 
sugar glass.  It is perceived that this set up may provide a robust platform for the assessment 
of biodegradable MN devices by others in future studies.  However, a potential limitation of 
this arrangement may be that dissolution of MNs and drug delivery are overestimated when 
utilising epidermal membrane as a model barrier.  In this instance an artificially aqueous 
environment may be created leading to more rapid dissolution of MNs than would occur in 
vivo.  It was speculated that it may be possible to circumvent this issue through the use of 
dermatomed or split thickness skin in future.  Furthermore, future studies should be 
conducted in vivo to assess the dissolution kinetics of SGMNs in living organisms.                 
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A feature of the SGMN arrays developed in this work was that drug incorporated within the 
MN structure was released rapidly upon dissolution in a bolus dose manner.  In some instances 
this may be advantageous, for example in osteoporosis treatment with parathyroid hormone, 
where it has been shown that rapid high concentrations followed by a short drug half-life are 
most effective at increasing bone density (Cosman et al. 2010).  However, often it is desirable 
to deliver a drug over a prolonged period of time for maximum therapeutic benefit and 
increased patient compliance.  In an attempt to address this issue, it was shown in Chapters 5 
and 6 that a model hydrophilic drug substance could be incorporated within adhesive backing 
layers to control its rate of release following SGMN microporation.  In this embodiment, it was 
speculated that the SGMNs created channels within the SC and rapidly dissolved to leave 
aqueous pathways for wetting of the adhesive layer.  Drug suspended within the adhesive was 
then free to permeate across the skin as occurs in a conventional transdermal patch system.  
In this study it was found that only a small proportion of the total quantity of drug contained 
within the adhesive permeated across SGMN treated skin by 48 h.  It was speculated that this 
was due to a combination of the physical characteristics of the adhesive and the 
physicochemical properties of the permeant.  Both these factors can be optimised in a 
conventional transdermal patch system to maximise the thermodynamic potential of the 
substance within the adhesive matrix.  Consequently, it is envisaged that future studies could 
lead to production of viable integrated SGMN transdermal patches for controlled release of 
medicaments.    
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7.1 Future work 
The results presented throughout this thesis demonstrate the principle that sugar glasses may 
be a suitable material for biodegradable MN manufacture.  However, due to time restraints it 
was not possible to conduct all the experiments desired to fully characterise the SGMN array 
system.  One of the most important areas to investigate would be the behaviour of SGMNs 
applied to an in vivo skin model.  In vitro studies conducted in this work have shown that 
SGMNs may facilitate transdermal drug delivery as a proof of principle.  To fully probe this 
potential, the delivery of medicaments to in vivo models, along with the study of 
pharmacokinetic profiles, would be desirable to fully examine the utility of SGMNs as a 
transdermal drug delivery device.  In this way, it would be possible to examine the therapeutic 
potential of SGMNs prior to clinical trials of the device.   
 
Furthermore, it would be desirable to fabricate SGMNs with differing geometries and 
dimensions to probe the optimal utility of these MNs.  A significant constraint of this work was 
the silicon MN master structures that were used for micromoulding SGMNs.  It was 
hypothesised that SGMNs with a greater aspect ratio and length would facilitate more reliable 
skin penetration thereby leading to more consistent delivery of model substances.  Alongside 
such studies, it would be important to probe the long-term stability of SGMN arrays further.  A 
more extensive range of storage conditions could be explored over longer time periods to fully 
characterise optimal storage for SGMNs and maintenance of MN morphology and viability.  
Such studies could also be designed to probe the stability of model medicaments incorporated 
within the matrix of SGMN arrays.   
 
Finally, it would be of interest to investigate the potential utility of integrated SGMN 
transdermal patches further.  This novel design provides many exciting opportunities for 
controlled transdermal drug delivery of medicaments that are currently challenging to deliver 
across skin barrier.  Investigation of parameters such as drug solubilisation and stabilisation 
within adhesive layers may provide improved delivery kinetics from these systems.  Similarly, it 
would be desirable to examine the behaviour of these devices in vivo to fully characterise their 
transdermal drug delivery potential.                         
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7.2 General conclusion        
In summary, this work is significant in that it demonstrates for the first time the utility of 
amorphous sugar glass material to formulate biodegradable MN structures via a low 
temperature process.  The SGMN arrays developed in this paper have shown reliable 
penetration of human skin for cutaneous drug delivery applications.  Furthermore, SGMNs 
formed by this process have demonstrated potential for the incorporation of a range of model 
compounds.  This suggests that SGMNs may be capable of facilitating the delivery of 
macromolecular medicaments, such as insulin and growth hormone, via the transdermal 
route.  Furthermore, a novel integrated SGMN adhesive patch system has been presented 
which may enable the controlled and prolonged delivery of molecules across skin.  It is 
envisaged that such a system may offer real opportunity for patient controlled transdermal 
drug delivery to treat a variety of chronic conditions in a safe and convenient manner.         
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9 Appendix 
9.1 Appendix 1 
To qualitatively confirm the presence of protein within the samples obtained in the FITC-BSA 
diffusion study, a polyacrylamide gel was run to examine the samples (Figure 1). 
 
Figure 1  Polyacrylamide gel of samples obtained from FITC-BSA diffusion study.  Lanes marked as 
follows, M = marker, B = BSA control, F = FITC-BSA control, 1-3 = hypodermic treated membranes, 4-6 = 
SGMN treated membranes, 9 & 11 = untreated membrane controls where fluorescence observed in 
receptor and 10 = untreated membrane controls where fluorescence not observed in receptor (n=2).     
As Figure 1 shows, all samples investigated, except sample 10, showed the presence of FITC-
BSA in the receptor solution.  It had been noted during the diffusion study that the receptor 
solution at 24 h in cells 10 and 12 remained visually transparent and hence cell 10 was chosen 
as a representative sample.  The gel confirmed that protein did permeate the untreated 
membranes in cells 9 and 11 and therefore further suggested that the barrier integrity of these 
membranes was compromised prior to the study.   
 
9.2 Appendix 2 
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Transdermal drug delivery is limited by the barrier properties of the outer skin layer. Microneedles (MNs) 
effectively circumvent the skin barrier to offer this route as a potential alternative to oral and parenteral 
delivery of therapeutics. Biodegradable microneedles offer particular advantages however processing com- 
monly requires elevated temperatures that may adversely affect heat-labile molecules and macromolecules. 
In this study, solid amorphous sugar glasses containing low residual quantities of water were created by 
dehydration of trehalose and sucrose sugar combination solutions. Biodegradable sugar glass MNs were fab- 
ricated following optimisation of a simple and novel low temperature vacuum deposition micromoulding 
methodology. These had absolute morphological ﬁdelity to silicon master structures and demonstrated suf- 
ﬁcient structural rigidity to efﬁciently penetrate excised human breast skin. Sugar glass MNs incorporating 
a marker compound dissolved rapidly and completely in situ releasing dye into deeper skin layers. The bio- 
logical activity of a model macromolecule was partially retained over extended storage following incorpora- 
tion into sugar glass. This is the ﬁrst demonstration that MNs created from amorphous sugar glasses can be 
used for incorporating and delivering molecules, and potentially biologically active macromolecules, via 
the transdermal route. 
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1. Introduction 
    Microneedles (MNs) offer an innovative approach to transdermal 
drug delivery. MNs transiently puncture the outermost skin barrier 
layer, the stratum corneum (SC), facilitating efﬁcient delivery of ther- 
apeutics and vaccines in a manner similar to injections whilst retain- 
ing the convenience of the transdermal patch [1,2]. MNs have been 
shown to increase skin permeability by orders of magnitude for com- 
pounds ranging from low molecular weight molecules [3] to proteins 
[4,5], nanoparticles [6] nucleic acids [7,8] and vaccines [9,10]. 
    MNs prepared from silicon [4,11], metal [12,13] and glass [14,15] 
are typically used to facilitate drug delivery through depositing a 
dried surface-coating of active into the skin or enabling injection of 
a liquid formulation through multiple hollow channels. As an alterna- 
tive polymer MNs can be manufactured from biocompatible materials 
using moulding processes that lend themselves to inexpensive 
and robust mass production [6]. Importantly, polymer MNs can be 
designed to degrade within biological tissues to release an incorpo- 
rated medicament cargo. To date biodegradable MNs have been 
fashioned from a range of synthetic and natural materials including 
 ⁎ Corresponding author at: Welsh School of Pharmacy, Redwood Building, King 
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0168-3659/$ – see front matter © 2011 Elsevier B.V. All rights reserved. 
doi:10.1016/j.jconrel.2011.10.024 
poly-lactide-co-glycolide [16], polyvinylpyrrolidone [2], carboxy- 
methylcellulose [17], amylopectin [17], dextrin [18], galactose [19] 
and maltose [13], [20]. A number of model compounds of various 
size, for example, sodium salicylate, calcein, [20] sulforhodamine, bo- 
vine serum albumin and β-galactosidase enzyme [2] have been suc- 
cessfully incorporated into biodegradable MNs. 
    Whilst biodegradable MNs have been shown to facilitate perme- 
ation of a drug formulation [21], loading of drug into the MN itself 
can be problematic due to the high processing temperatures usually 
required to produce MNs. For example, Park et al. observed extensive 
denaturation of bovine serum albumin (BSA) incorporated within 
poly-lactide-co-glycolide MNs [16] and BSA and 5-aminolevulinic 
acid were degraded upon incorporation into galactose MNs [19]. 
The production of sugar MNs utilising a simple process that does 
not require high processing temperatures would allow the incorpora- 
tion of heat-labile medicaments including biologically active macro- 
molecules such as proteins and peptides, molecules that represent 
an increasingly signiﬁcant proportion of new medicinal products 
[22]. Whilst oral delivery would be desirable the bioavailability of 
proteins and peptides via this route is often restrictive [1,23] and 
they are commonly administered by hypodermic injection, a proce- 
dure that, whilst effective, causes pain, apprehension [24,25] and in- 
convenience and requires medical training and expertise [26]. This 
can be particularly problematic when the treatment needs to be 
regularly administered over prolonged periods. 
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    Carbohydrates play an essential role in the stabilisation of biolog- 
ical components under water stress [27]. In nature, anhydrobiotic or- 
ganisms are able to survive extreme dehydration due to their ability 
to accumulate high levels of disaccharides, such as sucrose or treha- 
lose. These sugars protect and preserve sensitive biological structures 
via a synergistic mechanism involving direct interactions with 
biomolecules and formation of sugar glasses [28]. Sugar glasses are 
formed by rubber to glass transitions that can be generated by cooling 
or drying processes applied to many amorphous compounds. These 
transitions signify the behavioural change of a carbohydrate from a 
viscous liquid-like material to a vitreous solid-like state [29]. In theo- 
ry, the molecular mobility in glassy state systems is many orders of 
magnitude lower than in liquid systems [30] and this facilitates the 
stabilisation of delicate biological structures within glasses. 
    The focus of this study was to investigate the feasibility of using a 
low temperature processing method to produce biodegradable MNs 
from sugar glasses, to demonstrate that they have sufﬁcient physical 
strength for skin puncture, proffer improved stability of a model pro- 
tein and are able to deposit an incorporated model compound into 
skin through biodegradation. 
2. Materials and methods 
2.1. Materials 
   All reagents were obtained from Fisher Scientiﬁc Ltd. (Loughbor- 
ough, UK) and were of analytical grade unless stated otherwise. 
   Master silicon MN arrays used in this study were fabricated by 
the Microsystems Centre, Tyndall National Institute, University 
College Cork, Ireland using a previously reported wet-etching process 
and subsequent coating with a 0.3 μm layer of platinum [11]. The 
master MN structures were octagonal pyramid in morphology being 
approximately 250 μm in length and 200 μm at base width. 
2.2. Methods 
2.2.1. Preparation of sugar glasses 
    Dehydrated sugar formulations were prepared using trehalose 
anhydrous (TRA), trehalose dihydrate (TRD), sucrose (SUC), maltose 
(MAL), mannitol (MAN) and xylitol (XYL). Four hundred milligrams 
of sugar (either individual sugars or binary mixtures) was dissolved 
in 2 mL of deionised water to give a 16.7% w/v solution. These solu- 
tions were added to 100 mL beakers and allowed to dehydrate in 
a fume cupboard, ﬂow rate 0.53 m/s, at room temperature (RT) for 
24 h followed by 24 h at 50 °C. 
2.2.2. Preparation and scanning electron microscopy of sugar glass ﬁlms 
    Polydimethylsiloxane (PDMS) pre-polymer (Sylgard 184 silicone; 
RW Greef, Glasgow) and catalyst were combined in a 10:1 ratio, 
mixed and degassed for 30 min under 900 mbar vacuum at RT. 
A PDMS mould of a glass slide was prepared by covering the 
slide with PDMS solution, degassing under vacuum (RT 30 min 
900 mbar), and curing at 100 °C for 1 h. This formed a PDMS well of 
approximately 1 × 25 × 75 mm into which sugar solutions were 
pipetted and dehydrated for 48 h to form sheets of sugar glass. Sam- 
ples were stored under vacuum desiccation before analysis. The sam- 
ples were manually sectioned transversely and sputter coated with 
gold prior to visualisation using scanning electron microscopy 
(SEM; Philips XL-20, Philips, Eindhoven, The Netherlands). 
2.2.3. Thermal characterisation of sugars 
    Unprocessed sugars and solid sugar ﬁlms of 100% TRA, 100% 
SUC, TRA/SUC 75:25% and TRD/SUC 75:25% w/w (prepared as de- 
scribed in Section 2.2.2) were analysed by differential scanning cal- 
orimetry (DSC; Perkin-Elmer Series 7). Samples (approximately 
10 mg) in crimped aluminium pans were heated between 20 and 
220 °C at a rate of 10 °C min − 1. Samples of 5 mg were further ana- 
lysed by thermogravimetric analysis (TGA; Perkin-Elmer Series 7) 
in a platinum pan between 20 and 220 °C at a heating rate of 
10 °C min − 1. 
2.2.4. Determination of residual water content of sugar glasses 
    Three sugar solutions, (TRA/SUC 75:25% w/w, TRD/SUC 75:25% 
w/w, MAL/TRA 75:25% w/w) were dehydrated for 48 h (as described 
in Section 2.2.1). Following the initial 48 h of drying, samples were 
maintained at 50 °C under ambient humidity. Thereafter samples 
were placed under ambient temperature and humidity conditions 
and stored up to 360 h. Sample weight was recorded throughout 
the dehydration step, at the end of the raised temperature storage 
and throughout storage under ambient conditions. Residual water 
content was inferred by subtracting the initial powder mass from 
sample weight. 
2.2.5. Assessment of macromolecule stability within sugar glasses 
    A 16.7% w/v solution of TRA/SUC (75:25% w/w) was prepared by 
dissolving the sugars in 1 mL sodium phosphate buffer (PB). β- 
Galactosidase enzyme (β-gal; Sigma-Aldrich, Poole, UK) was 
added to a ﬁnal concentration of 5 IU/mL. To form sugar glasses, 
200 μL samples of solution were dehydrated, as described in 
Section 2.2.1, within 24-well polystyrene plates. Following dehy- 
dration, samples were re-hydrated with 200 μL deionised water 
and left for 10 min to dissolve. Enzyme was quantiﬁed by adding 
100 μL of sample to a reaction vessel containing 100 μL 2- 
nitrophenyl β-D-galactopyranoside (ONPG) substrate, equilibrated 
to 37 °C, and incubated at 37 °C for 90 min. The reaction was 
stopped with 1 M sodium carbonate solution and samples were 
analysed by a UV spectrophotometer (Fluostar Optima™, BMG Lab- 
tech, Aylesbury, UK), with absorbance at 405 nm. Further samples 
were stored under vacuum desiccation at 20 ± 2 °C or desiccation 
at 4 ± 2 °C for up to 3 months. Samples were re-hydrated as stated 
previously and residual enzyme activity was determined at 7, 35 
and 95 days following sugar glass formation. A one-way ANOVA 
with Bonferroni's multiple comparison post hoc test was performed 
on the experimental data using the GraphPad Prism 5 software 
package. In all cases, statistical signiﬁcance was determined by a 
value of p b 0.05. 
2.2.6. Polydimethylsiloxane micromoulding 
    PDMS micromoulds were created from master silicon MNs. PDMS 
was added to a well containing the master array, prior to degassing 
for 30 min and curing (Section 2.2.2) to form the mould. The master 
array was subsequently removed to yield the MN mould. 
2.2.7. Fabrication of sugar glass MNs incorporating powdered methylene 
blue 
2.2.7.1. Standard deposition method. A 16.7% w/v solution of TRA/SUC 
75:25 w/w was prepared as in Section 2.2.1. Methylene blue (MB) 
powder was incorporated at 5% w/w of ﬁnal sugar glass weight. 
Two hundred microlitres of a sugar solution containing 5% w/w MB 
was pipetted onto the surface of a micromould and viewed by a dig- 
ital camera, (Nikon, Coolpix 5600, Japan), and a light microscope 
(Olympus BH-2, Japan). The micromould was then placed into a 
vacuum oven at 300 mbar for 60 min to form MNs. The solution 
was dehydrated (Section 2.2.1) with the mould being viewed with 
time to show MN formation. Once formed, sugar glass arrays were 
removed by hand and stored in a vacuum desiccator at room 
temperature. 
2.2.7.2. Vacuum deposition method. Sugar glass MNs containing 2% 
w/w MB were fabricated using an improved vacuum-loading 
methodology. A micromould was placed into a 100 mL conical 
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vacuum ﬂask. The ﬂask was sealed and held under a vacuum of ap- 
proximately 100 mbar for 30 min. Two hundred microlitres of a 
20% w/v solution of TRA/SUC 75:25 w/w was injected onto the 
mould surface and the vacuum was then released immediately. 
The micromould was removed from the vacuum chamber and 
dehydrated as described in Section 2.2.1. Once formed, sugar 
glass arrays were removed by hand and stored in a vacuum desic- 
cator at RT. 
2.2.8. Scanning electron microscopy of sugar glass MN arrays 
    SEM was used to characterise the shape and morphology of sugar 
glass MN arrays. The arrays were mounted onto aluminium stubs, 
sputter coated with gold and imaged as in Section 2.2.2. 
2.2.9. Sugar glass MN penetration of human skin 
    Human breast skin was obtained from surgical procedures 
under ethical approval and informed patient consent. A previously 
frozen full-thickness skin sample was defrosted for 60 min. Subcu- 
taneous fat was removed by blunt dissection and the sample 
pinned onto a semicircular cork board. The skin surface was patted 
dry with tissue paper. Sugar glass MN arrays (not loaded with any 
model compounds) and silicon MN arrays were mounted onto ﬂat- 
tened 2.0 mL syringe plungers using double-sided adhesive tape. 
Plungers were applied to the skin in a rolling fashion with down- 
ward pressure being applied for 10 s and the array being rolled off 
in the same direction as the application. Following application, 
the MNs were viewed under light microscopy (Zeiss Stemi 2000- 
C, Hertfordshire, UK) to observe structural integrity. Ten microlitres 
of a 2% w/v MB staining solution was pipetted onto the treated skin 
area and left to air dry for 10 min. Excess dye was removed with tis- 
sue paper soaked in ethanol prior to viewing under light 
microscopy. 
2.2.10. Human skin sectioning and staining 
    Samples of MN treated skin were mounted transversely onto 
cork sections and covered with OCT embedding media (RA Lamb, 
Thermo Fisher Scientiﬁc) before snap freezing in hexane and stor- 
age at − 80 °C. Skin samples removed from the freezer were main- 
tained on dry ice before cryosectioning (Leica CM3050s, Wolf 
Laboratories Limited). Sections (10 μm) were mounted onto glass 
slides, rinsed in phosphate buffered saline and ﬁxed in acetone. 
Slides were stained with eosin and counterstained with hematoxy- 
lin, rapidly dehydrated in an ethanol gradient and then xylene be- 
fore permanently mounting in Histomount (National Diagnostics, 
GA, USA). 
2.2.11. Measurement of transepidermal water loss (TEWL) 
    TEWL readings were taken immediately prior to and following 
MN array application to skin using a Dermalab® open chamber 
TEWL apparatus (Cortex Technology, Smedevaenget, DK). A one- 
way ANOVA with Dunnett's multiple comparison post hoc test was 
performed on the experimental data using the GraphPad Prism 5 soft- 
ware package. In all cases, statistical signiﬁcance was determined by 
a value of p b 0.05. 
2.2.12. Dissolution of sugar glass MNs in situ 
    Ex vivo human skin was defrosted and prepared as in Section 2.2.9. 
Sugar glass MN arrays containing 2% w/w MB powder were mounted 
onto syringe barrels and rolled onto the skin. The plunger was 
pressed down for 10 s before being secured in place with adhesive 
plaster (Fastaid, Robinson Healthcare, Nottinghamshire, UK). The 
arrays were left in situ, under ambient conditions, for time periods 
up to 5 h before removal. Arrays were viewed before and after appli- 
cation under a light microscope (Olympus BH-2, Japan). Residual MB 
was removed (Section 2.2.9) prior to visualisation of the skin under 
light microscopy. 
3. Results 
3.1. Sugar glass fabrication 
    Solutions of individual sugars and sugar alcohols, and binary com- 
binations of these, were dehydrated to determine those that formed 
solid sugar glasses and those that crystallised. Table S1 provides a 
full list of the 32 different sugar formulations investigated and the na- 
ture of the products formed following dehydration. Each of the solu- 
tions containing single sugars crystallised upon dehydration; Fig. 1A 
shows the crystalline nature of dehydrated sucrose as an example. 
Certain combinations of sugars and sugar alcohols also crystallised 
upon dehydration; Fig. 1B shows one such example (TRA/MAN 
50:50% w/w). Where a sugar combination consisted of two sugar 
molecules of approximately the same molecular weight however, 
for example two disaccharides, a stable solid sugar glass could be 
formed at certain composite ratios; for example TRD/SUC 75:25% w/ 
w (Table S1), TRA/SUC 75:25% w/w Fig. 1C and TRA/SUC 50:50% w/ 
w Fig. 1D. It was speculated that sugar combinations containing mol- 
ecules of different relative molecular sizes did not interact during de- 
hydration and therefore co-crystallised. Sugar combinations 
containing xylitol did not form a stable solid product by the end of 
the dehydration period, this behaviour being attributed to the hygro- 
scopic nature and extremely low glass transition temperature (Tg) of 
xylitol, 247 K, making the glass unstable at RT. 
    To support the data obtained in Fig. 1 the solid sugar products 
were further examined using SEM. Transverse sections of the solid 
mass formed from dehydrated single sugars suggested an ordered 
structure of crystalline nature (Fig. 1E, F). SEM images of transverse 
sections of sugar solid formed from combinations of sugars shown 
to form a non-crystalline mass, e.g. TRA/SUC 75:25% w/w (Fig. 1G), 
provided no evidence of order. It was not clear whether the material 
formed by the sugar combination was less ordered through its amor- 
phous nature or was more prone to melting under the electron beam. 
Nevertheless, these data suggest the utility of this simple dehydration 
methodology to form sugar glasses from selected sugar combination 
solutions. 
3.2. Thermal characterisation of sugars 
   Individual sugars and promising sugar glass forming combinations 
were further analysed by DSC and TGA. The DSC scan of a 100% TRA 
dehydrated ﬁlm is characterised by two sharp endotherms with 
peaks at 101 and 214 °C with a third more poorly deﬁned 
Fig. 1. Images of dehydrated solid sugar products. Macro photographic images of 
sugars following dehydration. (A) D (+) - sucrose (SUC) 100%, (B) D (+) - trehalose 
dihydrate (TRD) / D-mannitol (MAN) 50:50% w/w, (C) D-trehalose anhydrous (TRA) / 
SUC 75:25% w/w, (D) TRA / SUC 50:50% w/w. Scanning electron micrographs of trans- 
verse sections of dehydrated sugar ﬁlms: (E) TRA 100%, (F) SUC 100%, (G) TRA/SUC 
75:25% w/w (Bar = 500 µm). 
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75:25% w/w dehydrated ﬁlm (Fig. 2F) was shown to be very similar 
to the TRA/SUC 75:25% w/w dehydrated ﬁlm (Fig. 2E), supporting 
the similar apparent nature of the dehydrated products (Table S1). 
In replicate samples, the endothermic peak at 97 °C was not always 
observed (data not shown), correlating with the duration of storage 
under desiccation following formation of the glass. However, the 
key feature in all replicate samples was the absence of endothermic 
peaks at elevated temperatures indicating that the samples were 
non-crystalline in nature. 
3.3. Determination of residual water content in sugar glasses 
    The degree of residual water content in dehydrated samples was 
further explored by measuring the sample weight of three binary 
sugar combinations following initial dehydration over 48 h to form 
solid glasses. Fig. 3 depicts the change in water content of three differ- 
ent sugar solutions with dehydration time. For all sugar solutions the 
majority of water loss occurred during the ﬁrst 24 h. A further 24 h of 
dehydration at elevated temperature removed the remaining water 
to leave a solid glass. The TRA/SUC 75:25% w/w sugar glass retained 
approximately 9% w/w water in its structure at 48 h. The reason 
why this value appears higher than the TRD/SUC 75:25% w/w sample 
relates to the fact that there was no bound water in TRA powder at 
the beginning of the study. The MAL/TRA 75:25% w/w sample con- 
tained less TRA and therefore retained less water. 
    The weight of all of the sugar glasses decreased slightly between 
48 and 192 h whilst maintained at 50 °C (Fig. 3). However, following 
re-introduction into ambient conditions, the weight of each of the 
sugar glasses increased marginally, returning to the levels observed 
at 48 h. This was expected as sugar glasses have a hygroscopic nature 
[31]. 
3.4. Assessment of macromolecule stability within sugar glasses 
    To investigate whether a heat-labile macromolecule could be 
loaded into a solid sugar glass using the novel methodology, a 
model protein macromolecule, β-galactosidase (β-gal) enzyme, was 
incorporated into dehydrated TRA/SUC (75:25% w/w) sugar glasses. 
Fig. 4 shows that whilst β-gal enzyme activity diminished over the 
Fig. 2. Thermal characterisation of solid sugar ﬁlms. Differential scanning calorime- 
try (DSC; solid line) and thermogravimetric analysis (TGA; dashed line) proﬁles of 
unprocessed and dehydrated sugars. (A) 100% TRA dehydrated sugar ﬁlm, (B) 100% 
SUC dehydrated sugar ﬁlm, (C) unprocessed TRD powder, (D) unprocessed TRA pow- 
der, (E) TRA/SUC 75:25% w/w (F) TRD/SUC 75:25% w/w dehydrated sugar ﬁlm. Unpro- 
cessed powders were analysed once and dehydrated sugar ﬁlms were analysed in 
triplicate. Representative thermograms are shown. 
endothermic region between 130 and 150 °C (Fig. 2A). The weight 
loss proﬁle with temperature (TGA) for the same material is superim- 
posed in Fig. 2A and shows a total weight loss of approximately 10% 
w/w over the heating range. This water loss was greatest over the 
temperature range 90–140 °C and hence the endothermic peaks ob- 
served over this range correspond to dehydration of the dihydrate 
crystal. This suggests that the hydrated form of the sugar was formed 
during the process and that residual water remained within the glass 
following dehydration. 
    Fig. 2C and D show the DSC and TGA scans of unprocessed TRD 
and TRA powder respectively. Unprocessed TRA (Fig. 2D) shows a dis- 
tinctly different thermal proﬁle to the dehydrated TRA ﬁlm (Fig. 2A), 
showing only a single melting endotherm at approximately 200 °C, 
corresponding to melting of the trehalose crystal. No weight loss 
was observed through the temperature range, indicating that no 
water was present in the sample. Fig. 2C however, displays endother- 
mic peaks and respective weight losses at approximately the same 
temperatures as the dehydrated TRA ﬁlm, further indicating that 
TRD was formed following dehydration of aqueous TRA solution. 
The thermal proﬁle of 100% SUC dehydrated ﬁlm (Fig. 2B) suggests 
no residual water content as demonstrated by the single endothermic 
peak observed at 191 °C attributed to melting of pure SUC crystal, and 
no evidence of weight loss. Fig. 2E shows DSC and TGA scans of a TRA/ 
SUC 75:25% w/w dehydrated ﬁlm. This ﬁlm appeared to have a more 
complex nature than the individual sugar ﬁlms. A sharp endothermic 
peak was observed at 97 °C, corresponding with the loss of water 
from the sample, but no other discrete thermal events were observed. 
A poorly deﬁned endothermic region was shown between 130 and 
170 °C and a gradual weight loss of the sample was observed from ap- 
proximately 80 to 220 °C. The thermal behaviour of the TRD/SUC 
Fig. 3. Analysis of water content in sugar solutions. Sugar solutions were dehydrated 
at ambient temperature for 24 h then at 50 °C until 192 h. After 192 h solid sugar 
glasses were maintained under ambient conditions until 356 h. Changes in sample 
weight upon dehydration and storage were used to determine water content. Data 
represented as mean ± SD (n = 3). 
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Fig. 4. Assessment of biomolecule stability within sugar glasses. β-galactosidase en- 
zyme was incorporated within solid sugar glasses (black and white bars) or dehydrated 
PB only (grey and stripped bars) as a control. Samples were stored under vacuum des- 
iccation at 20 ± 2 °C (white and stripped bars) or desiccation at 4 ± 2 °C (black and 
grey bars) for a period of 3 months. Residual enzyme activity was quantiﬁed at time 
points by 2-nitrophenyl β‐D-galactopyranoside assay. Data represented as mean ± SD 
(n = 3). 
ﬁrst week of storage the activity was signiﬁcantly (p b 0.0001) higher 
when the enzyme was stored within a sugar glass matrix when 
compared to storage in PB alone. Whilst the enzyme was almost 
completely denatured following dehydration in PB alone, enzyme 
activity was retained above 40% for over 3 months storage under 
vacuum or refridgeration. 
    As a result of these initial characterisation studies the TRA/SUC 
75:25% w/w sugar combination was selected for microneedle fabrica- 
tion studies. This material was chosen on the basis of reliable and 
reproducible non-crystalline sugar glass formation and partial stabili- 
sation of a model protein cargo. 
3.5. Polydimethylsiloxane micromoulding and fabrication of sugar glass 
MNs 
   The SEM in Fig. 5A shows a silicon master array prepared at Tyn- 
dall National Institute by wet-etch fabrication. A single silicon MN is 
shown in Fig. 5B displaying the octagonal pyramidal geometry of 
the master structure with base width of approximately 200 μm and 
needle length of approximately 250 μm. To form a micromould, pre- 
polymerised PDMS was poured over the surface of the MN array. 
Due to the low surface tension of the polymer [32] it easily conformed 
to the high aspect ratio structure of the master arrays producing an 
inverse mould of the master array that had a strong correlation to 
the geometry of the master array; an example of a single channel 
created within the cured PDMS micromould being shown in Fig. 5D. 
    The initial stages involved in sugar glass MN manufacture were 
studied using MNs incorporating methylene blue dye and created 
using the simple methodology described in Section 2.2.7.1. When 
the sugar solution was placed onto the mould it initially remained 
on the mould surface forming a large droplet with a high contact 
angle (Fig. 6A). None of the micromould invaginations contained 
any solution at this stage, which would be expected as PDMS is a hy- 
drophobic material and the sugar solution is hydrophilic. After the 
moulds had been placed under vacuum for 1 h however, the sugar so- 
lution was observed to have ﬁlled the micromould invaginations 
(Fig. 6B). The height and contact angle of the solution droplet had 
also decreased following vacuum exposure. It is apparent from 
Fig. 6B that not all of the PDMS micromould invaginations were ﬁlled 
with sugar solution (black arrow) at this stage. After 48 h dehydration 
however the sugar glass material appeared to have ﬁlled the micro- 
mould entirely as conﬁrmed by light microscopy (Fig. 6C). 
    To conﬁrm successful formation of sugar glass MNs, the newly 
formed MN arrays were removed from the PDMS moulds and individ- 
ual MNs viewed by light microscopy. Fig. 6D shows that sugar glass 
MNs that were fully formed had a strong morphological correlation 
to the master structure, as shown in Fig. 5B. However, in this ﬁrst pro- 
totype only 22 sugar glass MNs were exact replicas of the 36 silicon 
MN master needles with the remainder being incompletely formed 
(Fig. 6E). In subsequent studies (at least 6 repeats were performed) 
the number of completely formed sugar glass MNs varied widely 
and it was never possible to produce a complete array of 36 needles. 
Whilst it was unknown at this stage whether the MNs were incom- 
pletely formed in the mould or damaged upon removal from the 
mould, the processing method was clearly sub-optimal. 
3.6. Optimised fabrication of sugar glass MN arrays 
    To overcome the deﬁciencies in formation of a complete biodegrad- 
able sugar glass MN array a novel vacuum-forming methodology 
was developed (Fig. 7). In the original vacuum oven method 
(Section 2.2.7.1) vacuum pressure could not be applied before the 
sugar solution was placed on the mould surface. Subsequently when 
the droplet of sugar solution was applied air was entrapped within 
the micromould invaginations. An optimised method (Section 2.2.7.2) 
was developed whereby a vacuum was produced within an enclosed 
chamber before the sugar solution was applied to the mould surface 
(Fig. 7). 
    As a corollary no air was entrapped within the micromould dur- 
ing application of the sugar solution. The individual sugar glass 
MNs formed using this improved methodology (Fig. 8A) had an 
identical morphological ﬁdelity to the master structure (Fig. 5B). 
More importantly this process development enabled the precise fab- 
rication of a complete sugar glass MN array, i.e. 36 out of 36 replicate 
structures (Fig. 8B). As we used the same procedure to extract the 
microneedles from the PDMS mould this suggests that the incom- 
pletely formed microneedles produced using the previous fabrica- 
tion process (Fig. 6E) were as a result of incomplete ﬁlling of the 
mould rather than fracture of the microneedle upon removal from 
the mould. Replicate studies (at least 6 repeats) have showed this re- 
vised process to be reliable in forming sugar glass MN arrays of 36 
needles that do not contain any entrapped air. Sugar glass MNs fab- 
ricated using this novel vacuum-forming methodology were used in 
all subsequent studies. 
Fig. 5. Micromoulding silicon MN templates. Polydimethylsiloxane (PDMS) micro- 
moulds were prepared against a master silicon MN array, fabricated by collaborators 
at Tyndall National Institute, Ireland. (A) Scanning electron micrograph of master sili- 
con MN array following micromoulding (Bar = 1 mm), (B) light photomicrograph of an 
individual silicon MN (Bar = 100 µm), (C) PDMS micromould and (D) light photomi- 
crograph of a transverse section through the micromould showing an individual 
mould channel (Bar = 100 µm). 
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MNs effectively punctured human SC to facilitate diffusion of methy- 
lene blue dye, applied post-application, into the epidermal layer 
(Fig. 9D) in a manner analogous to silicon MNs (Fig. 9C). Whilst the 
master silicon MNs were largely unaffected by the skin application 
process (Fig. 9E), sugar glass MNs were physically altered following 
10 second insertion into human skin; Fig. 9F shows a representative 
sugar glass MN following skin application. 
    Skin puncture performance was further assessed by measurement 
of transepidermal water loss (TEWL) from skin following MN applica- 
tion. TEWL data conﬁrmed that human skin insertion of both silicon 
and sugar glass MNs signiﬁcantly (p b 0.05) increased water loss 
over that of intact non-treated skin (Fig. 9G). 
3.8. Dissolution kinetics of sugar glass MNs in skin 
    The sugar glass MNs were designed to dissolve rapidly and 
completely within skin to deposit the incorporated drug cargo. To 
test this, sugar MNs incorporating 2% w/w methylene blue powder 
were inserted into ex vivo human skin and left in situ for various 
time periods. Fig. 10 shows the dissolution status of the MNs, with 
complete dissolution being evident between 10 min (Fig. 10B) and 
20 min (Fig. 10C) after skin insertion. 
    Sugar glass MNs were shown to penetrate the SC and to dissolve in 
situ (Fig. 10D). Fig. 10E and F show the degree of skin staining arising 
from dissolution of MNs containing methylene blue within the needle 
structure at 10 and 20 min respectively. These images generally sup- 
port the dissolution kinetics detailed above and further conﬁrm the 
utility of these MNs for creating microchannels within skin and re- 
leasing material incorporated within the matrix of the array. 
4. Discussion 
Fig. 6. Initial process of sugar glass MN fabrication. Macro images of a PDMS micro- 
mould showing (A) sugar solution containing 5% w/w methylene blue powder on 
mould surface (prior to vacuum), (B) mould following processing under 300 mBar vac- 
uum for 60 min (arrow indicates empty mould invaginations), (C) light photomicro- 
graph of a sugar glass MN array within the micromould following 48 h dehydration. 
(D) and (E) representative light photomicrographs of two ‘MNs’ formed by this process 
(Bar = 100 µm). 
3.7. Human skin penetration study 
   To investigate the structural rigidity and skin puncture perfor- 
mance of sugar glass MNs the arrays were inserted into excised 
human skin obtained from surgical procedures. Methylene blue 
post-staining of the punctures generated in skin following MN array 
application for 10 s showed that sugar glass MNs (Fig. 9B) appeared 
to puncture human skin with the same efﬁcacy as silicon MNs 
(Fig. 9A). Transverse skin sections further conﬁrmed that sugar glass 
Fig. 7. Schematic of novel vacuum deposition methodology for sugar glass MN fabri- 
cation. A PDMS micromould was placed within a vacuum ﬂask held under vacuum (ap- 
proximately 100 mBar for 30 min). Sugar solution was injected through the septum 
onto the micromould surface. The vacuum was released immediately and the mould re- 
moved prior to dehydration at room temperature for 24 h followed by 24 h at 50 °C. 
SGMN = sugar glass MN array. 
    The aim of this work was to manufacture novel biodegradable 
sugar glass MNs for transdermal drug delivery. Glass forming sugars 
are used in nature to protect biological tissues in the dehydrated 
state [33]. These protective properties are exploited pharmaceutically 
to stabilise biological molecules including proteins [34,35], liposomes 
and lipoplexes [36,37] and viruses [38,39] during lyophilisation and 
subsequent product storage. It was therefore anticipated that sugar 
glass MNs may be advantageous for the incorporation of thermolabile 
macromolecular drugs within their matrices, our long-term aim. 
    A glass is an amorphous solid in which the molecules form a non- 
periodic and non-symmetric network as a result of rubber to glass 
phase transitions generated by cooling or drying processes [29]. This 
behaviour was exploited in this study to produce solid sugar glasses 
at low processing temperatures. Dehydration of solutions comprising 
a single sugar, namely trehalose anhydrous (TRA), trehalose dihy- 
drate (TRD), sucrose (SUC), mannitol (MAN) and xylitol (XYL) did 
not result in the formation of sugar glasses. This was unsurprising 
given that crystallisation occurs when sugar solutions of pure sugars 
are evaporated slowly at low or ambient temperatures [40]. Calori- 
metric analysis suggested that dehydrated pure TRA ﬁlms retained 
water from solution to form hydrated trehalose as demonstrated by 
the loss of approximately 10% w/w water between 100 and 150 °C 
and the endotherm at 100 °C in the DSC proﬁle. We speculate that 
this water was bound to the trehalose molecule to form the dihydrate 
form of the sugar and hence that it would not adversely affect the sta- 
bility of any incorporated medicaments. Following water loss, TRA 
showed a clear endotherm at approximately 214 °C, correlating with 
literature values for the melting point of the anhydrous trehalose 
crystal at 210.5 °C [41]. Dehydrated SUC alone was shown to re- 
crystallise without incorporating water, as demonstrated by the sin- 
gle endothermic peak observed at 191 °C. 
    Dehydration of binary mixtures consisting of two sugar molecules 
of similar molecular weight, for example two disaccharides, appeared 
to result in sugar glass formation. Similar observations have been 
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Fig. 8. Sugar glass MN array formed by the vacuum deposition method. (A) Light 
photomicrograph of an individual sugar glass MN (Bar = 100 µm), (B) scanning elec- 
tron micrograph of entire sugar glass MN array (Bar = 1 mm). 
noted by Wright et al. who reported that using a mixture of disaccha- 
rides circumvented crystallisation of sugar solutions evaporated 
slowly at low or ambient temperatures [40,42]. Whilst Wright et al. 
utilised 1/1 mixtures of trehalose and sucrose, in this study we 
found that 75:25% w/w combinations were better at forming sugar 
glasses. Calorimetry data demonstrated an absence of anhydrous 
crystalline melting endotherms for the TRA/SUC 75:25% w/w sugar 
glass with SEM images also reﬂecting the non-ordered nature of this 
material. We speculate that this phenomenon was due to the interac- 
tion between two different sugar molecules in solution to hinder the 
formation of individual sugar crystals during dehydration. Mixtures 
containing disaccharides and sugar alcohols failed to form sugar 
glasses under the same processing conditions. It was speculated that 
the low Tg of MAN and XYL, 303 and 247 K respectively, hindered 
the formation of a solid glass under these conditions. The Tg of 
these two sugar alcohols is close to ambient temperature and there- 
fore sugar combinations containing these sugars will have lower 
Tgs [43] and hence are less likely to form a stable amorphous state 
under ambient conditions. 
    The presence of water can affect the chemical stability of solid pro- 
tein formulations in at least three ways: (i) as a solvent, (ii) as a sub- 
strate in a reaction such as hydrolysis, and (iii) as a plasticiser, 
inducing a physical transition from a brittle, dynamically constrained 
glassy state to a more mobile, less viscous, rubbery state at the glass 
transition temperature [44]. The amount of water present in a sugar 
glass will therefore be a key determinant in governing thermodynam- 
ic properties and stability. Monitoring the weight of dehydrated sam- 
ples suggests that TRA/SUC 75:25% w/w sugar glasses formed at low 
processing temperatures retain 9% w/w water. Previous studies 
showing that trehalose may associate with two molecules of water, 
which account for approximately 10% w/w of the crystal [45], sup- 
ports this ﬁnding. Sugar glasses containing TRA increased in water 
content marginally upon storage under ambient conditions, which 
was expected as sugar glasses are known to have a hygroscopic na- 
ture [31], a factor that will require consideration when deﬁning opti- 
mal packaging and storage requirements for sugar glass MNs. 
    A more detailed discussion of the macromolecular stabilisation 
capacity of this material will be discussed in a future paper; here we 
Fig. 9. Human skin penetration capability of sugar glass MNs. MNs were inserted 
into excised human skin and removed prior to staining with 2% w/v methylene blue 
dye. En face images of microchannels following insertion of (A) silicon and (B) sugar 
glass MN arrays (Bar = 1 mm). Light photomicrographs of transverse skin sections 
taken from skin shown in (A) (silicon MNs, panel C) and (B) (sugar glass MNs, panel 
D) respectively (Bar = 100 µm). Light photomicrographs of representative silicon (E) 
and sugar glass (F) MNs following rapid (10 seconds) skin insertion (Bar = 100 µm). 
(G) Trans-epidermal water loss (TEWL) measurement across human skin following 
microneedle treatment. Both sugar glass (n = 3) and silicon MN treatments (n = 4) 
were shown to signiﬁcantly increase TEWL versus intact skin (n = 3). Data presented 
as mean ± SEM. * denotes statistical signiﬁcance at p b 0.05. 
Fig. 10. In situ dissolution kinetics of sugar glass MNs incorporating 2% w/w meth- 
ylene blue. Representative light photomicrographs of sugar glass MNs: (A) after for- 
mation, (B) following 10 min insertion into ex vivo human skin and (C) following 
20 min insertion into ex vivo human skin (n = 4) (Bar = 1 mm). (D) 10 µm hematoxy- 
lin and eosin stained transverse tissue section of skin showing a single microneedle 
puncture site following 20 min insertion (Bar = 100 µm). En face images of skin after 
removal of sugar glass MNs incorporating dye at 10 min (E) and 20 min (F) insertion 
time (Bar = 1 mm). 
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have shown that biologically active protein can successfully be incor- 
porated into sugar glasses and retain some activity throughout the 
SGMN production conditions and subsequent medium-term storage. 
Whilst the model enzyme was shown to initially lose some activity 
following dehydration of the sugar solution, enzyme activity 
remained 100% stable thereafter throughout 3 months of storage at 
both room temperature and 4 °C. Therefore whilst further optimisa- 
tion of both the formulation components and the dehydration condi- 
tions may be required to reduce or abolish the initial adverse effects 
on the incorporated macromolecule the data suggests that macromol- 
ecules will be very well preserved once they are embedded with 
the fully formed sugar glass. As such this preliminary study provides 
early evidence that an amorphous sugar combination can offer pro- 
tection to biological macromolecules and that such materials can be 
loaded into, stored within and thereafter delivered from, sugar glass 
MNs. 
    Our early studies showed that whilst a PDMS micromould can be 
created with precise morphological ﬁdelity to master MN structures, 
sugar solutions did not completely ﬁll the micromould invaginations 
due to the high surface tension of the solution, as demonstrated by 
the initial high contact angle of the solution on the mould surface. It 
was postulated that the applied vacuum was insufﬁcient to release 
all of the air bubbles trapped beneath the solution, or the vacuum 
was not applied for a sufﬁcient duration to evacuate all the air 
trapped within the micromould indentations. To improve ﬁlling of 
the micromould, a novel processing method was developed to main- 
tain vacuum during loading of the sugar solution onto the mould. Fol- 
lowing optimisation of processing conditions this new method was 
able to reproducibly fabricate complete arrays of 36 sugar glass MNs. 
    The resulting sugar glass MNs possess suitable structural rigidity 
and sharpness to efﬁciently penetrate the SC of human skin as 
demonstrated by external application of a marker dye following MN 
array insertion and removal. The sugar glass MNs were damaged or 
partially dissolved during this process rendering their re-use for 
skin puncturing purposes unlikely. More importantly, as these MNs 
are designed for in situ deposition of incorporated drug, a further 
study showed that the sugar glass MNs dissolved completely in 
human skin to efﬁciently release a model marker compound. It is an- 
ticipated that the MNs developed in this study will be appropriate for 
the stable incorporation of macromolecular drugs to enable rapid and 
painless delivery to human skin leaving behind no hazardous waste. 
    Previous studies that have developed MNs to dissolve or degrade 
in skin have generally focussed on melting polymers into a mould at 
temperatures that are potentially deleterious to the incorporated 
drug [16,6,20]. Another approach involves hand assembly of individ- 
ual needles of millimetre dimensions [18], which could be a poorly 
controlled and non-scalable process [17]. The methodology we use 
to prepare novel sugar glass MNs in this study provides another alter- 
native for making biodegradable microneedles at low temperatures 
and it is anticipated that such systems could be inexpensively pro- 
duced on a mass scale as neither the materials nor the processing 
conditions are costly or complex. As the sugar glass MNs can be pro- 
duced at a temperature of 50 °C and have been shown to partially 
preserve macromolecular enzyme functionality, it is speculated that 
the processing conditions would be favourable for the inclusion and 
preservation of a range of molecules and macromolecules, including 
proteins, peptides and nucleic acids, for intradermal and transdermal 
drug delivery applications. 
5. Conclusion 
    This study has shown for the ﬁrst time that sugar glass MNs can be 
fabricated from sugar combination solutions using a low temperature 
vacuum-forming methodology. The MNs possess suitable structural 
rigidity to effectively puncture human skin. The prompt and complete 
dissolution of sugar glass MNs within skin suggests that they may ﬁnd 
utility in the transdermal delivery of potent therapeutics, potentially 
including hydrophilic macromolecules. Further studies, using thera- 
peutically relevant molecules and macromolecules, are currently 
underway to improve the loading and stabilisation capacity of the 
sugar glass materials and the temporal and spatial distribution of 
delivered material. 
    Supplementary materials related to this article can be found on- 
line at doi:10.1016/j.jconrel.2011.10.024. 
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